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Summary 
This thesis is composed by two parts: Combinatorial Synthesis of N-Heterocycles (Part 1) and 
Development of a Polymer-Supported Hantzsch Ester (Part 2). 
Part 1 comprises four projects focusing on the development of solid-phase synthetic 
methodologies for preparing pharmaceutically and medicinally important N-heterocycles. 
The first two projects aim to develop solid-phase synthetic routes toward xanthines. Efforts in 
the first project has resulted in a highly efficient and scaleable synthetic procedure affording 
1,3-substituted xanthines. This was the first reported traceless solid-phase synthesis of 
1,3-substituted xanthines. The solid-phase synthesis was achieved using PS-MB-CHO resin. 
Cyclocondensation of the polymer-bound aminoimidazole with isocyanates followed by 
alkylation provided 1,3-substituted xanthines. A representative set of 12 xanthines and 4 
thioxanthines was prepared. 
In the second project, a traceless solid-phase route to substituted xanthines based on the late 
stage pyrimidine ring closure was developed. This method was found to be especially useful 
for the preparation of xanthines containing a variety of substituents at the N1, N3, N7 and C8 
positions. These subsituents could be introduced onto the xanthine ring in an unambiguous 
manner. A library of 22 compounds was prepared. 
The third project investigated the combinatorial solution-phase parallel synthesis of 
polycyclic guanines. A highly efficient synthetic route involving 9 steps was developed. 
Unlike previous syntheses of polycyclic guanines which use 2-chloropurine as the necessary 
intermediate, this method made use of thioxanthine as the key intermediate. This provided a 
 xiv
more efficient construction of the third ring. To demonstrate the versatility of this chemistry, 
a set of 6 compounds was prepared.  
The fourth project involves the development of a microwave-assisted traceless solid-phase 
synthetic route to pyrazolidine-3,5-diones. This was the first reported solid-phase synthesis 
methodology for the preparation of pyrazolidine-3,5-diones. Using our synthetic protocol, we 
have demonstrated that pyrazolidine-3,5-diones could be obtained in extremely high overall 
yields. A representative library of 27 pyrazolidine-3,5-diones was prepared.  
Part 2 of this thesis focuses on the design, development and applications of a soluble 
polymer-supported Hantzsch ester as a reducing agent. An efficient synthetic method was 
developed for the synthesis of this polymer-supported Hantzsch ester. The polymer-supported 
Hantzsch ester was successfully applied for the reduction of α,β-unsaturated aldehydes, 
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Chapter 1 Introduction 
Combinatorial chemistry has its origins in solid-phase peptide synthesis for which Bruce 
Merrifield was awarded the Nobel Prize in 1984.1 In solid-phase peptide synthesis, peptide 
couplings were carried out on a polymeric support which simplified the purification process. 
This method was so reliable and consistent that in the 1980s, it was used to make many 
peptides simultaneously in the same reaction container. Houghten’s “tea-bag” method was 
particularly appealing as the same peptide coupling step could be applied to many different 
polymer-supported peptide sequences simultaneously.2 Three years later, Furka described a 
mix-split procedure3 which was shortly adopted by Houghten4 and Lam5 for the synthesis of 
large numbers of peptides in a very few number of chemical steps. During this time, the 
concept of combinatorial chemistry was formed. 
As the essence of combinatorial chemistry is the ability to generate large numbers of chemical 
compounds efficiently, it has had important impact on both academic and industrial fields. 
Today, combinatorial chemistry has become a critical and necessary tool for lead 
identification and optimization in the drug discovery process where thousands of compounds 
should be tested per week. It is combinatorial chemistry that changed the way we approach 
synthetic chemistry and that allowed drug discovery process to be much more efficient 
compared to previous times. It is for this reason that nearly every pharmaceutical company 
has now established at least one group working in this area. Besides its application in 
pharmaceutical research, combinatorial chemistry has also been applied to the optimization of 
catalyst, materials, and receptors.6 
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1.1 Combinatorial solid-phase synthesis 
The majority of combinatorial libraries synthesis reported in the literature employ solid-phase 
synthesis, a process in which compounds are synthesized on a heterogeneous polymeric 
support. The primary advantages of solid-phase synthesis are (i) simple filtration can be used 
as a separation and purification method, thus eliminating the tedious and time-consuming 
workup often associated with solution-phase organic synthesis, and (ii) a large excess of 
reagents may be added to drive the reactions to completion.  
Generally, two strategies are used in combinatorial solid-phase synthesis: mix-split synthesis 
and parallel synthesis. 
In mix-split synthesis (Figure 1-1), the starting resin is split into 3 portions and reacted with 
the first set of reagents (A1-A3). After the reaction, the resulting resins are mixed thoroughly 
and the mixture is split into 5 portions, each consisting of 3 compounds. After the reaction 
with the second set of reagents (B1-B5), a library of 15 different compounds is obtained. The 
resulting resins are mixed thoroughly and the mixture is split into 4 portions, each consisting 
of 15 compounds. After the reaction with the third set of reagents (C1-C4), a library of 60 
different compounds is obtained. The primary advantage of this method is that by executing 
this mix-split-reaction cycle repetitively, a large library of compounds can be generated. 
Since the resulting compounds of this method are in a mixture, methods have to be developed 
for identifying the biologically active components from the mixture. Three approaches are 
generally used for the structural deconvolution of bioactive compounds from assay data: 
iterative deconvolution,4 position scanning deconvolution7a and tagging.7b   
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Parallel synthesis (Figure 1-2) is a strategy whereby sets of discrete compounds are 
synthesized in arrays of physically separate reaction vessels or microcompartments without 
interchange of intermediates during the process. The advantage of this method is that it 
removes some of the ambiguities associated with pooling compounds. In addition, analytical 
evaluation of the chemical integrity of the compounds is straightforward. The primary 
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disadvantage of this method is that the number of compounds that can be synthesized is more 
limited. 
Figure 1-2 Parallel Synthesis 
A1 A2 A3
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1.1.1 Solid supports in combinatorial solid-phase synthesis 
Different types of solid supports ranging from polymers to photolithographic chips to 
membranes have been used for solid-phase synthesis. As organic reactions could be 
conducted in various reaction conditions, such as different solvents, temperatures, reagents, 
and so on, selection of an appropriate solid support is very important in solid-phase synthesis. 
1.1.1.1 Polystyrene 
The polystyrene supports used for solid-phase synthesis are normally cross-linked by addition 
of 1-2% divinylbenzene to the polymerization mixture. Polystyrene is presently the most 
common support material used in solid-phase synthesis because of its good swelling property 
and high loading. Solvents such as DMF, THF or CH2Cl2 swell polystyrene resin while 
solvents like MeOH, ether, or water shrink it.8 Merrifield’s resin is a 
divinylbenzene/polystyrene copolymer, which upon chloromethylation yields reactive benzyl 
chloride functional groups.8 
 5
1.1.1.2 Tentagel 
This is a polystyrene-poly(ethylene glycol) graft copolymer. Compared to polystyrene, 
Tentagel has better swelling ability in polar solvents, such as water, which makes this support 
a good alternative in solid-phase synthesis. However its hydroscopic character and chemical 
instability in strongly basic condition limit its application as a solid support. 
1.1.1.3 Polyamide 
Various polyamide supports have been developed and these include Pepsyn, which is a 
copolymer of N,N-dimethylacrylamide, bis(acrylamidoethane), and N-acryloylsarcosine 
methyl ester,9a Pepsyn K, a Kieselguhr supported polyamide which was the first polymeric 
support used in continuous-flow solid-phase synthesis,9b and PolyHIPE, which is prepared by 
polymerizing polyamide into macroporous polystyrene particles.10 Each of these polyamide 
supports has its advantages and disadvantages. For example, Pepsyn has high polarity but low 
mechanical stability, Pepsyn K has good mechanical stability but low loading capacity and 
PolyHIPE has higher loading capacity and compatibility with various solvents. 
1.1.1.4 Poly(acrylic amide-ethylene glycol) copolymers 
This class of polymer includes PEGA, which has a high degree of cross-linking and 
non-reduced swelling properties, CLEAR which has higher cross-linking and good swelling 
ability in both polar and non-polar solvents, POEPS and POEPOP which have great chemical 
and mechanical stability and allow macromolecules such as enzyme to access the interior of 
the polymer thus allowing the polymer to be used in support-enzyme assays.11 
1.1.1.5 Inorganic materials 
Although organic polymers are the most widely used supports, inorganic materials have also 
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been reported as supports. Typical examples are controlled pore glass and controlled pore 
ceramics which were originally used as chromatographic supports. These supports are 
particularly useful in continuous-flow synthesis and are used in oligonucleotide synthesis. 
Their loading capacity exceeds that of Pepsyn K. 
1.1.2 Linkers in combinatorial solid-phase synthesis 
A linker is usually a bifunctional molecule that connects the first building block in the 
solid-phase synthesis to the solid support.12 The linker must be compatible with all the 
synthetic steps, yet labile under certain conditions called cleavage, and should have minimum 
structural and chemical effects on the sought after properties of the synthesized compounds. 
Therefore choosing the correct linker is a crucial step in combinatorial solid-phase synthesis. 
Various linkers have been described in the past decades and some of which are described 
below. 
1.1.2.1 Acid-labile linkers 
Acid-labile linkers are one of the most common linkers in solid-phase peptide synthesis. They 
can be classified according to their ability to stabilize the benzylic carbocations generated 
during cleavage which, in turn, facilitates cleavage of the product from the polymeric support. 




























































1.1.2.2 Nucleophile-labile linkers 
Nucleophile-labile linkers are applicable to the synthesis of target compounds which are 
unstable or decompose rapidly in acidic condition. When such a linker is used, a nucleophilic 
displacement occurs during the cleavage step to release the compound from the solid support 
(Scheme 1-1). 
Examples of a nucleophile-labile linker (Figure 1-4) are 
- REM resin, which is compatible with acid and base, and allows the anchoring of 
primary and secondary amines via Michael addition and releases the tertiary amine as 
product via Hoffman elimination (Scheme 1-1);13 
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- HMBA and bromoacetyl resins which are stable in strong acids and liberate products 
by the treatment with NaOH, TEA, NH3, or hydrazine; 
- N-methoxypropionic acid amide resin which is used to immobilize carboxylic acids 
and release them as their corresponding aldehydes by Weinreb’s method;14 and 
- Kaiser oxime resin which yields hydrazones, amides or carboxylic acids by cleavage 
with hydrazine, amine or hydroxypiperidine/Zn/HOAc. 
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1.1.2.3 Photo-labile linkers 
Unlike traditional cleavage which employs chemical reagents, photo-labile anchors release 
products by irradiation at λ = 320-365 nm. This cleavage can be carried out in aqueous 
solution which makes this approach particularly useful for biological assays (Scheme 1-2).15 
Examples of photo-labile resins are shown in Figure 1-5. 



















5-nitrophenoxy resin  
 
























1.1.2.4 Safety-catch linkers 
The cleavage of safety-catch linkers involves two steps - the first step is a reaction that 
activates the secured product into a cleavable stage, whilst the second step liberates the 
product (Scheme 1-3). Many safety-catch linkers have been developed in solid-phase 
synthesis and three of them are shown in Figure 1-6. For example, Kenner’s safety-catch resin 
is stable to most nucleophiles before activation but becomes susceptible after activation with 
diazomethane or iodoacetonitrile. Treating the activated resin with amines or alkoxides 
generates the corresponding amides or esters (Scheme 1-3).16 
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1.1.2.5 Traceless linkers 
Traceless linkers release products in a way such that no trace or memory of the solid-phase 
synthesis can be observed.17a Such linkers are highly desirable as they minimize the effects of 
residual functionality on the synthesized compounds. The most widely exploited class of 
these linkers is based on silicon chemistry (Figure 1-7). Their cleavage is often achieved by 
fluoride salts or by ipso-substitution with C-H, C-I, C-Br at the Si-C bond.17a Scheme 1-4 
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1.1.2.6 Other linkers 
Besides the aforementioned linkers, some other linkers release products via special cleavage 
conditions, for example, hydrogenolysis with hydrogen or ammonium formate in the presence 
of Pd(OAc)2 (Scheme 1-5)18 or enzyme promoted cleavage (Scheme 1-6).19 The specificity of 
enzyme enables products to be released in a highly selective manner such that no other parts 
of the synthesized compounds will be altered. 
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Enzyme X = C, O, NH
S = Substrate for enzyme in infected cells
 
1.1.3 Analytical methods in solid-phase synthesis 
Organic reactions on solid-phase require different monitoring and analytical methods from 
solution-phase due to the solid support’s insolubility in solvents. Thus many on-support 
analytical techniques have been developed and used for the characterizations of substrates on 
solid supports. 
1.1.3.1 FTIR method 
The most widely used on-support characterization technique for the monitoring of solid-phase 
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synthesis is FTIR. It provides qualitative analysis of solid bound substrates. In particular, 
single bead FTIR microspectroscopy technique which performs a non-destructive analysis on 
a single bead is advantageous as it contains both sensitivity and speed.20 
1.1.3.2 Gel-phase NMR 
Due to the restricted mobility and the magnetically inhomogeneous environment throughout 
the substrate, the NMR spectra of solid-supported substrates appear as broad lines which does 
not allow for meaningful analysis. To circumvent this problem, gel-phase NMR was 
introduced and this involves analyzing solvent swollen resins with a standard liquid NMR 
probe. In gel-phase NMR, the resin is allowed to swell in a solvent so as to provide the 
molecules with a greater degree of mobility. This helps in narrowing the NMR spectra to a 
limited extent and is thus practical only for nuclei with a large chemical shift range (e.g., 13C, 
19F, 31P NMR). 
1.1.3.3 High-resolution magic angle spinning (HR-MAS) NMR 
As proton NMR spectra are crucial in reaction monitoring and structure elucidation, HR-MAS 
NMR technique is used to solve the line-broadening problem in proton NMR. It requires the 
use of a high resolution MAS probe which allows the magnetic susceptibility-induced line 
broadening terms to average out by a special angle spinning. HR-MAS NMR technique is a 
useful tool in resin-bound substrates characterization. 
1.1.3.4 Spectrophotometric methods 
Spectrophotometric methods have been developed for the analysis of solid-phase peptide 
synthesis. By using molecular markers that react specifically with a functional group, together 
with UV-visible or fluorescence spectroscopy, quantitative analysis of aldehyde, ketone, 
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hydroxyl and carboxy groups has been done.21 
 
1.2 Combinatorial solution-phase synthesis 
The concept of combinatorial chemistry is often associated with solid-phase synthesis, which 
offers many advantages for easy and reliable combinatorial libraries generation. Nevertheless, 
a significant amount of combinatorial efforts have also been done by solution-phase work. 
The selection of combinatorial synthesis strategy is determined by many factors such as (i) 
the purpose of the synthesis, i.e., is it for lead discovery or lead optimization, (ii) the format 
of screen, and (iii) the required purity of the final compounds. Unlike solid-phase synthesis, 
solution-phase synthesis does not require the design and development of a strategy for the 
attachment and cleavage of a substrate from the solid support. This simplification, as well as 
the maturity of solution-phase chemistry, shortens the synthesis time. 
1.2.1 Combinatorial solution-phase pool synthesis 
This strategy prepares libraries of target compounds in mixtures, which is useful for the quick 
identification of the most biologically active compounds from libraries. The first example was 
described by a group from Glaxo who synthesized a total of 1600 amides and esters from 40 
acid chlorides with 40 amines and alcohols.22 In their experiment, two libraries were prepared. 
In each pool of the first library, a single acid chloride was reacted with an equal molar mixture 
of amines and alcohols, and 40 pools with each pool containing 40 compounds were prepared. 
In each pool of the second library, a single amine or alcohol was reacted with an equal molar 
mixture of acid chlorides and 40 pools were also prepared. Subsequently the libraries were 
screened for biological activity in a pool identified manner to find the most active amide or 
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ester. 
1.2.2 Combinatorial solution-phase parallel synthesis 
Compared to combinatorial solution-phase pool synthesis, parallel synthesis which gives 
products as individual component is less frequently used for large library generation. 
However, Watson and his coworkers have reported a single step synthesis for the generation 
of a modest library of 20 discrete 2-amino-thiazoles using this methodology.23 In their 
experiment, 5 primary thioureas were reacted with 4 α-bromoketones in DMF to give 
2-aminothiazoles. The reaction tolerated the presence of both acidic and basic functionalities 
on the reactants without protection, and the products did not require purification. 
Additionally, a few research groups have reported using solution-phase parallel synthesis for 
multi-component reactions. One example involves the Ugi reaction which is a one-pot, 
four-component condensation reaction for the synthesis of α-acylaminoamide. Weber has 
reported the preparation of 20 libraries, each containing 20 individual Ugi products, which 
were tested for thrombin-inhibitory activity.24a Similar work on this reaction was also 
conducted by Keating.24b 
 
1.3 Objectives of our studies 
As mentioned earlier, combinatorial synthesis plays a very important role in the drug 
discovery process. Since peptides and oligonucleotides are problematic for drug development 
because their oral bioavailability is poor and they are degraded rapidly by enzymes, the focus 
of combinatorial research has shifted in recent years to libraries of nonpolymeric small 
molecules having molecular weights of about 500 daltons or less.25 Thus, one of the purposes 
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of this project is to investigate the combinatorial synthesis of small N-heterocycles. In 
particular, we plan to: 
1) develop solid-phase synthetic routes to xanthines and pyrazolidine-3,5-diones, and prepare 
representative sets of these compounds using a combinatorial solid-phase parallel synthesis 
strategy, and 
2) develop a solution-phase synthetic route to polycyclic guanines, and prepare representative 
sets of polycyclic guanines using a combinatorial solution-phase parallel synthesis strategy. 
The advantages of solid-phase reactions could be combined with the benefits of solution 
phase chemistry through the use of polymer-supported reagents. In the second part of this 
project, we intend to develop a polymer-supported Hantzsch ester and examine its application 
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Chapter 2 Combinatorial Solid-Phase Synthesis of Xanthines 
2.1 Introduction 
2.1.1 Importance of xanthines 
Xanthines constitute an important class of pharmacologically active compounds which are 
commonly used for their effects as mild stimulants, bronchodilators, phosphodiesterase 
inhibitors, CFTR chloride channel activators and adenosine receptor antagonists.1 In recent 
years, the spectrum of clinical applications of xanthines has continued to widen and presently 
include their use as anticonvulsants,2 nootropics,3 and therapeutics for the treatment of 
migraine headaches and illnesses where under-activation of the HM74A receptor contributes 
to the disease.4 
There are many drugs that are xanthine derivatives (Figure 2-1). These include caffeine, 
which is the most popular psychostimulant drug in the world; theophylline, an anti-asthmatic 
drug; lisofylline, an experimental anti-inflammatory drug; and so on. 







































2.1.2 General methods for solution-phase synthesis of xanthines 
The first solution-phase synthetic method to the preparation of xanthine was reported by W. 
Traube5 in 1900. Since then, other synthetic methods have been developed.6 Most of these 
methods employed substituted 5,6-diamino uracil as the key precursor for the xanthine 
formation (Scheme 2-1). In this classical method, substituents R1 and R2 are introduced in the 
early stages of the synthesis, which requires that nearly the entire synthesis had to be repeated 
for each combination of R1 and R2. Additionally, the reactions for the formation of the 5-
membered ring were either harsh, had long reaction times, required non-readily accessible 
reagents, or involved a tedious workup.7 These disadvantages made this method less useful in 
modern synthetic organic chemistry, especially in combinatorial chemistry. 


















An alternative method for the preparation of xanthines involves the cyclocondensation of 4-
amino-5-alkoxycarbonylimidazole.6a,6d,6e In this synthetic strategy, the 5-membered ring is 
built prior to the 6-membered ring (Scheme 2-2). We felt that this was a more attractive 
method than the one described earlier as it allows the N1 and N3 substituents to be introduced 
later in the synthesis, thus avoiding the need to repeat almost the entire synthesis for each 





















2.1.3 Objectives and scope of this study 
As mentioned earlier, numerous solution-phase routes for the synthesis of xanthines have 
been developed. However, to the best of our knowledge, the only solid-phase procedure 
reported to-date involves the derivatization of a xanthine scaffold (Scheme 2-3).8 

































Since the solid-phase synthesis of xanthines is not well-explored, this project aims to develop 
solid-phase synthetic methodologies to this class of compounds. In this project, we plan to: 
1) design and develop solid-phase synthetic routes to xanthines, 
2) optimize the reaction conditions for each step of the reaction, and 
3) prepare representative sets of xanthines using these solid-phase synthesis methodologies to 
illustrate its versatility. 
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2.2 Results and Discussion  
2.2.1 Solid-phase synthesis of 1,3-substituted xanthines 
2.2.1.1 Solution-phase synthesis of 1,3-substituted xanthines 
Prior to solid-phase synthesis, preliminary solution-phase studies (Scheme 2-4) were carried 
out to survey the required reaction conditions and establish the conditions required for solid-
phase synthesis. 

















































































2.2.1.1.1 Synthesis of ethyl N-(2,4-dimethoxybenzyl) glycinate (2-1-8) 
To begin our investigation, ethyl N-(2,4-dimethoxybenzyl) glycinate 2-1-8 was prepared by 
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reductively alkylating 2,4-dimethoxybenzaldehyde (a mimic of the PS-MB-CHO resin) with 
ethyl glycinate. Attempts to carry out the reaction with NaBH4/EtOH,9a 
NaB(OAc)3H/NaOAc/MeOH9b or NaB(OAc)3H/DMF gave yields of 20-63% which were not 
optimal for solid-phase synthesis. Further experimentation eventually provided 
NaB(OAc)3H/1% HOAc/DMF, which gave 2-1-8 in 95% yield, and no improvement was 
observed when more HOAc was added to the reaction system (Table 2-1). 
Table 2-1 Synthesis of 2-1-8 
Entry Reagent and solvent Conditions Result 
1 NaBH4/EtOH rt, 24 h 20% yield 
2 NaB(OAc) 3H/NaOAc/MeOH rt, 96 h 63% yield 
3 NaB(OAc) 3H/DMF rt, 72 h 57% yield 
4 NaB(OAc) 3H/1% HOAc/DMF rt, 8 h 95% yield 
 
2.2.1.1.2 Synthesis of ethyl 5-amino-3-(2,4-dimethoxybenzyl)-3H-imidazole-4-
carboxylate (2-1-10) 
Subsequently 2-1-8 was treated with ethoxymethylene cyanamide using a slightly modified 
form of the procedure described by Asberom et al,10 to give the intermediate 2-1-9, which was 
cyclized with NaOEt in an one-pot reaction to give 2-1-10 in 70% overall yield. We realized 
that to obtain higher yields, it was essential to keep the reaction mixture at low temperature 






Figure 2-2 X-Ray Structure of 2-1-10  
 
2.2.1.1.3 Synthesis of ethyl 3-(2,4-dimethoxybenzyl)-5-(3-phenylureido)-3H-imidazole-4-
carboxylate (2-1-11) 
Treatment of 2-1-10 with phenyl isocyanate in o-xylene (120 °C, 8 h) provided 2-1-11 in 90% 
yield. However when 2-1-10 was reacted with isothiocyanates, the reaction mixtures had to be 
heated in o-xylene at 140 °C for 24 h to give the products in 83% yield and traces of 
unreacted 2-1-10. Attempts to drive the reaction to completion by prolonging the heating time, 
addition of a base as a catalyst11 or using microwave irradiation proved futile.  
2.2.1.1.4 Synthesis of 7-(2,4-dimethoxybenzyl)-1-phenylxanthine (2-1-12) 
Subsequent ring closure of 2-1-11 with NaOEt/MeOH afforded 1-substituted xanthine 2-1-12 
in quantitative yield. Since MeOH was not a good solvent for the swelling of a polystyrene 
resin (a required condition for solid-phase synthesis), we therefore repeated the reaction with 
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a MeOH-THF mixture and were gratified to obtain the same result. In this reaction, an acid-
base workup was sufficient to obtain the product in high purity. This greatly simplified the 
purification step. 
2.2.1.1.5 Synthesis of 7-(2,4-dimethoxybenzyl)-1-phenyl-3-substitutedxanthine (2-1-13) 
To obtain 1,3-substituted xanthines, 2-1-12 was treated with various alkyl halides in DMF 
under basic conditions. The reaction proceeded readily at rt to provide 2-1-13 in good yields 
(Table 2-2). 
Table 2-2 Synthesis of 2-1-13 
Entry Alkylating reagent Base and Solvent Conditions Result 
1 CH3I DIEA/DMF rt, 0.5 h 92% yield 
2 BnBr DIEA/DMF rt, 4 h 88% yield 
3 BuI DIEA/DMF rt, 24 h 70% yield 
4 Propargyl bromide DIEA/DMF rt, 1 h 90% yield 
 
2.2.1.1.6 Synthesis of 3-methyl-1-phenylxanthine (2-1-7b) 
Removal of the 2,4-dimethoxybenzyl moiety was achieved by refluxing 2-1-13 in 90% TFA/ 
CH2Cl2. Using lower concentrations of TFA in CH2Cl2 (such as 30%, 50% and 70%) also 
worked well but longer reaction times were needed (Table 2-3). 
Table 2-3 Synthesis of 2-1-7b 
Entry Reagent Conditions Result 
1 30% TFA in CH2Cl2 60-70 °C Reaction completed in 6 h 
2 50% TFA in CH2Cl2 60-70 °C Reaction completed in 5 h 
3 70% TFA in CH2Cl2 60-70 °C Reaction completed in 3 h 
4 90% TFA in CH2Cl2 60-70 °C Reaction completed in 1 h 
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2.2.1.2 Solid-phase synthesis of 1,3-substituted xanthines 
With the solution-phase pathway established, we proceeded to adapt the methodology to 
solid-phase synthesis (Scheme 2-5). 







































































90% TFA/DCM, rt 





To facilitate the solid-phase synthesis of 4-amino-5-alkoxycarbonylimidazole, we required 
ready access to multigram quantities of CHO resin. Amongst the CHO functionalized resins 
available, the ArgoGel-MB-CHO or ArgoPore-MB-CHO resins are commonly used for solid-
phase reactions due to their good swelling property in most organic solvents.12 However these 
resins are highly expensive, which limits their potential use on a large scale. The PS-MB-
CHO resin 2-1-1 is a cheaper resin, but it has rarely been used in solid-phase synthesis due to 
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its poor swelling in some solvents. We figured that by circumventing this problem, wider 
applicability could be achieved for resin 2-1-1. 
Resin 2-1-1 was converted to 2-1-2 by reductive amination in DMF. The formation of 2-1-2 
was amenable to KBr FTIR monitoring (i.e. disappearance of the CH stretch of aldehyde at 
2763 cm-1 and the shift of the C=O stretch at 1681 cm-1 to 1737 cm-1, indicating the presence 
of an ester). Due to the poor swelling ability of polystyrene/1% divinylbenzene in EtOH, 
treatment of 2-1-2 with ethoxymethylene cyanamide was carried out in a DMF/EtOH (v/v 1:2) 
mixture. This was followed by the addition of NaOEt/EtOH to afford the polymer-supported 
4-amino-5-ethoxycarbonylimidazole 2-1-3. Treatment of 2-1-3 with various isocyanates in o-
xylene (120 °C, 24 h) provided 2-1-4a, which was cyclized using NaOEt in MeOH/THF (v/v 
1:4) to give 2-1-5. The N1 substituted xanthines could be released from the solid support with 
90% TFA/CH2Cl2 at rt or they could be treated with alkyl halides in DIEA/DMF to afford 2-1-
6. To illustrate the versatility of this chemistry, a small library of 12 compounds (2-1-7a - 2-1-
7l) was prepared (Figure 2-3). The overall yields obtained were 35-64% (purities of > 95% by 
NMR) indicating an average yield of 86-93% for each step of the SPS.  
We have also examined the application of this methodology for the synthesis of thioxanthines. 
Due to the lower reactivity of isothiocyanates, formation of 2-1-4b was carried out at 140 °C 
and by iterating this procedure 3 times, the yield was increased more than four-fold. Cleavage 
of 2-1-5 from the support with 90% TFA/CH2Cl2 at rt liberated products which did not 
correspond to the desired substituted thioxanthines (2-1-7m - 2-1-7p) whilst treatment with 
refluxing glacial acetic acid gave a mixture of 2-1-7 and byproducts. Hence, to simplify the 
purification of 2-1-7, a two-step cleavage procedure was used: the resin was first treated with 
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90% TFA/CH2Cl2 at rt to detach the byproducts before liberating the thioxanthines with 
refluxing glacial acetic acid. By using this novel solid-phase synthesis methodology, a 
representative set of 4 thioxanthines was prepared (Figure 2-3) in acceptable overall yields 
and purities. 





























































































































2-1-7a (64%) 2-1-7b (60%) 2-1-7c (53%) 2-1-7d (55%)
2-1-7e (53%) 2-1-7f (43%) 2-1-7g (49%) 2-1-7h (40%)
2-1-7i (53%) 2-1-7j (48%) 2-1-7k (48%) 2-1-7l (35%)
2-1-7m (28%) 2-1-7n (24%) 2-1-7o (19%) 2-1-7p (17%)  
To illustrate the structure of xanthine derivatives, an X-ray structure of compound 2-1-7h was 








Figure 2-4 X-Ray Structure of 2-1-7h 
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2.2.2 Traceless solid-phase synthesis of substituted xanthines 
2.2.2.1 Solution-phase synthesis of substituted xanthines 


























































2.2.2.1.1 Synthesis of benzyl N-butyl glycinate (2-2-10) 
To begin our investigation, we had to prepare benzyl N-substituted glycinate 2-2-10 which 
was initially achieved by coupling benzyl alcohol 2-1-8 with Fmoc-glycine followed by 
Fmoc-deprotection and reductive amination or alkylation (Scheme 2-7). The yield obtained 
was only 30% which was unacceptable for application in solid-phase synthesis. 




















Further experimentation showed that 2-2-10 could be obtained more expediently and in better 
yields by reacting 2-2-8 with bromoacetic acid to give 2-2-9 which, in turn, could be 
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efficiently treated with butylamine in THF to provide 2-2-10 in 75% overall yield. Good 
yields can also be achieved by reacting 2-2-9 with benzylamine and methylamine. 
2.2.2.1.2 Synthesis of benzyl 2-(N-butyl-N'-cyanoformamidino)acetate (2-2-11) 
Treatment of 2-2-10 with ethoxymethylene cyanamide gave intermediate 2-2-11 which upon 
reaction with NaOEt in anhydrous EtOH underwent rapid imidazole ring formation.6 
However 1H NMR data of the product obtained showed that the benzyl group had been 
replaced by an ethyl moiety (Scheme 2-8) which meant the procedure could not be applied to 
a solid-phase format. Attempts to lower the reaction temperature to 0 °C did not prevent the 
loss of the benzyl moiety and at -30 °C, the cyclization reaction ceased to proceed.  




























To effect the formation of 2-2-12, we eventually replaced NaOEt/EtOH with KOtBu/tBuOH 
which also provided a rapid imidazole ring formation but without displacement of the benzyl 
group. Due to the EtOH formation during the reaction from 2-2-10 to 2-2-11, it was 
impossible to carry out these two steps in one pot as demonstrated in our solution-phase study 





2.2.2.1.3 Synthesis of benzyl 2-(N-butyl-N'-cyanoacetamidino)acetate (2-2-11a) and 
benzyl 2-(N-butyl-N'-cyanobenzamidino)acetate (2-2-11b) 
To increase the diversity of substituents at the C8 position, benzyl N-methyl glycinate (2-2-
10a), was treated with methyl ethoxymethylene cyanamide or phenyl ethoxymethylene 
cyanamide. Unlike the reaction of 2-2-10 with ethoxymethylene cyanamide, which occurred 
very rapidly in either EtOH, THF or DMF without any other reagents or catalysts, these 
reactions only proceeded in the presence of base (Schemes 2-9 and 2-10, Table 2-4). Various 
conditions were tested to improve the yield and it was found that DBU was a better base for 
this reaction than DIEA. 



















Table 2-4 Synthesis of 2-2-11a 
Entry Base Solvent Conditions Result 
1 None THF rt, 24 h No reaction 
2 None THF reflux, 24 h Trace product 
3 DIEA THF rt, 2.5 h 20% yield 
4 DIEA THF rt, 24 h 48% yield 

























2.2.2.1.4 Synthesis of benzyl 5-amino-3-butyl-3H-imidazole-4-carboxylate (2-2-12) 
As ethoxide is able to attack the ester group of 2-2-11 easily, we reasoned that a bulky 
alkoxide must be used to avoid such a reaction from occurring. Hence KOtBu/tBuOH was 
tried, and we found that the reaction was completed in 30 min to give 2-2-12 in moderate 
yield (52%). 
2.2.2.1.5 Synthesis of benzyl 3-butyl-5-(3-hexylureido)-3H-imidazole-4-carboxylate (2-2-
13) and 7-butyl-1-hexylxanthine (2-2-7a) 
With 2-2-12 in hand, we proceeded to treat it with hexyl isocyanate which provided 2-2-13 in 
90% yield. Subsequent ring closure of 2-2-13 with NaOEt in MeOH-THF mixture afforded 2-










2.2.2.2 Traceless solid-phase synthesis of substituted xanthines 























































1. NaOEt, THF       
    MeOH
2. R4X, DIEA          




With the solution-phase pathway established, we proceeded to prove the applicability of this 
methodology in solid-phase synthesis (Scheme 2-11). 
Wang resin 2-2-1 in DCC/DMAP/DMF was allowed to react with bromoacetic acid at rt. The 
formation of 2-2-2 was amenable to KBr FTIR monitoring (i.e. disappearance of the OH 
stretch at 3566 cm-1 and the appearance of a strong C=O stretch at 1744 cm-1). Resin 2-2-2 
was then treated with various primary amines in THF to give 2-2-3, which was subsequently 
reacted with ethoxymethylene cyanamide, methyl ethoxymethylene cyanamide or phenyl 
ethoxymethylene cyanamide in the presence of DBU, to provide resin 2-2-4.  Due to the poor 
swelling ability of polystyrene/1% divinylbenzene in tBuOH, cyclization of 2-2-4 using 
KOtBu was carried out in a DMF/tBuOH (v/v 1:1) mixture. The disappearance of the CN 
stretch at 2178 cm-1 and the shift of the C=O stretch from 1744 cm-1 to 1690 cm-1 were 
indicative of the formation of 2-2-5.  Treatment of 2-2-5 with various isocyanates in o-xylene 
(120-125 °C, 24 h) provided 2-2-6, which underwent a concomitant cyclization-cleavage in 
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NaOEt in MeOH/THF (v/v 1:2) to give 1,7- or 1,7,8- substituted xanthines which was 
subsequently alkylated in an one-pot reaction to afford the fully-substituted xanthines. To 
illustrate the versatility of this chemistry, a representative set of 22 compounds (2-2-7a - 2-2-
7v) was prepared (Figure 2-5). The overall yields obtained were 14-35% (purities of > 95% 
by NMR) for compounds 2-2-7a - 2-2-7t, indicating an average yield of ≥ 75% for each step 
of the solid-phase reaction. However for compounds 2-2-7u and 2-2-7v, where the C8 
substituent is a phenyl group, lower yields were obtained. 



























































































































2-2-7b (35%)2-2-7a (35%) 2-2-7c (34%) 2-2-7d (29%)
2-2-7h (27%)2-2-7f (30%)2-2-7e (25%) 2-2-7g (23%)
2-2-7k (20%) 2-2-7l (19%)



































2-2-7v (6%)  
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2.3 Conclusion 
These studies investigated the methodologies for the solid-phase synthesis of xanthines. Two 
solution-phase synthetic routes were successfully carried out to obtain the required reaction 
conditions which would be adaptable to solid-phase reactions. Eventually two solid-phase 
synthetic routes to xanthines were developed.  
2.4 Experimental 
Wang resin was purchased from Tianjin Nankai Hecheng Science and Technology Co (100-
200 mesh, 1.4 mmol/g, 1% divinylbenzene cross-linking). All other chemical reagents were 
obtained from Aldrich, Merck, Lancaster or Fluka and used without further purification. The 
solid-phase rt reactions were agitated on a SF1 flask shaker (Stuart Scientific). Analytical 
TLC was carried out on pre-coated plates (Merck silica gel 60, F254) and visualized with UV 
light or stained with ninhydrin. CC was performed with silica (Merck, 70-230 mesh). 1H 
NMR and 13C NMR spectra were measured at 298 K on a Bruker DPX 300 or DPX 500 
Fourier Transform spectrometer. Chemical shifts are reported in δ (ppm), relative to the 
internal standard of TMS. The signals observed are described as: s, d, t, q, m. The number of 
protons (n) for a given resonance is indicated as nH. All Infra-red spectra were recorded on a 
Bio-Rad FTS 165 spectrometer. Mass spectra were performed on VG Micromass 7035 
spectrometer under EI, Finnigan/MAT LCQ under ESI (Normal), and Finnigan/MAT 95XL-T 
under ESI (Accurate). 
2.4.1 Solid-phase synthesis of 1,3-substituted xanthines 
2.4.1.1 Synthesis of ethyl N-(2,4-dimethoxybenzyl) glycinate (2-1-8) 
To 2,4-dimethoxylbenzaldehyde (0.1660 g, 1 mmol) in DMF (5 mL) was added ethyl 
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glycinate hydrochloride (0.2790 g, 2 mmol) and triethylamine (0.2780 mL, 2 mmol). The 
mixture was stirred for 5 min and sodium triacetoxyborohydride (0.4240 g, 2 mmol) and 
HOAc (0.1 mL) were added. After that, the reaction mixture was stirred at rt for another 8 h. 
The reaction was quenched with saturated NaHCO3 and concentrated. The residue obtained 
was diluted with water (50 mL), and extracted with EtOAc (50 mL x 3). The combined 
organic layer was dried with MgSO4, filtered, concentrated and purified by CC 
(EtOAc:hexane = 4:1, then MeOH:CH2Cl2 = 1:7) to give 2-1-8 as a colorless liquid (0.2400 g, 
95% yield). 1H NMR (CDCl3): δ 7.12-7.09 (d, J = 7.7 Hz, ArH, 1H), 6.44-6.39 (m, ArH, 2H), 
4.18-4.10 (q, J = 7.1 Hz, CH3CH2, 2H), 3.80 (s, ArOCH3, 3H), 3.78 (s, ArOCH3, 3H), 3.73 (s, 
ArCH2, 2H), 3.35 (s, NHCH2CO, 2H), 2.10 (s, NH, 1H), 1.27-1.22 (t, J = 7.1 Hz, CH3CH2, 
3H); 13C NMR (CDCl3): δ 172.2, 160.0, 158.4, 130.3, 119.8, 103.5, 98.2, 60.3, 55.0, 49.8, 
47.8, 13.9; Mass spectrum (EI) m/z 253.2 (M+) Exact mass calcd for C13H19NO4: m/z 
253.1314; found 253.1304. 
2.4.1.2 Synthesis of ethyl 5-amino-3-(2,4-dimethoxybenzyl)-3H-imidazole-4-carboxylate 
(2-1-10) 
Compound 2-1-8 (0.1226 g, 0.484 mmol) was dissolved in EtOH (5 mL) and the solution was 
cooled in a dry ice-acetone bath. Ethoxymethylene cyanamide (0.0520 g, 0.532 mmol) in 
EtOH (5 mL) was added dropwise, after which the dry ice-acetone bath was removed and the 
reaction mixture was stirred at rt for 2 h. The reaction mixture was subsequently cooled in a 
dry ice-acetone bath and NaOEt (21% (w/w) in denatured EtOH, 0.18 mL, 0.484 mmol) was 
then added. The reaction mixture was stirred at rt for another 20 h. After which, the mixture 
was concentrated and purified by CC (EtOAc:CH2Cl2 = 2:1) to give 2-1-10 as a colorless solid 
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(0.1030 g, 70% yield). 1H NMR (CDCl3): δ 7.18 (s, CH, 1H), 7.09-7.06 (d, J = 8.0 Hz, ArH, 
1H), 6.45-6.40 (m, ArH, 2H), 5.25 (s, ArCH2, 2H), 4.83 (s, NH2, 2H), 4.32-4.25 (q, J = 7.2 Hz, 
CH3CH2, 2H), 3.81 (s, ArOCH3, 3H), 3.79 (s, ArOCH3, 3H), 1.34-1.29 (t, J = 7.1 Hz, CH3CH2, 
3H); 13C NMR (CDCl3): δ 161.1, 161.0, 158.2, 155.4, 139.5, 130.3, 117.1, 104.2, 102.0, 98.4, 
59.5, 55.3, 55.3, 45.5, 14.4; Mass spectrum (EI) m/z 305.0 (M+) Exact mass calcd for 
C15H19N3O4: m/z 305.1376; found 305.1377. 
2.4.1.3 Synthesis of ethyl 3-(2,4-dimethoxybenzyl)-5-(3-phenylureido)-3H-imidazole-4-
carboxylate (2-1-11) 
To 2-1-10 (0.1000 g, 0.328 mmol) was added o-xylene (6 mL), and phenyl isocyanate (0.12 
mL, 0.984 mmol) and the mixture was heated at 120 °C for 8 h. After which, the mixture was 
concentrated and purified by CC (EtOAc:hexane = 1:3) to give 2-1-11 as a colorless oil 
(0.1253 g, 90% yield). 1H NMR (CDCl3): δ 11.06 (s, ArNHCO, 1H), 8.08 (s, NH, 1H), 7.58-
7.55 (CH and ArH, 2H), 7.33-7.26 (m, ArH, 3H), 7.14-7.12 (d, J = 8.0 Hz, ArH, 1H), 7.05-
7.00 (t, J = 7.0 Hz, ArH, 1H), 6.46-6.42 (m, ArH, 2H), 5.32 (s, ArCH2, 2H), 4.40-4.33 (q, J = 
7.1 Hz, CH3CH2, 2H), 3.80 (s, ArOCH3, 3H), 3.78 (s, ArOCH3, 3H), 1.39-1.34 (t, J = 7.0 Hz, 
CH3CH2, 3H); 13C NMR (CDCl3): δ 161.3, 159.9, 158.3, 151.8, 147.2, 138.6, 137.7, 130.8, 
128.7, 122.9, 119.7, 115.7, 104.3, 103.8, 98.5, 60.5, 55.2, 45.9, 14.3; Mass spectrum (EI) m/z 
424.0 (M+) Exact mass calcd for C22H24N4O5: m/z 424.1747; found 424.1739. 
2.4.1.4 Synthesis of 7-(2,4-dimethoxybenzyl)-1-phenylxanthine (2-1-12) 
To 2-1-11 (0.1920 g, 0.450 mmol) in MeOH (6 mL) was added NaOEt (21% (w/w) in 
denatured EtOH, 0.5 mL, 1.360 mmol). The mixture was refluxed for 2 h, after which the 
mixture was concentrated and the resulting residue was diluted with water (10 mL) and 
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acidified with 1.5 M HCl. The white precipitate which formed was filtered, washed with 
water and dried to give 2-1-12 as a white power (0.1702 g, 100% yield). 1H NMR (DMSO-d6): 
δ 11.96 (s, NH, 1H), 7.95 (s, CH, 1H), 7.48-7.36 (m, ArH, 3H), 7.24-7.22 (d, J = 7.0 Hz, ArH, 
2H), 7.14-7.12 (d, J = 8.3 Hz, ArH, 1H), 6.57-6.45 (m, ArH, 2H), 5.28 (s, ArCH2, 2H), 3.81 (s, 
ArOCH3, 3H), 3.73 (s, ArOCH3, 3H); 13C NMR (DMSO-d6): δ 160.7, 158.1, 155.0, 150.9, 
148.0, 143.1, 135.8, 130.3, 129.3, 128.6, 127.8, 116.4, 106.1, 104.6, 98.4, 55.4, 55.2, 44.3, 
40.3; Mass spectrum (EI) m/z 378.2 (M+) Exact mass calcd for C20H18N4O4: m/z 378.1328; 
found 378.1339. 
2.4.1.5 Synthesis of 7-(2,4-dimethoxybenzyl)-3-methyl-1-phenylxanthine (2-1-13) 
To a mixture of 2-1-12 (0.0200 g, 0.0529 mmol) in DMF (3 mL) and DIEA (0.19 mL, 1.060 
mmol) was added MeI (0.033 mL, 0.529 mmol) dropwise. The reaction mixture was stirred 
for 1 h at rt and then concentrated. The resulting residue was purified by CC (MeOH:CH2Cl2 
= 1:7) to give 2-1-13 as a white solid (0.0199 g, 96% yield). 1H NMR (CDCl3): δ 7.71 (s, CH, 
1H), 7.54-7.41 (m, ArH, 4H), 7.27-7.24 (m, ArH, 2H), 6.45-6.41 (m, ArH, 2H), 5.40 (s, 
ArCH2, 2H), 3.85 (s, ArOCH3, 3H), 3.79 (s, ArOCH3, 3H), 3.58 (s, CH3, 3H); 13C NMR 
(CDCl3): δ 161.7, 158.6, 155.2, 151.7, 149.3, 142.1, 135.7, 132.3, 129.3, 128.8, 128.6, 116.0, 
107.1, 104.4, 98.6, 55.4, 45.2, 29.7; Mass spectrum (EI) m/z 392.0 (M+) Exact mass calcd for 
C21H20N4O4: m/z 392.1485; found 392.1482. 
2.4.1.6 Synthesis of 3-methyl-1-phenylxanthine (2-1-7b) 
A mixture of 2-1-13 (0.1000 g, 0.255 mmol), TFA (9 mL) and CH2Cl2 (1 mL) was refluxed 
for 1 h. The mixture was concentrated and purified by CC (MeOH:CH2Cl2 = 1:10) to give 2-
1-7b as a white solid (0.0555 g, 90% yield). 1H NMR (CDCl3): δ 12.41 (s, N7H, 1H), 7.52-
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7.42 (m, ArH and CH, 4H), 7.26-7.24 (d, J = 7.3 Hz, ArH, 2H), 3.64 (s, CH3, 3H); 13C NMR 
(CDCl3): δ 155.8, 151.6, 149.4, 140.6, 135.5, 129.4, 128.8, 128.7, 107.1, 30.3; Mass spectrum 
(EI) m/z 242.1  (M+) Exact mass calcd for C12H10N4O2: m/z 242.0804; found 242.0802. 
2.4.1.7 Preparation of ethyl N-(2-methoxy-4-phenoxybenzyl) glycinate resin (2-1-2) 
PS-MB-CHO resin 2-1-1 (3.000 g, 4.02 mmol) was placed in a dry 100 mL round bottom 
flask, ethyl glycinate hydrochlodride (1.6830 g, 12.06 mmol), DMF (30 mL) and TEA (1.68 
mL, 12.06 mmol) were added and the mixture was shaken at rt for 30 min. After which, 
sodium triacetoxyborohydride (2.5560 g, 12.06 mmol) and HOAc (0.3 mL) were added and 
the reaction mixture was shaken at rt for another 24 h. The reaction was quenched with 
saturated NaHCO3, filtered and washed with DMF (20 mL x 3), H2O (20 mL x 3), EtOH (20 
mL x 3), CH2Cl2 (20 mL x 3) and Et2O (20 mL x 3). The resin was then dried overnight at 50 
°C in a vacuum oven. 
2.4.1.8 Preparation of ethyl 4-amino-1-(2-methoxy-4-phenoxybenzyl)-imidazole-5-
carboxylate resin (2-1-3) 
To a stirring suspension of 2-1-2 (3.325 g, 4.02 mmol) in DMF (52.8 mL) and EtOH (80 mL) 
was cooled in a dry ice-actone bath. A solution of ethoxymethylene cyanamide (0.7880 g, 
8.04 mmol) in anhydrous EtOH (25 mL) was added dropwise and the mixture was shaken at 
rt for 24 h. After which, the reaction mixture was cooled in a dry ice-acetone bath again and 
NaOEt (21% (w/w) in denatured EtOH, 3 mL, 8.04 mmol) was added dropwise. The mixture 
was shaken at rt for another 24 h. The resin was filtered, washed with DMF (20 mL x 3), H2O 
(20 mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 mL x 3), Et2O (20 mL x 3) and dried overnight at 
50 °C in a vacuum oven. 
 42
 
2.4.1.9 Preparation of ethyl 4-(3-substitutedureido)-1-(2-methoxy-4-phenoxybenzyl)-
imidazole-5-carboxylate resin (2-1-4) 
Resin 2-1-3 (0.3000 g, 0.3386 mmol), isocyanates (5 equiv), and o-xylene (6 mL) were heated 
at 120 °C for 24 h. The resin was then filtered, washed with EtOH (20 mL x 3), CH2Cl2 (20 
mL x 3), Et2O (20 mL x 3) and dried overnight at 50 °C in vacuum oven. 
2.4.1.10 Preparation of 1-substituted-7-(2-methoxy-4-phenoxybenzyl)xanthine resin (2-1-
5) 
A mixture of resin 2-1-4 (0.3300 g, 0.3386 mmol), NaOEt (21% (w/w) in denatured EtOH, 
0.8 mL, 5 equiv), anhydrous THF (5 mL) and anhydrous MeOH (15 mL) was refluxed for 12 
h. The resin was then filtered, acidified with 1.5 M HCl, washed with H2O (20 mL x 3), EtOH 
(20 mL x 3), CH2Cl2 (20 mL x 3) and dried overnight at 50 °C in a vacuum oven. 
2.4.1.11 Preparation of 1,3-substituted-7-(2-methoxy-4-phenoxybenzyl)xanthine resin (2-
1-6) 
Resin 2-1-5 (0.3300 g, 0.3386 mmol) was swelled in DMF (6 mL). DIEA (1.2 mL, 20 equiv) 
and the respective halide (10 equiv) were added and the mixture was shaken at rt for 24 h. 
After which, the resin was filtered, washed with DMF (20 mL x 3), H2O (20 mL x 3), EtOH 
(20 mL x 3), CH2Cl2 (20 mL x 3), Et2O (20 mL x 3) and dried overnight at  50  °C in vacuum 
oven. 
2.4.1.12 Preparation of 1,3-substituted xanthine (2-1-7a - 2-1-7l) 
A mixture of resin 2-1-6 (0.3400 g, 0.3386 mmol), TFA (9 mL) and CH2Cl2 (1 mL) was 
shaken at rt for 12 h. The resin was then filtered and washed with MeOH (20 mL x 3) and 
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CH2Cl2 (20 mL x 3). The combined filtrate was concentrated and the residue was purified by 
CC (EtOAc:CH2Cl2 = 1.5:1) to give xanthine 2-1-7. 
2.4.1.13 Preparation of 1-substituted thioxanthine (2-1-7m - 2-1-7p) 
A mixture of resin 2-1-6 (0.3600 g, 0.3386 mmol), TFA (9 mL) and CH2Cl2 (1 mL) was 
shaken at rt for 12 h. After which, the resin was filtered and washed with MeOH (20 mL x 3) 
and CH2Cl2 (20 mL x 3). The resulting resin was then refluxed with HOAc (8 mL, 140 mmol) 
for 24 h. After which, the resin was filtered and washed with MeOH (20 mL x 3) and CH2Cl2 
(20 mL x 3). The combined filtrate was concentrated to dryness and the solid obtained was 
washed with cold EtOAc to give thioxanthine 2-1-7. 
2-1-7a: 1-Phenylxanthine. 1H NMR (DMSO-d6): δ 13.48 (s, N3H, 1H), 11.95 (s, N7H, 1H), 
8.01 (s, CH, 1H), 7.48-7.37 (m, ArH, 3H), 7.27-7.24 (d, J = 7.3 Hz, ArH, 2H); 13C NMR 
(DMSO-d6): δ 155.1, 151.1, 147.7, 140.9, 136.2, 129.3, 128.7, 127.8, 106.5; Mass spectrum 
(EI) m/z 228.2 (M+) Exact mass calcd for C11H8N4O2: m/z 228.0647; found 228.0644. 
2-1-7c: 3-Benzyl-1-phenylxanthine. 1H NMR (CDCl3): δ 12.29 (s, N7H, 1H), 7.57-7.39 (m, 
CH and ArH, 6H), 7.33-7.22 (m, ArH, 5H), 5.31 (s, ArCH2, 2H); 13C NMR (CDCl3): δ 155.9, 
151.3, 149.2, 140.5, 136.1, 135.4, 129.4, 129.0, 128.8, 128.7, 128.5, 128.0, 107.2, 47.2; Mass 
spectrum (EI) m/z 318.0 (M+) Exact mass calcd for C18H14N4O2: m/z 318.1117; found 
318.1111. 
2-1-7d: 1-Phenyl-3-propargylxanthine. 1H NMR (CD3OD): δ 8.00 (s, CH, 1H), 7.53-7.42 
(m, ArH, 3H), 7.29-7.26 (d, J = 7.0 Hz, ArH, 2H), 4.89-4.88 (d, J = 2.4 Hz, N3CH2, 2H), 
2.71-2.69 (t, J = 2.3 Hz, CH2CCH, 1H); 13C NMR (CD3OD): δ 156.3, 152.6, 149.0, 142.0, 
137.1, 130.3, 130.1, 129.7, 108.9, 78.6, 73.3, 33.9; Mass spectrum (EI) m/z 266.0 (M+) Exact 
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mass calcd for C14H10N4O2: m/z 266.0804; found 266.0805. 
2-1-7e: 1-Allylxanthine. 1H NMR (CD3OD): δ 7.88 (s, CH, 1H), 5.98-5.85 (m, CH2CHCH2, 
1H), 5.20-5.11 (m, CH2CHCH2, 2H), 4.58-4.55 (m, N1CH2, 2H); 13C NMR (CD3OD): δ 
156.97, 153.2, 148.4, 141.7, 133.7, 117.2, 108.6, 43.6; Mass spectrum (EI) m/z 192.0 (M+) 
Exact mass calcd for C8H8N4O2: m/z 192.0647; found 192.0648. 
2-1-7f: 1-Allyl-3-methylxanthine. 1H NMR (CDCl3): δ 13.02 (s, NH, 1H), 7.82 (s, CH, 1H), 
6.00-5.87 (m, CH2CHCH2, 1H), 5.29-5.18 (m, CH2CHCH2, 2H), 4.71-4.69 (d, J = 5.6 Hz, 
N1CH2, 2H), 3.65 (s, CH3, 3H); 13C NMR (CDCl3): δ 155.9, 151.0, 149.2, 140.4, 132.0, 117.7, 
106.9, 43.8, 30.2; Mass spectrum (EI) m/z 206.2 (M+) Exact mass calcd for C9H10N4O2: m/z 
206.0804; found 206.0808. 
2-1-7g: 1-Allyl-3-benzylxanthine. 1H NMR (CDCl3): δ 7.93 (s, CH, 1H), 7.40-7.24 (m, ArH, 
5H), 5.97-5.84 (m, CH2CHCH2, 1H), 5.29 (s, ArCH2, 2H), 5.17∼5.11 (m, CH2, 2H), 4.61-4.59 
(d, J = 5.2 Hz, N1CH2, 2H); 13C NMR (CDCl3): δ 155.7, 150.9, 148.8, 140.1, 136.3, 132.1, 
128.7, 128.6, 127.9, 117.9, 107.0, 47.1, 43.8; Mass spectrum (EI) m/z 282.2 (M+) Exact mass 
calcd for C15H14N4O2: m/z 282.1117; found 282.1118. 
2-1-7h: 1-Allyl-3-propargylxanthine. 1H NMR (CDCl3): δ 12.75 (s, NH, 1H), 7.87 (s, CH, 
1H), 6.01-5.88 (m, CH2CHCH2, 1H), 5.32-5.20 (m, CH2CHCH2, 2H), 4.95-4.95 (d, J = 2.5 
Hz, N3CH2, 2H), 4.72-4.70 (d, J = 5.9 Hz, N1CH2, 2H), 2.29-2.27 (t, J = 2.5 Hz, CH2CCH, 
1H); 13C NMR (CDCl3): δ 155.7, 150.2, 147.9, 140.5, 131.8, 118.0, 116.2, 107.1, 72.1, 43.9, 
33.0; Mass spectrum (EI) m/z 230.0 (M+) Exact mass calcd for C11H10N4O2: m/z 230.0804; 
found 230.0802. 
2-1-7i: 1-Benzylxanthine. 1H NMR (DMSO-d6): δ 13.43 (s, N3H, 1H), 11.93 (s, N7H, 1H), 
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7.99 (s, CH, 1H), 7.29-7.22 (m, ArH, 5H), 5.03 (s, ArCH2, 2H); 13C NMR (DMSO-d6): δ 
154.9, 151.0, 147.3, 141.0, 137.8, 128.2, 127.2, 126.8, 106.1, 42.9; Mass spectrum (EI) m/z 
242.0 (M+) Exact mass calcd for C12H10N4O2: m/z 242.0804; found 242.0795. 
2-1-7j: 1-Benzyl-3-methylxanthine. 1H NMR (CDCl3): δ 7.70 (s, CH, 1H), 7.47-7.45 (d, J = 
6.6 Hz, ArH, 2H), 7.32-7.25 (m, ArH, 3H), 5.27 (s, ArCH2, 2H), 3.64 (s, CH3, 3H); 13C NMR 
(CDCl3): δ 156.1, 151.3, 149.1, 140.4, 137.0, 128.5, 128.4, 127.6, 106.9, 45.0, 30.3; Mass 
spectrum (EI) m/z 256.1 (M+) Exact mass calcd for C13H12N4O2: m/z 256.0960; found 
256.0961. 
2-1-7k: 1,3-Dibenzylxanthine. 1H NMR (CDCl3): δ 12.78 (s, NH, 1H), 7.65 (s, CH, 1H), 
7.49-7.43 (m, ArH, 4H), 7.31-7.25 (m, ArH, 6 H), 5.32 (s, N1CH2, 2H), 5.27 (s, N3CH2, 2H); 
13C NMR (CDCl3): δ 156.2, 151.2, 148.9, 140.4, 137.0, 136.2, 128.5, 128.5, 128.4, 127.9, 
127.6, 107.0, 47.1, 45.1; Mass spectrum (EI) m/z 332.0 (M+) Exact mass calcd for 
C19H16N4O2: m/z 332.1273; found 332.1276. 
2-1-7l: 1-Benzyl-3-propargylxanthine. 1H NMR (CDCl3): δ 12.71 (s, NH, 1H), δ 7.75 (s, 
CH, 1H), δ 7.48-7.46 (d, J = 6.6 Hz, ArH, 2H), δ 7.34-7.24 (m, ArH, 3H), δ 5.28 (s, ArCH2, 
2H), δ 4.94-4.93 (d, J = 2.4 Hz, N3CH2, 2H), δ 2.28-2.27 (t, J = 2.4 Hz, CH2CCH, 1H); 13C 
NMR (CDCl3): δ 156.1, 150.6, 148.0, 140.5, 136.8, 128.7, 128.5, 127.8, 107.1, 77.4, 72.1, 
45.2, 33.1; Mass spectrum (EI) m/z 280.1 (M+) Exact mass calcd for C15H12N4O2: m/z 
280.0960; found 280.0958. 
2-1-7m: 1-Propyl-2-thioxanthine. 1H NMR (DMSO-d6): δ 13.65 (s, N3H, 1H), 13.49 (s, 
N7H, 1H), 8.09 (s, CH, 1H), 4.36-4.31 (t, J = 7.7 Hz, N1CH2, 2H), 1.71-1.63 (m, 
CH3CH2CH2, 2H), 0.91-0.87 (t, J = 7.3 Hz, CH3, 3H); 13C NMR (DMSO-d6): δ 173.9, 153.4, 
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147.2, 142.0, 109.8, 47.1, 19.7, 11.1; Mass spectrum (EI) m/z 210.0 (M+) Exact mass calcd 
for C8H10N4OS: m/z 210.0575; found 210.0570. 
2-1-7n: 1-Ethyl-2-thioxanthine. 1H NMR (DMSO-d6): δ 13.67 (s, N3H, 1H), 13.51 (s, N7H, 
1H), 8.11 (s, CH, 1H), 4.48-4.42 (q, J = 6.9 Hz, CH3CH2, 2H), 1.22-1.18 (t, J = 6.9 Hz, 
CH3CH2, 3H); 13C NMR (DMSO-d6): δ 173.6, 153.1, 147.2, 142.0, 109.0, 41.0, 12.0; Mass 
spectrum (EI) m/z 196.0 (M+) Exact mass calcd for C7H8N4OS: m/z 196.0419; found 
196.0412. 
2-1-7o: 1-Benzyl-2-thioxanthine. 1H NMR (DMSO-d6): δ 13.66 (s, N3H, 2H), 8.14 (s, CH, 
1H), 7.31-7.21 (m, ArH, 5H), 5.66 (s, ArCH2, 2H); 13C NMR (DMSO-d6): δ 174.5, 153.4, 
147.3, 142.2, 136.8, 128.1, 126.9, 126.7, 109.9, 48.6; Mass spectrum (EI) m/z 258.2 (M+) 
Exact mass calcd for C12H10N4OS: m/z 258.0575; found 258.0576. 
2-1-7p: 1-Phenyl-2-thioxanthine. 1H NMR (DMSO-d6): δ 14.15 (s, N3H, 1H), 8.66 (s, CH, 
1H), 8.00-7.89 (m, ArH, 3H), 7.73-7.71 (d, J = 7.3 Hz, ArH, 2H); 13C NMR (DMSO-d6): δ 
174.8, 153.3, 147.2, 141.4, 139.2, 128.7, 128.3, 127.3, 110.3; Mass spectrum (EI) m/z 244.1 
(M+) Exact mass calcd for C11H8N4OS: m/z 244.0419; found 244.0409. 
2.4.2 Traceless solid-phase synthesis of substituted xanthines 
2.4.2.1 Synthesis of benzyl bromoacetate (2-2-9) 
To benzyl alcohol 2-2-8 (0.2000 g, 1.849 mmol) in DMF (5 mL) was add bromoacetic acid 
(0.5131 g, 3.698 mmol), DCC (0.7630 g, 3.698 mmol) and DMAP (0.0677 g, 0.5547 mmol) 
in the stated order. The reaction mixture was stirred at rt for 2 h, then quenched with water (50 
mL) and extracted with EtOAc (50 mL x 3). The combined organic layer was dried with 
MgSO4, filtered, concentrated and purified by CC (EtOAc:hexane = 1:20) to give 2-2-9 as a 
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pale yellow liquid (0.4201 g, 99% yield). 1H NMR (CDCl3): δ 7.41-736 (m, ArH, 5H), 5.21 (s, 
ArCH2, 2H), 3.87 (s, CH2Br, 2H); 13C NMR (CDCl3): δ 166.8, 134.8, 128.4, 128.4, 128.2, 
67.7, 25.7; Mass spectrum (EI) m/z 227.8 (M+) Exact mass calcd for C9H9BrO2: m/z 227.9786; 
found 227.9790. 
2.4.2.2 Synthesis of benzyl N-butyl glycinate (2-2-10) 
Compound 2-2-9 (0.5031 g, 2.20 mmol) was dissolved in THF (25 mL) and the solution was 
cooled in an ice-water bath. Butylamine (0.3213 g, 4.40 mmol) was diluted in THF (25 mL) 
and the solution was added to 2-2-9 dropwise. After which, the ice-water bath was removed 
and the reaction mixture was stirred at rt for 2 h. This mixture was concentrated and purified 
by CC (EtOAc:hexane = 1:3 then MeOH:CH2Cl2 = 1:20) to give 2-2-10 as a colorless liquid 
(0.3702 g, 76% yield). 1H NMR (CDCl3): δ 7.35 (s, ArH, 5H), 5.16 (s, ArCH2, 2H), 3.45 (s, 
COCH2NH, 2H), 2.62-2.57 (t, J = 6.96 Hz, NHCH2CH2CH2CH3, 2H), 1.99 (s, NH, 1H), 1.52-
1.42 (m, NHCH2CH2CH2CH3, 2H), 1.40-1.28 (m, NHCH2CH2CH2CH3, 2H), 0.93-0.88 (t, J = 
7.14 Hz, NHCH2CH2CH2CH3, 3H); 13C NMR (CDCl3, 500 MHz): δ 172.3, 135.5, 128.4, 
128.2, 128.2, 66.3, 50.8, 49.1, 32.0, 20.2, 13.8; Mass spectrum (EI) m/z 221.1 (M+) Exact 
mass calcd for C13H19NO2: m/z 221.1416; found 221.1408. 
2.4.2.3 Synthesis of benzyl 2-(N-butyl-N'-cyanoformamidino)acetate (2-2-11) 
Compound 2-2-10 (0.1362 g, 0.6155 mmol) in THF (3 mL) was cooled in an ice-water bath 
and ethoxymethylene cyanamide (0.1207 g, 1.231 mmol) in THF (3 mL) was added dropwise. 
The reaction mixture was stirred at rt for 2 h. The mixture was concentrated and purified by 
CC (EtOAc:hexane = 1:1) to obtain 2-2-11 as a colorless liquid (0.1649 g, 98% yield). 1H 
NMR (CDCl3): δ 8.13 (s, CH, 1H), 7.37-7.32 (m, ArH, 5H), 5.17 (s, ArCH2, 2H), 4.14 (s, 
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COCH2N, 2H), 3.39-3.34 (t, J = 7.31 Hz, NCH2CH2CH2CH3, 2H), 1.60-1.50 (m, 
NCH2CH2CH2CH3, 2H), 1.36-1.24 (m, NCH2CH2CH2CH3, 2H), 0.93-0.89 (t, J = 7.40 Hz, 
CH2CH2CH2CH3, 3H);  13C NMR (CDCl3): δ 166.6, 163.9, 134.6, 128.3, 128.2, 127.9, 117.5, 
67.1, 52.8, 46.7, 29.6, 19.1, 13.2; Mass spectrum (EI) m/z 273.0 (M+) Exact mass calcd for 
C15H19N3O2: m/z 273.1477; found 273.1475. 
2.4.2.4 Synthesis of benzyl 5-amino-3-butyl-3H-imidazole-4-carboxylate (2-2-12) 
To 2-2-11 (0.1500 g, 0.5488 mmol) in THF (5 mL) was added tBuOH (5 mL) and KOtBu 
(0.0616 g, 1.0976 mmol) and the reaction mixture was stirred for 1 h. After which, the 
reaction mixture was quenched with NH4Cl, diluted with H2O (30 mL) and extracted with 
CH2Cl2 (30 mL x 3). The combined organic layer was dried with MgSO4, filtered, 
concentrated and purified by CC (EtOAc:CH2Cl2 = 2:1) to give a colorless solid 2-2-12 
(0.0757 g, 52% yield). 1H NMR (CDCl3): δ 7.33-7.21 (m, ArH, 5H), 7.09 (s, CH, 1H), 5.20 (s, 
ArCH2, 2H), 4.70 (s, NH2, 2H), 4.00-3.95 (t, J = 7.13 Hz, NCH2CH2CH2CH3, 2H), 1.63-1.53 
(m, NCH2CH2CH2CH3, 2H), 1.20-1.08 (m, NCH2CH2CH2CH3, 2H), 0.80-0.76 (t, J = 7.31 Hz, 
NCH2CH2CH2CH3, 3H);  13C NMR (CDCl3): δ 160.5, 155.8, 138.8, 136.0, 128.5, 128.1, 
128.1, 101.1, 65.4, 47.2, 32.7, 19.4, 13.4; Mass spectrum (EI) m/z 273.1 (M+) Exact mass 
calcd for C15H19N3O2: m/z 273.1477; found 273.1473. 
2.4.2.5 Synthesis of benzyl 3-butyl-5-(3-hexylureido)-3H-imidazole-4-carboxylate (2-2-13) 
To a solution of 2-2-12 (0.0814 g, 0.298 mmol) in o-xylene (7 mL) was added hexyl 
isocyanate (0.1895 g, 1.49 mmol) and the reaction mixture was heated at 120 °C for 8 h. After 
which, the resulting mixture was concentrated and purified by CC (EtOAc:hexane = 1:3 then 
EtOAc:hexane = 1:1) to give 2-2-13 (0.1133 g, 90% yield) as a white solid. 1H NMR (CDCl3): 
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δ 8.66 (s, C6H13NHCONH, 1H), 8.04 (s, C6H13NHCONH, 1H), 7.43-7.28 (m, CH and ArH, 
6H), 5.34 (s, ArCH2, 2H), 4.17-4.12 (t, J = 7.14 Hz, NCH2CH2CH2CH3, 2H), 3.35-3.28 (q, J 
= 6.50 Hz, NHCH2CH2CH2CH2CH2CH3, 2H), 1.73-1.52 (m, NHCH2CH2CH2CH2CH2CH3 
and NCH2CH2CH2CH3, 4H), 1.31-1.17 (m, NHCH2CH2CH2CH2CH2CH3 and 
NCH2CH2CH2CH3, 8H), 0.90-0.85 (m, NHCH2CH2CH2CH2CH2CH3 and NCH2CH2CH2CH3, 
6H);  13C NMR (CDCl3): δ 159.7, 154.6, 148.5, 137.2, 135.4, 128.8, 128.6, 128.5, 103.1, 66.3, 
47.8, 40.1, 32.9, 31.5, 29.9, 26.7, 22.5, 19.6, 14.0, 13.5; Mass spectrum (EI) m/z 400.1 (M+) 
Exact mass calcd for C22H32N4O3: m/z 400.2474; found 400.2471. 
2.4.2.6 Synthesis of 7-butyl-1-hexylxanthine (2-2-7a) 
THF (6 mL), MeOH (3 mL), followed by NaOEt (21% (w/w) in denatured EtOH, 0.32 mL, 
0.849 mmol) were added to 2-2-13 (0.1133 g, 0.283 mmol). The mixture was refluxed at 90 
°C for 1h. Subsequently, the mixture was concentrated and water (10 mL) was added. The 
precipitate that formed was removed after filtration. To the filtrate was added 1.5 M HCl acid 
dropwise till the pH < 6 and the precipitate that formed was collected and washed with cold 
water to give 2-2-7a as a white solid (0.0744 g, 90% yield). 1H NMR (Acetone-d6): δ 10.83 (s, 
NH, 1H), 7.87 (s, CH, 1H), 4.35-4.30 (t, J = 7.07 Hz, NCH2CH2CH2CH2CH2CH3, 2H), 3.94-
3.89 (t, J = 7.47 Hz, NCH2CH2CH2CH3, 2H), 1.89-1.80 (m, NCH2CH2CH2CH2CH2CH3, 2H), 
1.63-1.58 (m, NCH2CH2CH2CH3, 2H), 1.43-1.29 (m, NCH2CH2CH2CH2CH2CH3 and 
NCH2CH2CH2CH3, 8H), 0.95-0.86 (m, CH2CH2CH2CH2CH2CH3 and CH2CH2CH2CH3, 6H); 
13C NMR (CDCl3): δ 156.8, 152.5, 149.3, 143.6, 108.0, 47.7, 41.5, 34.3, 32.9, 29.4, 28.0, 23.9, 
20.8, 14.9, 14.5; Mass spectrum (EI) m/z 292.2 (M+) Exact mass calcd for C15H24N4O2: m/z 
292.1899; found 292.1901. 
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2.4.2.7 Preparation of benzyl bromoacetate resin (2-2-2) 
Wang resin (2-2-1) (2 g, 2.8 mmol) was swollen in DMF (15 mL) for 30 min. Bromoacetic 
acid (0.7781 g, 5.6 mmol), DCC (1.1554 g, 5.6 mmol), DMAP (0.103 g, 0.84 mmol) were 
added in the stated order. The reaction mixture was shaken at rt for 5 h. After which, the resin 
was filtered, washed with DMF (20 mL x 3), H2O (20 mL x 3), EtOH (20 mL x 3), CH2Cl2 
(20 mL x 3), Et2O (20 mL x 3) and dried overnight at 50 °C in a vacuum oven. 
2.4.2.8 Preparation of benzyl N-substituted glycinate resin (2-2-3) 
Resin 2-2-2 (2.8516 g, 2.8 mmol) was swollen in THF (30 mL) for 30 min and then cooled in 
an ice-water bath. The respective primary amine (3 equiv) diluted in THF (25 mL) was added 
dropwise. After which the water bath was removed and the reaction mixture was shaken at rt 
for 12 h. The resin were then filtered and washed with DMF (20 mL x 3), H2O (20 mL x 3), 
EtOH (20 mL x 3), CH2Cl2 (20 mL x 3), Et2O (20 mL x 3) and dried overnight at 50 °C in a 
vacuum oven. 
2.4.2.9 Preparation of benzyl 2-(N-substituted-N'-cyanoformamidino)acetate resin (2-2-4) 
Resin 2-2-3 (2.2698 g, 2.8 mmol) was swollen in THF (15 mL) for 30 min and then cooled in 
an ice-water bath. Ethoxymethylene cyanamide (0.8236 g, 8.4 mmol) in THF (15 mL) was 
added dropwise and the reaction mixture was shaken at rt for 12 h. After which, the resin was 
filtered and washed with DMF (20 mL x 3), H2O (20 mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 
mL x 3), Et2O (20 mL x 3) and dried overnight at 50 °C in a vacuum oven. 
2.4.2.10 Preparation of benzyl 2-(N-substituted-N'-cyanoacetamidino)acetate resin (2-2-
4) (R2=CH3) 
Resin 2-2-3 (2.2551 g, 2.8 mmol) was swollen in THF (20 mL) for 30 min and then cooled in 
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an ice-water bath. DBU (1.066 g, 14 mmol) was added followed by dropwise addition of 
methyl ethoxymethylene cyanamide (0.9416 g, 8.4 mmol) in THF (15 mL). After which, the 
reaction mixture was shaken at rt for 12 h. The resin was then filtered and washed with DMF 
(20 mL x 3), H2O (20 mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 mL x 3), Et2O (20 mL x 3) and 
dried overnight at 50 °C in a vacuum oven. 
2.4.2.11 Preparation of benzyl 2-(N-substituted-N'-cyanobenzamidino)acetate resin (2-2-
4) (R2=Ph) 
Resin 2-2-3 (2.2551 g, 2.8 mmol) was swollen in THF (20 mL) for 30 min and then cooled in 
an ice-water bath. DBU (1.066 g, 14 mmol) was added, followed by addition of phenyl 
ethoxymethylene cyanamide (1.463 g, 8.4 mmol) in THF (15 mL). After which, the reaction 
mixture was refluxed for 12 h. The resin was then filtered and washed with DMF (20 mL x 3), 
H2O (20 mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 mL x 3), Et2O (20 mL x 3) and dried 
overnight at 50 °C in a vacuum oven. 
2.4.2.12 Preparation of benzyl 5-amino-(3-substituted)-imidazole-4-carboxylate resin (2-
2-5) 
Resin 2-2-4 (2.2876 g, 2.8 mmol) was swollen in DMF (15 mL) for 30 min then cooled in an 
ice-water bath. KOtBu (0.6284 g, 5.6 mmol) in tBuOH (15 mL) was added and the reaction 
mixture was stirred at rt for 2 h. After which, the reaction mixture was quenched with NH4Cl 
and the resin were filtered, washed with DMF (20 mL x 3), H2O (20 mL x 3), EtOH (20 mL x 




2.4.2.13 Preparation of benzyl 5-(3-substitutedureido)-imidazole-4-carboxylate resin (2-
2-6) 
2-2-5 (0.3054 g, 0.3756 mmol) was swollen in o-xylene (10 mL) for 30 min. Isocyanate (3 
equiv) was added and the reaction mixture was heated at 120-125 °C for 24 h. The resin was 
filtered, washed with DMF (20 mL x 3), H2O (20 mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 mL 
x 3), Et2O (20 mL x 3) and dried overnight at 50 °C in a vacuum oven. 
2.4.2.14 Preparation of 1,7- or 1,7,8-substituted xanthines (2-2-7) 
THF (6 mL), MeOH (3 mL), and NaOEt (21% (w/w) in denatured EtOH, 0.42 mL, 1.1268 
mmol) were added to resin 2-2-6 (0.3249 g, 0.3756 mmol) and the reaction mixture was 
refluxed at 90 °C for 2 h. After which, the reaction mixture was filtered and the resin washed 
with MeOH (10 mL x 3) and CH2Cl2 (10 mL x 3). The combined organic layer was 
concentrated and purified by CC (EtOAc:hexane = 2:1 then MeOH:CH2Cl2 = 1:10) to give 2-
2-7. 
2.4.2.15 Preparation of 1,3,7- or 1,3,7,8-substituted xanthines (2-2-7) 
THF (6 mL), MeOH (3 mL), and NaOEt (21% (w/w) in denatured EtOH, 0.42 mL, 1.1268 
mmol) were added to 2-2-6 (0.3249 g, 0.3756 mmol) and the mixture was refluxed at 90 °C 
for 2 h. After which, the mixture was concentrated and THF (8 mL), DIEA (5 equiv) and the 
respective halide (3 equiv) were added. The reaction mixture was stirred at rt for 12 h and 
filtered. The resin was washed with MeOH (10 mL x 3), CH2Cl2 (10 mL x 3) and the 
combined organic layer was concentrated and purified by CC (EtOAc:hexane = 2:1 then 
MeOH:CH2Cl2 = 1:10) to give 2-2-7. 
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2-2-7b: 1-Allyl-7-butylxanthine. 1H NMR (CDCl3): δ 10.40 (s, NH, 1H), 7.60 (s, CH, 1H), 
6.00-5.87 (m, NCH2CHCH2, 1H), 5.30-5.18 (m, NCH2CHCH2, 2H), 4.62-4.60 (d, J = 5.58 Hz, 
NCH2CHCH2, 2H), 4.31-4.26 (t, J = 7.14 Hz, NCH2CH2CH2CH3, 2H), 1.91-1.81 (m, 
NCH2CH2CH2CH3, 2H), 1.42-1.30 (m, NCH2CH2CH2CH3, 2H), 0.99-0.94 (t, J = 7.49 Hz, 
NCH2CH2CH2CH3, 3H); 13C NMR (CDCl3): δ 155.1, 151.1, 147.3, 141.0, 132.1, 117.5, 107.0, 
47.1, 42.8, 32.7, 19.6, 13.5; Mass spectrum (EI) m/z 248.2 (M+) Exact mass calcd for 
C12H16N4O2: m/z 248.1273; found 248.1272. 
2-2-7c: 7-Butyl-1-phenylxanthine. 1H NMR (CDCl3): δ 7.70 (s, CH, 1H), 7.54-7.41 (m, ArH, 
3H), 7.29-7.26 (m, ArH, 2H), 4.28-4.23 (t, J = 7.31 Hz, NCH2CH2CH2CH3, 2H), 1.90-1.80 
(m, NCH2CH2CH2CH3, 2H), 1.41-1.31 (m, NCH2CH2CH2CH3, 2H), 0.96-0.91 (t, J = 7.31 Hz, 
NCH2CH2CH2CH3, 3H); 13C NMR (CDCl3): δ 155.5, 151.5, 147.9, 141.3, 134.9, 129.4, 129.2, 
128.8, 107.2, 42.2, 32.7, 19.6, 13.4; Mass spectrum (EI) m/z 283.9 (M+) Exact mass calcd for 
C15H16N4O2: m/z 284.1273; found 284.1270. 
2-2-7d: 1-Benzyl-7-butylxanthine. 1H NMR (CDCl3): δ 10.55 (s, NH, 1H), 7.60 (s, CH, 1H), 
7.50-7.47 (m, ArH, 2H), 7.32-7.24 (m, ArH, 3H), 5.17 (s, ArCH2, 2H), 4.30-4.25 (t, J = 7.14 
Hz, NCH2CH2CH2CH3, 2H), 1.90-1.80 (m, NCH2CH2CH2CH3, 2H), 1.41-1.29 (m, 
NCH2CH2CH2CH3, 2H), 0.98-0.93 (t, J = 7.31 Hz, NCH2CH2CH2CH3, 3H); 13C NMR 
(CDCl3): δ 155.4, 151.4, 147.3, 141.0, 137.2, 128.8, 128.4, 127.5, 107.0, 47.0, 43.9, 32.7, 
19.5, 13.5; Mass spectrum (EI) m/z 298.2 (M+) Exact mass calcd for C16H18N4O2: m/z 
298.1430; found 298.1435. 
2-2-7e: 7-Benzyl-1-hexylxanthine. 1H NMR (CDCl3): δ 11.26 (s, NH, 1H), 7.62 (s, CH, 1H), 
7.44-7.35 (m, ArH, 5H), 5.48 (s, ArCH2, 2H), 3.99-3.94 (t, J = 7.31 Hz, 
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NCH2CH2CH2CH2CH2CH3, 2H), 1.64-1.62 (m, NCH2CH2CH2CH2CH2CH3, 2H), 1.31-1.25 
(m, NCH2CH2CH2CH2CH2CH3, 6H), 0.89-0.85 (t, J = 6.09 Hz, CH3, 3H); 13C NMR (CDCl3): 
δ 155.7, 151.4, 147.2, 140.8, 134.9, 129.1, 128.7, 128.2, 107.0, 50.3, 40.9, 31.5, 28.0, 26.6, 
22.5, 14.0; Mass spectrum (EI) m/z 326.0 (M+) Exact mass calcd for C18H22N4O2: m/z 
326.1743; found 326.1740. 
2-2-7f: 7-Benzyl-1-phenylxanthine. 1H NMR (CDCl3): δ 11.47 (s, NH, 1H), 7.69 (s, CH, 1H), 
7.53-7.25 (m, ArH, 10H), 5.44 (s, CH2, 2H); 13C NMR (CDCl3): δ 155.7, 151.4, 147.8, 141.2, 
134.8, 134.7, 129.3, 129.1, 128.8, 128.8, 128.4, 107.1, 50.5; Mass spectrum (EI) m/z 318.0  
(M+) Exact mass calcd for C18H14N4O2: m/z 318.1117; found 318.1118. 
2-2-7g: 1,7-Dibenzylxanthine. 1H NMR (DMSO-d6): δ 8.21 (s, CH, 1H), 7.33-7.26 (m, ArH, 
10H), 5.46 (s, NCH2, 2H), 4.99 (s, NCH2, 2H); 13C NMR (DMSO-d6): δ 155.0, 150.9, 148.0, 
143.1, 137.7, 137.0, 128.7, 128.2, 128.0, 127.5, 127.3, 127.0, 105.7, 48.9, 42.8; Mass 
spectrum (EI) m/z 331.9 (M+) Exact mass calcd for C19H16N4O2: m/z 332.1273; found 
332.1274. 
2-2-7h: 1-Allyl-7-benzylxanthine. 1H NMR (CDCl3): δ 11.60 (s, NH, 1H), 7.63 (s, CH, 1H), 
7.40-7.33 (m, ArH, 5H), 5.99-5.79 (m, NCH2CHCH2, 1H), 5.48 (s, NCH2, 2H), 5.28-5.09 (m, 
NCH2CHCH2, 2H), 4.61-4.59 (d, J = 5.58 Hz, NCH2CHCH2, 2H);  13C NMR (CDCl3): δ 
155.3, 151.2, 147.5, 141.0, 135.3, 132.1, 129.1, 128.8, 128.2, 117.4, 106.9, 50.4, 42.7; Mass 
spectrum (EI) m/z 282.0 (M+) Exact mass calcd for C15H14N4O2: m/z 282.1117; found 
282.1115. 
2-2-7i: 7-Benzyl-3-methyl-1-phenylxanthine. 1H NMR (CDCl3): δ 7.55 (s, CH, 1H), 7.46-
7.16 (m, ArH, 10H), 5.40 (s, CH2, 2H), 3.54 (s, CH3, 3H); 13C NMR (CDCl3): δ 155.2, 151.6, 
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149.5, 141.1, 135.4, 129.4, 129.1, 128.7, 128.2, 107.2, 50.4, 29.8; Mass spectrum (EI) m/z 
332.0 (M+) Exact mass calcd for C19H16N4O2: m/z 332.1273; found 332.1274. 
2-2-7j: 7-Benzyl-1-phenyl-3-propargylxanthine. 1H NMR (CDCl3): δ 7.65 (s, CH, 1H), 
7.53-7.25 (m, ArH, 10H), 5.47 (s, NCH2, 2H), 4.91-4.90 (d, J = 2.46 Hz, N3CH2CCH, 2H), 
2.28-2.27 (t, J = 2.43 Hz, CH2CCH, 1H); 13C NMR (CDCl3): δ 155.0, 150.7, 148.2, 141.3, 
135.1, 134.9, 129.4, 129.1, 128.8, 128.7, 128.4, 107.4, 72.0, 50.5, 32.6; Mass spectrum (EI) 
m/z 356.0 (M+) Exact mass calcd for C21H16N4O2: m/z 356.1273; found 356.1272. 
2-2-7k: 1-Allyl-7-benzyl-3-methylxanthine. 1H NMR (CDCl3, 500 MHz): δ 7.54 (s, CH, 
1H), 7.38-7.32 (m, ArH, 5H), 5.96-5.88 (m, NCH2CHCH2, 1H), 5.49 (s, NCH2, 2H), 5.28-
5.17 (m, NCH2CHCH2, 2H), 4.63-4.62 (m, NCH2, 2H), 3.57 (s, NCH3, 3H); 13C NMR (CDCl3, 
500 MHz): δ 154.8, 151.2, 149.0, 140.9, 135.2, 132.3, 129.1, 128.7, 128.0, 117.5, 107.0, 50.3, 
43.4, 29.7; Mass spectrum (EI) m/z 296.0 (M+) Exact mass calcd for C16H16N4O2: m/z 
296.1273; found 296.1280. 
2-2-7l: 1-Allyl-7-benzyl-3-propargylxanthine. 1H NMR (CDCl3, 500 MHz) : δ 7.58 (s, CH, 
1H), 7.39-7.33 (m, ArH, 5H), 5.96-5.88 (m, NCH2CHCH2, 1H), 5.49 (s, NCH2, 2H), 5.29-
5.18 (m, NCH2CHCH2, 2H), 4.88-4.87 (d, J = 1.90 Hz, NCH2CCH, 2H), 4.64-4.62 (m, 
NCH2CHCH2, 2H), 2.25-2.25 (t, J = 2.20 Hz, NCH2CCH, 1H); 13C NMR (CDCl3, 500 MHz): 
δ 154.7, 150.4, 147.7, 141.1, 135.0, 132.0, 129.1, 128.7, 128.2, 117.8, 107.2, 77.6, 71.8, 50.4, 
43.5, 32.5; Mass spectrum (EI) m/z 320.0 (M+) Exact mass calcd for C18H16N4O2: m/z 
320.1273; found 320.1275. 
2-2-7m: 7-Benzyl-1,3-diallylxanthine. 1H NMR (CDCl3, 500 MHz): δ 7.54 (s, CH, 1H), 
7.38-7.33 (m, ArH, 5H), 6.00-5.88 (m, NCH2CHCH2, 2H), 5.49 (s, NCH2, 2H), 5.32-5.19 (m, 
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NCH2CHCH2, 4H), 4.71-4.62 (m, NCH2CHCH2, 4H); 13C NMR (CDCl3, 500 MHz): δ 154.8, 
150.7, 148.5, 141.0, 135.1, 132.2, 131.5, 129.1, 128.7, 128.1, 118.0, 117.5, 107.0, 50.3, 45.3, 
43.3; Mass spectrum (EI) m/z 321.8 (M+) Exact mass calcd for C18H18N4O2: m/z 322.1430; 
found 322.1435. 
2-2-7n: 1-Allyl-3,7-dibenzylxanthine. 1H NMR (CDCl3): δ 7.46 (s, CH, 1H), 7.42-7.41 (m, 
ArH, 2H), 7.29-7.14 (m, ArH, 8H), 5.91-5.78 (m, NCH2CHCH2, 1H), 5.40 (s, NCH2, 2H), 
5.19-5.08 (m, NCH2 and NCH2CHCH2, 4H), 4.56-4.54 (m, NCH2CHCH2, 2H); 13C NMR 
(CDCl3): δ 154.8, 151.0, 148.7, 140.9, 136.4, 135.1, 132.2, 129.1, 128.7, 128.5, 128.2, 127.8, 
117.5, 107.1, 50.3, 46.6, 43.4; Mass spectrum (EI) m/z 371.7 (M+) Exact mass calcd for 
C22H20N4O2: m/z 372.1586; found 372.1584. 
2-2-7o: 3-Allyl-7-benzyl-1-phenylxanthine. 1H NMR (CDCl3): δ 7.54 (s, CH, 1H), 7.45-
7.17 (m, ArH, 10H), 6.00-5.87 (m, NCH2CHCH2, 1H), 5.40 (s, NCH2, 2H), 5.30-5.15 (m, 
NCH2CHCH2, 2H), 4.67-4.65 (d, J = 5.91 Hz, NCH2CHCH2, 2H); 13C NMR (CDCl3): δ 
155.2, 151.1, 149.0, 141.2, 135.3, 135.0, 131.4, 129.3, 129.1, 128.7, 128.7, 128.4, 118.6, 
107.3, 50.4, 45.6; Mass spectrum (EI) m/z 358.1 (M+) Exact mass calcd for C21H18N4O2: m/z 
358.1430; found 358.1422. 
2-2-7p: 3,7-Dibenzyl-1-phenylxanthine. 1H NMR (CDCl3): δ 7.54-7.15 (m, CH and ArH, 
16H), 5.36 (s, NCH2, 2H), 5.20 (s, NCH2, 2H); 13C NMR (CDCl3): δ 155.1, 151.4, 149.1, 
141.0, 136.2, 135.3, 135.0, 129.3, 129.2, 129.1, 128.7, 128.6, 128.5, 128.4, 127.9, 107.3, 50.3, 
46.7; Mass spectrum (EI) m/z 408.1 (M+) Exact mass calcd for C25H20N4O2: m/z 408.1586; 
found 408.1588. 
2-2-7q: 1-Allyl-7,8-dimethylxanthine. 1H NMR (DMSO-d6): δ 11.76 (s, NH, 1H), 5.90-5.75 
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(m, NCH2CHCH2, 1H), 5.08-5.00 (m, NCH2CHCH2, 2H), 4.42-4.40 (d, J = 4.89 Hz, 
NCH2CHCH2, 2H), 3.78 (s, NCH3, 3H), 2.36 (s, CCH3, 3H); 13C NMR (DMSO-d6): δ 154.0, 
151.0, 150.0, 146.3, 132.8, 115.4, 105.8, 41.0, 30.8, 12.2; Mass spectrum (EI) m/z 219.9 (M+) 
Exact mass calcd for C10H12N4O2: m/z 220.0960; found 220.0960. 
2-2-7r: 7,8-Dimethyl-1-phenylxanthine. 1H NMR (DMSO-d6): δ 11.85 (s, NH, 1H), 7.48-
7.21 (m, ArH, 5H), 3.76 (s, NCH3, 3H), 2.39 (s, CCH3, 3H); 13C NMR (DMSO-d6): δ 155.0, 
151.6, 150.9, 147.2, 136.0, 129.4, 128.7, 127.8, 106.6, 31.3, 12.7; Mass spectrum (EI) m/z 
255.9 (M+) Exact mass calcd for C13H12N4O2: m/z 256.0960; found 256.0960. 
2-2-7s: 1-Allyl-3-benzyl-7,8-dimethylxanthine. 1H NMR (CDCl3): δ 7.41-7.17 (m, ArH, 
5H), 5.90-5.72 (m, NCH2CHCH2, 1H), 5.23-5.03 (m, ArCH2 and NCH2CHCH2, 4H), 4.54-
4.53 (d, J = 5.58 Hz, NCH2CHCH2, 2H), 3.81 (s, NCH3, 3H), 2.38 (s, CCH3, 3H); 13C NMR 
(CDCl3): δ 154.8, 151.0, 150.8, 147.8, 136.6, 132.5, 128.6, 128.4, 127.7, 117.2, 107.5, 46.4, 
43.2, 31.8, 13.1; Mass spectrum (EI) m/z 310.2 (M+) Exact mass calcd for C17H18N4O2: m/z 
310.1430; found 310.1430. 
2-2-7t: 1-Phenyl-3,7,8-trimethylxanthine. 1H NMR (CDCl3): δ 7.46-7.16 (m, ArH, 5H), 
3.82 (s, NCH3, 3H), 3.52 (s, NCH3, 2H), 2.42 (s, CCH3, 3H); 13C NMR (CDCl3): δ 155.2, 
151.7, 151.1, 148.6, 135.7, 129.3, 128.8, 128.6, 107.7, 31.9, 29.7, 13.1; Mass spectrum (EI) 
m/z 270.1 (M+) Exact mass calcd for C14H14N4O2: m/z 270.1117; found 270.1110. 
2-2-7u: 1-Allyl-7-methyl-8-phenylxanthine. 1H NMR (CDCl3, 500 MHz): δ 10.26 (s, NH, 
1H), 7.71-7.53 (m, ArH, 5H), 5.99-5.91 (m, NCH2CHCH2, 1H), 5.30-5.19 (m, NCH2CHCH2, 
2H), 4.65-4.63 (m, NCH2CHCH2, 2H), 4.06 (s, CH3, 3H); 13C NMR (CDCl3, 500 MHz): δ 
155.6, 152.5, 151.1, 146.7, 132.2, 130.5, 129.3, 128.9, 128.0, 117.4, 108.5, 42.7, 33.9; Mass 
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spectrum (ESI) m/z 283.1 (M+H+) Exact mass calcd for C15H14N4O2: m/z 282.1117; found 
283.1190 (M+H+). 
2-2-7v: 1-Allyl-3,7-dimethyl-8-phenylxanthine. 1H NMR (CDCl3, 500 MHz): δ 7.69-7.52 
(m, ArH, 5H), 5.99-5.91 (m, NCH2CHCH2, 1H), 5.31-5.19 (m, NCH2CHCH2, 2H), 4.67-4.66 
(m, NCH2CHCH2, 2H), 4.06 (s, NCH3, 3H), 3.63 (s, NCH3, 3H); 13C NMR (CDCl3, 500 
MHz): δ 155.2, 152.2, 151.3, 148.5, 132.4, 130.4, 129.2, 128.9, 128.4, 117.4, 108.6, 43.3, 
33.9, 29.7; Mass spectrum (ESI) m/z 297.1 (M+H+) Exact mass calcd for C16H16N4O2: m/z 
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Chapter 3 Combinatorial Solution-Phase Synthesis of Polycyclic Guanines 
3.1 Introduction 
3.1.1 Importance of polycyclic guanines 
Phosphodiesterase (PDE) V inhibitor compounds inhibit the PDE V isoenzyme, and therefore 
are of potential pharmaceutical and therapeutic interest.1 One example is Viagra (Pfizer, NY), 
which is used for treating erectile dysfunction (impotency).2 Polycyclic guanines are an 
important class of PDE V inhibitors for treating urological, vascular or pulmonary disorders.2 
Figure 3-1 shows the general structure of polycyclic guanines. 






















ViagraPolycyclic guanines  
3.1.2 General methods for solution-phase synthesis of polycyclic guanines 
Many methods have been reported for the synthesis of polycyclic guanines.2a,3 Most of them 
employ xanthine as the key intermediate, which can be prepared from 
4-amino-5-alkoxycarbonylimidazole or substituted 5,6-diamino uracil (Scheme 3-1).2a,3a-3f In 
these methods, xanthine is chlorinated at the C2-position and then reacted with amino alcohol 
to give a precursor, which is subsequently cyclized to afford the polycyclic guanines. 
Chlorination and the accompanying substitution reactions generally occur with moderate 
yields (Scheme 3-1), which makes these multi-step syntheses less attractive for library 
generation in pharmaceutical research. Although some modifications, such as using 
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thioxanthine as the intermediate, have been developed, the yields for the ring C construction 
were even poorer.3g 
























































Besides the aforementioned methods, another reported synthesis involves building rings A 
and B prior to ring C (Scheme 3-2).3h In this synthesis, a thiomethyl pyrimidine was reacted 
with an amino alcohol to give an intermediate which was cyclized to complete the 
construction of rings A and B. Subsequent ring C formation afforded the polycyclic guanines. 
Although this is a novel route, the preparation of the thiomethyl pyrimidine was rather 
complicated and the average yield for each reaction step was lower than the above mentioned 
methods. 






























3.1.3 Objectives and scope of this study 
This project aims to develop an alternative synthetic route to polycyclic guanines which 
would be applicable to combinatorial synthesis and library generation. 
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3.2 Results and Discussion 
Since low yields were obtained during the chlorination of xanthines,3 we decided that using a 
thioxanthine as an intermediate would be a preferred choice. This is because S-alkylation of 
the thioxanthine would readily give a sulfide that can be oxidized to the corresponding 
sulfone, which is an activated leaving group. 






































































R1 = Et, Pr, Ph, Bn
n = 1, 2, 3  
3.2.1 Synthesis of 2-thioxanthines (3-5) 
To begin our investigation, we had to prepare 2-thioxanthines (3-5) whose synthesis have 
been developed in our previous study.4 As shown in Scheme 3-3, ethyl bromoacetate (3-1) 
was reacted with benzyl amine in THF to afford ethyl N-benzyl glycinate (3-2) in 93% yield. 
Compound 3-2 was then treated with ethoxymethylene cyanamide to give an intermediate 
which was cyclized with NaOEt in an one-pot reaction to give ethyl 
5-amino-3-benzyl-3H-imidazole-4-carboxylate (3-3) in 86% overall yield. Treatment of 
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compound 3-3 with isothiocyanates in o-xylene (140 ºC, 24 h) provided 3-4 in good yield. 
Subsequent ring closure of 3-4 with NaOEt/MeOH afforded 1,7-substituted 2-thioxanthines 
3-5 in quantitative yield. 
3.2.2 Synthesis of 7-benzyl-2-(methylthio)-1-substituted-1H-purin-6(7H)-one (3-6) 
A typical S-alkylation was performed in DMF or THF in the presence of a base.5 However 
Kang has reported a S-alkylation of thiopyrimidine using 10% KOH solution and diethyl 
sulfate.6 The product formed precipitated from the solution so that only a filtration was 
needed for purification. We thought that this method could be adopted for the synthesis of 3-6, 
as compound 3-5 also contained a similar thiopyrimidine structure. Hence, by applying 
Kang’s protocol, 3-6 was successfully prepared in quantitative yield. The reaction proceeded 
rapidly at room temperature and the product was collected in pure form by filtration and 
washing with H2O. 
3.2.3 Synthesis of 7-benzyl-2-(methylsulfonyl)-1-substituted-1H-purin-6(7H)-one (3-7) 
The oxidation of sulfide 3-6 to sulfone 3-7 was conducted with m-CPBA. This reaction was 
completed in 3 h and gave 3-7 in over 90% yield. It is worth noting that m-CPBA should be 
added slowly to the reaction mixture which should be kept at a low temperature during this 
addition. 
3.2.4 Synthesis of 7-benzyl-2-(hydroxyalkylamino)-1-substituted-1H-purin-6(7H)-one 
(3-8) 
We had initially considered converting 3-6 directly to 3-8. However all attempts to do this 
(Scheme 3-4) failed. Hence 3-8 was prepared by first oxidizing the sulfide group in 3-6 to a 
sulfone, which is a better leaving group. Compound 3-7 was then converted to 3-8 by 
 66
nucleophilic substitution. To optimize this reaction, compound 3-7b was treated with 
ethanolamine under various conditions to achieve 3-8b (Table 3-1). The reaction using a 
mixture of BuOH and DMSO as solvent gave product 3-8b and a byproduct in 66% and 34% 
yields, respectively. The byproduct obtained was analyzed and was found to have been 
derived from a nucleophilic substitution from BuOH (Entry 1, Table 3-1). Attempts to carry 
out the reaction in DMF at 80 ºC gave product 3-8b and the xanthine as byproduct. The 
formation of xanthine was attributed to the presence of moisture which acted as a nucleophile 
resulting in the hydrolysis of 3-7b. When the reaction temperature was raised from 80 ºC to 
130 ºC, the reaction time was significantly reduced from 30 h to 2 h, and the yield was 
improved slightly (Entry 3, Table 3-1). To avoid the formation of the hydrolyzed byproduct, 
molecular sieves were added to the reaction mixture and this resulted in better yield (Entry 4, 
Table 3-1). When the reaction was carried out without any solvent, the reaction time was 
shortened to 30 min, but no improvement to the yield of 3-7b was observed (Entry 5, Table 
3-1). Nevertheless, this method of synthesizing 3-8 from 3-6 via 3-7 was more efficient and 
gave higher yield than the methods reported earlier.3  
Having optimized the synthetic route to compound 3-8, different substrates and amino 
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Table 3-1 Synthesis of 3-8a 




80 ºC, 12 h p: 66%, byp: 34% 
2 Ethanolamine DMF 80 ºC, 30 h p: 66%, byp: 34% 








Ethanolamine 130 ºC, 30 min p: 84% 
 
3.2.5 Synthesis of polycyclic guanines (3-9) 
With 3-8 in hand, we proceeded to synthesize the third ring. In all previous reported methods, 
SOCl2 or CH3SO2Cl were used to for this ring formation,2a,3 and the yields were about 60%. 
To improve on this methodology, we tried different conditions, such as lowering the 
temperature or adding the reagent slowly. Eventually we found that the reaction worked well 
with SOCl2 and TEA in a temperature controlled method (Scheme 3-3). It is important to note 
that the equivalents of SOCl2 used should be larger than TEA and DIEA gave lower yields 
than TEA. 
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To illustrate the versatility of our synthetic route, 6 compounds were prepared (Figure 3-2). 
 































3-9a (47%) 3-9b (43%) 3-9c (41%)
3-9d (47%) 3-9e (48%) 3-9f (53%)  
 
3.3 Conclusion 
This study investigated the combinatorial solution-phase parallel synthesis of polycyclic 
guanines. A highly efficient synthetic route involving 9 steps in total was developed. Unlike 
previous synthesis of polycyclic guanines which use 2-chloropurine as the necessary 
intermediate, this method synthesized thioxanthine as the key intermediate. The use of 
thioxanthine provided a more efficient construction of the third ring. By using parallel 
synthesis, a set of 6 compounds was prepared. The overall yields of the final products were 
more than 41%, indicating that the yield for each step was more than 90%. 
3.4 Experimental 
All chemical reagents were obtained from Aldrich, Merck, Lancaster or Fluka and used 
without further purification. Analytical TLC was carried out on pre-coated plates (Merck 
silica gel 60, F254) and visualized with UV light or stained with ninhydrin. CC was 
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performed with silica (Merck, 70-230 mesh). 1H NMR and 13C NMR spectra were measured 
at 298 K on a Bruker DPX 300 or DPX 500 Fourier Transform spectrometer. Chemical shifts 
are reported in δ (ppm), relative to the internal standard of TMS. The signals observed are 
described as: s, d, t, q, m. The number of protons (n) for a given resonance is indicated as nH. 
All Infra-red spectra were recorded on a Bio-Rad FTS 165 spectrometer. Mass spectra were 
performed on VG Micromass 7035 spectrometer under EI, Finnigan/MAT LCQ under ESI 
(Normal), and Finnigan/MAT 95XL-T under ESI (Accurate). 
3.4.1 Synthesis of ethyl N-benzyl glycinate (3-2) 
Benzylamine (6.55 mL, 60 mmol) was added to ethyl bromoacetate (3-1) (2.22 mL, 20 mmol) 
in THF (100 mL). The mixture was quickly cooled in an ice-water bath and then stirred at rt 
for 1 h. After which, the reaction mixture was concentrated and purified by CC 
(EtOAc:hexane = 1:3) to give 3-2 as a colorless oil (3.6 g, 93% yield). 1H NMR (CDCl3): δ 
7.35-7.25 (m, ArH, 5H), 4.22-4.15 (q, J = 7.1 Hz, CH3CH2, 2H), 3.84 (s, ArCH2, 2H), 3.42 (s, 
CH2, 2H), 2.67 (s, NH, 1H), 1.29-1.25 (t, J = 7.1 Hz, CH3CH2, 3H); 13C NMR (CDCl3): δ 
171.9, 138.7, 128.5, 128.4, 127.3, 60.8, 53.0, 49.7, 14.2; Mass spectrum (EI) m/z 193.0 (M+) 
Exact mass calcd for C11H15NO2: m/z 193.1103; found 193.1100. 
3.4.2 Synthesis of ethyl 5-amino-3-benzyl-3H-imidazole-4-carboxylate (3-3) 
Compound 3-2 (2 mL, 10.67 mmol) was dissolved in EtOH (10 mL) and the solution was 
cooled in an ice-water bath. Ethoxymethylene cyanamide (1.119 g, 11.42 mmol) in EtOH (5 
mL) was added dropwise and upon completion of addition, the reaction mixture was stirred at 
rt for 2 h. After which, the reaction mixture was cooled in an ice-water bath and NaOEt (21% 
(w/w) in denatured EtOH, 4 mL, 10.67 mmol) was added. The reaction mixture was stirred at 
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rt for another 2 h, concentrated and purified by CC (EtOAc:CH2Cl2 = 2:1) to give 3-3 as a 
colorless solid (2.25 g, 86% yield). 1H NMR (CDCl3): δ 7.22-7.01 (m, ArH, 5H), 5.21 (s, 
ArCH2, 2H), 5.05 (s, NH2, 2H), 4.14-4.07 (q, J = 7.1 Hz, CH3CH2, 2H), 1.15-1.10 (t, J = 7.1 
Hz, CH3CH2, 3H); 13C NMR (CDCl3): δ 160.5, 155.6, 139.0, 136.5, 128.4, 127.4, 126.6, 
101.4, 59.3, 50.3, 14.1; Mass spectrum (EI) m/z 245.1 (M+) Exact mass calcd for C13H15N3O2: 
m/z 245.1164; found 245.1157. 
3.4.3 Synthesis of ethyl 3-benzyl-5-(3-alkylthioureido)-3H-imidazole-4-carboxylate (3-4) 
To compound 3-3 (0.5625 g, 2.29 mmol) was added ethyl isothiocyanate (0.301 mL, 3.44 
mmol) and o-xylene (6 mL) and the mixture was heated at 140 ºC for 24 h. After which, the 
mixture was concentrated and purified by CC (EtOAc:hexane = 1:3) to give ethyl 
3-benzyl-5-(3-ethylthioureido)-3H-imidazole-4-carboxylate (3-4a) as a white solid (0.64 g, 
85% yield). 1H NMR (CDCl3): δ 10.4 (s, CH3CH2NHCS, 1H), 9.13 (s, NH, 1H), 7.39 (s, CH, 
1H), 7.25-7.03 (m, ArH, 5H), 5.36 (s, ArCH2, 2H), 4.21-4.14 (q, J = 7.1 Hz, CH3CH2CO2, 2H), 
3.66-3.57 (m, CH3CH2NHCS, 2H), 1.22-1.16 (m, CH3, 6H); 13C NMR (CDCl3): δ 177.8, 
159.0, 147.1, 137.2, 135.2, 128.4, 127.8, 126.7, 103.5, 60.5, 50.5, 40.1, 13.8, 13.7; Mass 
spectrum (EI) m/z 332.0 (M+) Exact mass calcd for C16H20N4O2S: m/z 332.1307; found 
332.1305. 
3-4b: Ethyl 3-benzyl-5-(3-propylthioureido)-3H-imidazole-4-carboxylate. 1H NMR 
(CDCl3): δ 10.4 (s, CH3CH2CH2NHCS, 1H), 9.13 (s, NH, 1H), 7.34 (s, CH, 1H), 7.27-7.04 (m, 
ArH, 5H), 5.36 (s, ArCH2, 2H), 4.24-4.17 (q, J = 7.2 Hz, CH3CH2CO2, 2H), 3.59-3.53 (m, 
CH3CH2CH2NHCS, 2H), 1.67-1.55 (m, CH3CH2CH2NHCS, 2H), 1.25- 1.20 (t, J = 7.0 Hz, 
CH3CH2CO2, 3H), 0.93-0.88 (t, J = 7.3 Hz, CH3CH2CH2NHCS, 3H); 13C NMR (CDCl3): δ 
 71
178.1, 159.2, 147.2, 137.2, 135.2, 128.6, 128.0, 127.0, 103.7, 60.7, 50.7, 47.2, 21.8, 14.0, 11.3; 
Mass spectrum (EI) m/z 346.1 (M+) Exact mass calcd for C17H22N4O2S: m/z 346.1463; found 
346.1461. Yield: 83%. 
3-4c: Ethyl 3-Benzyl-5-(3-phenylthioureido)-3H-imidazole-4-carboxylate. 1H NMR 
(CDCl3): δ 12.4 (s, PhNHCS, 1H), 9.38 (s, NH, 1H), 7.34-7.15 (m, CH and ArH, 11H), 5.45 (s, 
ArCH2, 2H), 4.38-4.31 (q, J = 7.1 Hz, CH3CH2CO2, 2H), 1.38-1.34 (t, J = 7.0 Hz, 
CH3CH2CO2, 3H); 13C NMR (CDCl3): δ 177.3, 159.3, 147.0, 138.8, 137.3, 135.2, 128.9, 
128.5, 128.4, 127.2, 125.9, 124.4, 104.4, 61.1, 51.0, 14.2; Mass spectrum (EI) m/z 380.2 (M+) 
Exact mass calcd for C20H20N4O2S: m/z 380.1307; found 380.1295. Yield: 89%. 
3-4d: Ethyl 3-Benzyl-5-(3-benzylthioureido)-3H-imidazole-4-carboxylate. 1H NMR 
(CDCl3): δ 10.76-10.72 (t, J = 5.0 Hz, ArCH2NHCS, 1H), 9.21 (s, NH, 1H), 7.22-6.94 (m, CH 
and ArH, 11H), 5.22 (s, ArCH2, 2H), 4.78-4.76 (d, J = 5.2 Hz, ArCH2NHCS, 2H), 4.13-4.06 (q, 
J = 7.2 Hz, CH3CH2CO2, 2H), 1.14-1.09 (t, J = 7.1 Hz, CH3CH2CO2, 3H); 13C NMR (CDCl3): 
δ 178.3, 158.9, 146.9, 137.2, 137.0, 135.1, 128.3, 128.1, 127.7, 127.1, 126.9, 126.6, 103.5, 
60.4, 50.4, 49.0, 13.7; Mass spectrum (EI) m/z 394.2 (M+) Exact mass calcd for C21H22N4O2S: 
m/z 394.1463; found 394.14655. Yield: 90%. 
3.4.4 Synthesis of 2-thioxanthines (3-5) 
To compound 3-4a (0.64 g, 1.95 mmol) in MeOH (6 mL) was added NaOEt (21% (w/w) in 
denatured EtOH, 2 mL, 5.3 mmol). The mixture was refluxed for 2 h then concentrated and 
the resulting residue was diluted with water (10 mL) and acidified with 1.5 M HCl. The white 
precipitate which formed was filtered, washed with water and dried to give 
7-benzyl-1-ethyl-2-thioxanthine (3-5a) as a white power (0.56 g, 99% yield). 1H NMR 
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(DMSO-d6): δ 13.52 (s, NH, 1H), 8.28 (s, CH, 1H), 7.33-7.25 (m, ArH, 5H), 5.49 (s, ArCH2, 
2H), 4.45-4.38 (q, J = 6.9 Hz, CH2CH3, 2H), 1.20-1.15 (t, J = 6.8 Hz, CH2CH3, 3H); 13C 
NMR (DMSO-d6): δ 173.8, 153.2, 147.6, 143.9, 136.8, 128.7, 127.9, 127.4, 109.3, 49.0, 40.8, 
12.0; Mass spectrum (EI) m/z 286.0 (M+) Exact mass calcd for C14H14N4OS: m/z 286.0888; 
found 286.0875. 
3-5b: 7-Benzyl-1-propyl-2-thioxanthine. 1H NMR (DMSO-d6): δ 13.51 (s, NH, 1H), 8.28 (s, 
CH, 1H), 7.36-7.25 (m, ArH, 5H), 5.48 (s, ArCH2, 2H), 4.33-4.28 (t, J = 7.7 Hz, CH2CH2CH3, 
2H), 1.71-1.59 (m, CH2CH2CH3, 2H), 0.88-0.83 (t, J = 7.5 Hz, CH2CH2CH3, 3H); 13C NMR 
(DMSO-d6): δ 174.0, 153.4, 147.7, 143.9, 136.8, 128.7, 127.9, 127.5, 109.2, 49.0, 46.9, 19.7, 
11.0; Mass spectrum (EI) m/z 300.1 (M+) Exact mass calcd for C15H16N4OS: m/z 300.1045; 
found 300.1039. Yield: 99%. 
3-5c: 7-Benzyl-1-phenyl-2-thioxanthine. 1H NMR (DMSO-d6): δ 13.71 (s, NH, 1H), 8.36 (s, 
CH, 1H), 7.47-7.18 (m, ArH, 10H), 5.48 (s, ArCH2, 2H); 13C NMR (DMSO-d6): δ 175.5, 
153.8, 148.3, 143.9, 139.3, 136.7, 129.2, 128.9, 128.7, 128.0, 127.8, 127.6, 109.7, 49.0; Mass 
spectrum (EI) m/z 334.1 (M+) Exact mass calcd for C18H14N4OS: m/z 334.0888; found 
334.0877. Yield: 99%. 
3-5d: 1,7-Dibenzyl-2-thioxanthine. 1H NMR (DMSO-d6): δ 13.74 (s, NH, 1H), 8.34 (s, CH, 
1H), 7.31-7.18 (m, ArH, 10H), 5.63 (s, N1CH2, 2H), 5.48 (s, N7CH2, 2H); 13C NMR 
(DMSO-d6): δ 174.7, 153.5, 147.9, 144.2, 136.8, 136.7, 128.7, 128.1, 127.9, 127.4, 127.0, 
126.8, 109.2, 49.0, 48.5; Mass spectrum (EI) m/z 348.1 (M+) Exact mass calcd for 
C19H16N4OS: m/z 348.1045; found 348.1047. Yield: 99%. 
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3.4.5 Synthesis of 7-benzyl-2-methylthio-1-substituted-1H-purin-6(7H)-one (3-6) 
A suspension of compound 3-5a (0.3246 g, 1.13 mmol) in 10% KOH solution (10 mL) was 
cooled in an ice-water bath and CH3I (0.14 mL, 2.27 mmol) was added dropwise. The mixture 
was stirred at rt for 30 min. and the white precipitate which formed was filtered, washed with 
water and dried to give 7-benzyl-1-ethyl-2-methylthio-1H-purin-6(7H)-one (3-6a) as a white 
solid (0.56 g, 99% yield). 1H NMR (CDCl3): δ 7.75 (s, CH, 1H), 7.18-7.13 (m, ArH, 5H), 5.43 
(s, ArCH2, 2H), 4.08-4.01 (q, J = 7.1 Hz, CH2CH3, 2H), 2.51 (s, SCH3, 3H), 1.24-1.19 (t, J = 
7.1 Hz, CH2CH3, 3H); 13C NMR (CDCl3): δ 157.0, 155.8, 154.3, 142.5, 135.6, 128.5, 127.9, 
127.5, 111.5, 49.8, 38.9, 14.9, 12.8; Mass spectrum (EI) m/z 300.1 (M+) Exact mass calcd for 
C15H16N4OS: m/z 300.1045; found 300.1045. 
3-6b: 7-Benzyl-2-methylthio-1-propyl-1H-purin-6(7H)-one. 1H NMR (CDCl3): δ 7.75 (s, 
CH, 1H), 7.15-7.08 (m, ArH, 5H), 5.41 (s, ArCH2, 2H), 3.94-3.88 (t, J = 7.8 Hz, CH2CH2CH3, 
2H), 2.49 (s, SCH3, 3H), 1.70-1.57 (m, CH2CH2CH3, 2H), 0.87-0.82 (t, J = 7.5 Hz, 
CH2CH2CH3, 3H); 13C NMR (CDCl3): δ 157.0, 155.7, 154.3, 142.5, 135.6, 128.3, 127.7, 
127.3, 111.3, 49.7, 45.1, 20.9, 14.9, 10.7; Mass spectrum (EI) m/z 314.0 (M+) Exact mass 
calcd for C16H18N4OS: m/z 314.1201; found 314.1200. Yield: 99%. 
3-6c: 7-Benzyl-2-methylthio-1-phenyl-1H-purin-6(7H)-one. 1H NMR (CDCl3): δ 7.78 (s, 
CH, 1H), 7.41-7.17 (m, ArH, 10H), 5.39 (s, ArCH2, 2H), 2.39 (s, SCH3, 3H); 13C NMR 
(CDCl3): δ 158.8, 156.5, 154.8, 142.7, 135.4, 135.3, 129.7, 129.4, 129.0 128.7, 128.1, 127.8, 
111.7, 50.1, 15.7; Mass spectrum (EI) m/z 348.0 (M+) Exact mass calcd for C19H16N4OS: m/z 
348.1045; found 348.1044. Yield: 99%. 
3-6d: 1,7-Dibenzyl-2-methylthio-1H-purin-6(7H)-one. 1H NMR (CDCl3): δ 7.82 (s, CH, 
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1H), 7.25-7.18 (m, ArH, 10H), 5.49 (s, N1CH2, 2H), 5.31 (s, N7CH2, 2H), 2.53 (s, SCH3, 3H); 
13C NMR (CDCl3): δ 157.8, 156.0, 154.7, 142.8, 135.5, 135.0, 128.5, 128.1, 127.9, 127.5, 
127.2, 126.8, 111.4, 49.9, 46.4, 15.2; Mass spectrum (EI) m/z 362.1 (M+) Exact mass calcd 
for C20H18N4OS: m/z 362.1201; found 362.1207. Yield: 99%. 
3.4.6 Synthesis of 7-benzyl-2-methylsulfonyl-1-substituted-1H-purin-6(7H)-one (3-7) 
To compound 3-6a (0.2996 g, 0.998 mmol) in CH2Cl2 (10 mL) was added a solution of 
m-CPBA (70% purity, 0.5 g, 1.995 mmol) in CH2Cl2 (10 mL) dropwise in an ice-water bath. 
After that, the mixture was stirred at rt for 3 h, concentrated and purified by CC 
(EtOAc:hexane = 2:1) to give 7-benzyl-1-ethyl-2-methylsulfonyl-1H-purin-6(7H)-one (3-7a) 
as a white solid (0.315 g, 95% yield). 1H NMR (CDCl3): δ 7.93 (s, CH, 1H), 7.27-7.22 (m, 
ArH, 5H), 5.50 (s, ArCH2, 2H), 4.45-4.38 (q, J = 7.0 Hz, CH2CH3, 2H), 3.41 (s, SO2CH3, 3H), 
1.34-1.30 (t, J = 7.0 Hz, CH2CH3, 3H); 13C NMR (CDCl3): δ 153.5, 152.6, 151.8, 144.1, 
134.9, 128.9, 128.5, 127.8, 115.5, 50.4, 41.3, 39.7, 13.9; Mass spectrum (EI) m/z 331.9 (M+) 
Exact mass calcd for C15H16N4O3S: m/z 332.0943; found 332.0943. 
3-7b: 7-Benzyl-2-methylsulfonyl-1-propyl-1H-purin-6(7H)-one. 1H NMR (CDCl3): δ 7.94 
(s, CH, 1H), 7.25-7.20 (m, ArH, 5H), 5.48 (s, ArCH2, 2H), 4.28-4.23 (t, J = 8.0 Hz, 
CH2CH2CH3, 2H), 3.39 (s, SO2CH3, 3H), 1.79-1.67 (m, CH2CH2CH3, 2H), 0.89-0.85 (t, J = 
7.3 Hz, CH2CH2CH3, 3H); 13C NMR (CDCl3): δ 153.5, 152.5, 151.7, 144.1, 134.9, 128.8, 
128.4, 127.6, 115.3, 50.3, 45.5, 41.3, 22.0, 10.7; Mass spectrum (EI) m/z 346.1 (M+) Exact 
mass calcd for C16H18N4O3S: m/z 346.1100; found 346.1103. Yield: 93%. 
3-7c: 7-Benzyl-2-methylsulfonyl-1-phenyl-1H-purin-6(7H)-one. 1H NMR (CDCl3): δ 7.91 
(s, CH, 1H), 7.43-7.22 (m, ArH, 10H), 5.42 (s, ArCH2, 2H), 3.29 (s, SO2CH3, 3H); 13C NMR 
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(CDCl3): δ 154.1, 153.2, 151.7, 144.4, 134.8, 132.2, 130.2, 129.7, 129.0, 128.7, 128.6, 128.0, 
115.5, 50.5, 41.4; Mass spectrum (EI) m/z 380.2 (M+) Exact mass calcd for C19H16N4O3S: m/z 
380.0943; found 380.0942. Yield: 90%. 
3-7d: 1,7-Dibenzyl-2-methylsulfonyl-1H-purin-6(7H)-one. 1H NMR (CDCl3): δ 7.84 (s, 
CH, 1H), 7.19-7.10 (m, ArH, 10H), 5.58 (s, N1CH2, 2H), 5.38 (s, N7CH2, 2H), 3.40 (s, 
SO2CH3, 3H); 13C NMR (CDCl3): δ 153.6, 152.7, 152.0, 144.3, 135.1, 134.8, 128.9, 128.5, 
128.2, 127.9, 127.4, 127.0, 115.6, 50.5, 47.1, 41.4; Mass spectrum (EI) m/z 394.1 (M+) Exact 
mass calcd for C20H18N4O3S: m/z 394.1100; found 394.1100. Yield: 95%. 
3.4.7 Synthesis of 7-benzyl-2-hydroxyalkylamino-1-substituted-1H-purin-6(7H)-one 
(3-8) 
To compound 3-7b (0.0335 g, 0.097 mmol) in ethanolamine (1 mL) was added molecular 
sieves (0.5 g) and the mixture was heated at 130 ºC for 30 min. After which, it was 
concentrated and purified by CC (EtOAc, then MeOH:CH2Cl2 = 1:5) to give 
7-benzyl-2-(2-hydroxyethyl)amino-1-propyl-1H-purin-6(7H)-one (3-8a) as a colorless oil 
(0.0267 g, 84% yield). 1H NMR (CD3OD): δ 8.19 (s, CH, 1H), 7.37-7.28 (m, ArH, 5H), 5.54 
(s, ArCH2, 2H), 4.01-3.96 (t, J = 7.8 Hz, CH2CH2CH3, 2H), 3.77-3.73 (m, NCH2CH2OH, 2H), 
3.60-3.57 (t, J = 5.6 Hz, NCH2CH2OH, 2H), 1.75-1.62 (m, CH2CH2CH3, 2H), 0.99-0.94 (t, J 
= 7.5 Hz, CH2CH2CH3, 3H); 13C NMR (CD3OD): δ 157.1, 156.3, 154.0, 143.2, 137.8, 129.9, 
129.3, 128.9, 108.8, 61.5, 51.4, 45.5, 43.2, 21.7, 11.2; Mass spectrum (EI) m/z 327.2 (M+) 
Exact mass calcd for C17H21N5O2: m/z 327.1695; found 327.1691. 
3-8b: 7-Benzyl-2-(3-hydroxypropyl)amino-1-propyl-1H-purin-6(7H)-one. 1H NMR  
(CD3OD): δ 7.97 (s, CH, 1H), 7.32-7.26 (m, ArH, 5H), 5.50 (s, ArCH2, 2H), 3.98-3.92 (t, J = 
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7.7 Hz, CH2CH2CH3, 2H), 3.68-3.64 (m, NCH2CH2CH2OH, 2H), 3.59-3.54 (t, J = 6.6 Hz, 
NCH2CH2CH2OH, 2H), 1.93-1.82 (m, NCH2CH2CH2OH, 2H), 1.73-1.60 (m, CH2CH2CH3, 
2H), 0.98-0.93 (t, J = 7.3 Hz, CH2CH2CH3, 3H); 13C NMR (CD3OD): δ 158.9, 156.6, 153.4, 
144.5, 138.4, 129.1, 128.7, 108.9, 61.0, 50.9, 43.0, 40.7, 32.8, 21.8, 11.2; Mass spectrum (EI) 
m/z 341.1 (M+) Exact mass calcd for C18H23N5O2: m/z 341.1852; found 341.1846. Yield: 
78%. 
3-8c: 7-Benzyl-2-(4-hydroxybutyl)amino-1-propyl-1H-purin-6(7H)-one. 1H NMR (CDCl3): 
δ 7.75 (s, CH, 1H), 7.44-7.30 (m, ArH, 5H), 5.49 (s, ArCH2, 2H), 3.97-3.54 (m, CH2CH2CH3 
and NCH2CH2CH2CH2OH, 6H), 1.79-1.62 (m, CH2CH2CH3 and NCH2CH2CH2CH2OH, 6H), 
0.98-0.94 (t, J = 6.3 Hz, CH2CH2CH3, 3H); 13C NMR (CDCl3): δ 156.7, 155.0, 151.6, 141.9, 
135.9, 128.9, 128.3, 127.9, 108.2, 62.1, 50.3, 42.1, 37.9, 29.6, 25.8, 20.9, 11.2; Mass 
spectrum (EI) m/z 341.1 (M+) Exact mass calcd for C18H23N5O2: m/z 341.1852; found 
341.1846. Yield: 70%. 
3.4.8 Synthesis of polycyclic guanines (3-9) 
To compound 3-8a (0.0397 g, 0.121 mmol) and TEA (0.051 mL, 0.363 mmol) in CH2Cl2 (2 
mL) was added a solution of SOCl2 (0.045 mL, 0.605 mmol) in CH2Cl2 (1 mL) dropwise in 
an ice-water bath. After that, the mixture was stirred in the ice-water bath for an additional 30 
min and then at rt for 1 h. The reaction mixture was then refluxed at 50-60 ºC for another 1 h 
then quenched with 10% KOH solution (1 mL), diluted with water (10 mL) and extracted 
with CH2Cl2 (20 mL x 3). The combined organic layer was dried with MgSO4, filtered, 
concentrated and purified by CC (EtOAc, then MeOH:CH2Cl2 = 1:5) to give 
3-benzyl-5-propyl-7,8-dihydro-3H-imidazo [2,1-b]purin-4(5H)-one (3-9a) as a colorless oil 
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(0.033 g, 90% yield). 1H NMR (CD3OD): δ 8.00 (s, CH, 1H), 7.35-7.29 (m, ArH, 5H), 5.50 (s, 
ArCH2, 2H), 4.22-4.16 (t, J = 9.2 Hz, CH2CH2CH3, 2H), 4.01-3.95 (t, J = 9.1 Hz, 
N6CH2CH2N, 2H), 3.88-3.83 (t, J = 7.7 Hz, N6CH2CH2N, 2H), 1.74-1.61 (m, CH2CH2CH3, 
2H), 0.97-0.92 (t, J = 7.5 Hz, CH2CH2CH3, 3H); 13C NMR (CD3OD): δ 155.7, 155.5, 149.1, 
143.7, 137.6, 129.9, 129.4, 128.9, 106.6, 50.9, 50.1, 46.9, 45.1, 21.4, 11.2; Mass spectrum (EI) 
m/z 309.0 (M+) Exact mass calcd for C17H19N5O: m/z 309.1590; found 309.1587. 
3-9b: 3-Benzyl-5-propyl-8,9-dihydropyrimido[2,1-b]purin-4(5H)-one. 1H NMR (CD3OD): 
δ 8.03 (s, CH, 1H), 7.37-7.27 (m, ArH, 5H), 5.52 (s, ArCH2, 2H), 4.12-4.10 (t, J = 5.7 Hz, 
N6CH2CH2CH2N, 2H), 3.95-3.92 (t, J = 7.9 Hz, CH2CH2CH3, 2H), 3.59-3.56 (t, J = 5.7 Hz, 
N6CH2CH2CH2N, 2H), 2.08-2.05 (m, N6CH2CH2CH2N, 2H), 1.67-1.59 (m, CH2CH2CH3, 
2H), 0.96-0.93 (t, J = 7.3 Hz, CH2CH2CH3, 3H); 13C NMR (CD3OD): δ 155.2, 149.6, 147.4, 
143.5, 137.7, 129.9, 129.4, 128.9, 107.3, 51.1, 44.0, 43.6, 43.1, 21.2, 20.0, 11.3; Mass 
spectrum (EI) m/z 323.0 (M+) Exact mass calcd for C18H21N5O: m/z 323.1746; found 
323.1736. Yield: 89%. 
3-9c: 3-Benzyl-5-propyl-7,8,9,10-tetrahydro-3H-[1,3]diazepino[2,1-b]purin-4(5H)-one. 
1H NMR (CDCl3, 500 MHz): δ 7.81 (s, CH, 1H), 7.34-7.27 (m, ArH, 5H), 5.50 (s, ArCH2, 
2H), 3.98-3.95 (t, J = 7.6 Hz, CH2CH2CH3, 2H), 3.57-3.52 (m, N6CH2CH2CH2CH2N, 4H), 
1.85-1.66 (m, CH2CH2CH3 and N6CH2CH2CH2CH2N, 6H)  1.00-0.97 (t, J = 7.3 Hz, 
CH2CH2CH3, 3H); 13C NMR (CDCl3, 126 MHz): δ 156.2, 154.9, 151.4, 141.6, 135.7, 129.0, 
128.4, 127.9, 108.3, 50.4, 44.8, 42.2, 41.6, 29.9, 26.5, 20.9, 11.3; Mass spectrum (EI) m/z 
337.1 (M+) Exact mass calcd for C19H23N5O: m/z 337.1903; found 337.1899. Yield: 95%. 
3-9d: 3-Benzyl-5-ethyl-8,9-dihydropyrimido[2,1-b]purin-4(5H)-one. 1H NMR (CD3OD, 
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500 MHz): δ 7.97 (s, CH, 1H), 7.37-7.29 (m, ArH, 5H), 5.50 (s, ArCH2, 2H), 4.06-4.00 (m, 
CH2CH3 and N6CH2CH2CH2N, 4H), 3.56-3.54 (t, J = 5.7 Hz, N6CH2CH2CH2N, 2H), 
2.03-1.98 (m, N6CH2CH2CH2N, 2H), 1.19-1.16 (t, J = 7.0 Hz, CH2CH3, 3H); 13C NMR 
(CD3OD, 126 MHz): δ 155.5, 149.9, 146.6, 143.1, 137.7, 129.9, 129.3, 128.9, 106.8, 51.0, 
43.8, 43.7, 37.2, 20.4, 12.7; Mass spectrum (EI) m/z 309.0 (M+) Exact mass calcd for 
C17H19N5O: m/z 309.1590; found 309.1588. Yield: 94%. 
3-9e: 3-Benzyl-5-phenyl-7,8-dihydro-3H-imidazo[2,1-b]purin-4(5H)-one. 1H NMR 
(CD3OD): δ 8.01 (s, CH, 1H), 7.53-7.28 (m, ArH, 10H), 5.44 (s, ArCH2, 2H), 4.17-4.11 (t, J = 
9.2 Hz, N6CH2CH2N, 2H), 3.56-3.54 (t, J = 9.2 Hz, N6CH2CH2N, 2H); 13C NMR (CD3OD): 
δ 156.4, 156.4, 150.2, 143.7, 137.6, 136.9, 130.6, 130.1, 130.1, 129.9, 129.4, 129.0, 106.3, 
51.5, 50.9, 47.1; Mass spectrum (EI) m/z 343.0 (M+) Exact mass calcd for C20H17N5O: m/z 
343.1433; found 343.1418. Yield: 89%. 
3-9f: 3,5-Dibenzyl-7,8-dihydro-3H-imidazo[2,1-b]purin-4(5H)-one. 1H NMR (CD3OD, 500 
MHz): δ 7.93 (s, CH, 1H), 7.36-7.19 (m, ArH, 10H), 5.44 (s, N3CH2, 2H), 5.08 (s, N5CH2, 
2H), 4.11-4.08 (t, J = 9.1 Hz, N6CH2CH2N, 2H), 3.92-3.89 (t, J = 9.1 Hz, N6CH2CH2N, 2H); 
13C NMR (CD3OD, 126 MHz): δ 156.3, 155.7, 149.8, 143.4, 138.0, 137.7, 129.9, 129.4, 128.9, 
128.8, 128.4, 128.3, 105.9, 51.8, 50.9, 47.2, 46.2; Mass spectrum (EI) m/z 357.1 (M+) Exact 
mass calcd for C21H19N5O: m/z 357.1590; found 357.1560. Yield: 92%. 
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Chapter 4 Microwave-Assisted Combinatorial Solid-Phase Synthesis of 
Pyrazolidine-3,5-diones 
4.1 Introduction 
4.1.1 Importance of pyrazolidine-3,5-diones 
Pyrazolidine-3,5-diones are well known for their anti-inflammatory properties because their 
pharmacologic spectrum is very similar to Aspirin.1 Many derivatives have been clinically 
used for the treatment of various diseases. Phenylbutazone (brand name Butazolidine),2 
oxyphenbutazone (brand name Tandearil),2c,3 ketasone,4 sulfinpyrazone (brand name 
Anturane),5 are very effective in treating fever, pain, inflammation, arthritis, bursitis; and as a 
uric acid lowering drug in the prevention and treatment of gout. Besides these, there are also 
many other derivatives of pyrazolidine-3,5-diones which have been used for other 
anti-inflammatory applications.5b,6 More recently, this class of compounds was discovered to 
inhibit viral infections, especially those resulting in HIV/AIDS, and measles,7 as the 
compounds are able to reduce metabolic activity in cells affected with HIV/AIDS, measles 
and other viral diseases, thereby reducing viral production and potentially killing the infected 
cell. Studies have also shown that antiviral pyrazolidine-3,5-diones possess a better inhibitory 





























4.1.2 General methods for solution-phase synthesis of pyrazolidine-3,5-diones 
Among the various methods for synthesizing pyrazolidine-3,5-diones, the classical and most 
popular one is through the condensation of hydrazines with malonic acids or their derivatives 
(Scheme 4-1).5b,9 However the reaction conditions for these condensation are not mild - they 
either required long reaction times (up to a few days), high temperature (150 °C), or 
extremely expensive or uncommon reactants. A slightly different method was developed by 
Graziano Baccolini10 who prepared N-alkenyl-pyrazolidine-3,5-diones from ketone 
hydrazones, PC13 and malonic acid. 
Scheme 4-1 Synthesis of Pyrazolidine-3,5-diones via Malonic Acid Derivatives 
N N
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R3 R4






Using this synthetic route, non-substituted pyrazolidine-3,5-dione was prepared through the 
 83
cyclization of ethyl malonyl hydrazide (Scheme 4-2). This non-substituted 
pyrazolidine-3,5-dione was subsequently alkylated to provide the substituted products.11 Since 
all the 1, 2 and 4 positions of pyrazolidine-3,5-dione can be easily alkylated, it was difficult to 
realize the differences between R1, R2, R3 and R4, hence reducing the diversity of the final 
compounds. 













To circumvent this problem, Lawton and coworkers have reported the synthesis of substituted 
pyrazolidine-3,5-diones through a stepwise N-alkylation prior to ring closure (Scheme 4-3).12 
In this method, although the whole synthesis was few steps longer than the methods 
mentioned earlier, common reagents and mild reaction conditions were used, and the yield for 
each step was often more than 90%. Furthermore alkylations of N1 and N2 were carried out 
in different steps, which thus allowed a variety of substitutents to be used. 
















4.1.3 General methods for solid-phase synthesis of pyrazolidine-3,5-diones 
To our knowledge, there is thus far only one report on the polymer-supported synthesis of 
pyrazolidine-3,5-diones.14 In this paper (Scheme 4-4) liquid-phase approach using PEG as a 
polymeric support for the synthesis was described. Due to the nature and position of this 
support, the product released contained a remnant tether at the 4-position, which thus results 
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in the loss of one diversity point. 







































4.1.4 Objectives and scope of this study 
Since the solid-phase synthesis of pyrazolidine-3,5-diones has not been explored, we decided 
to embark on this project, which aims to develop a traceless solid-phase synthetic 
methodology to this class of compounds. 
 85
4.2 Results and Discussion 
4.2.1 Solution-phase synthesis of pyrazolidine-3,5-diones 
Prior to SPS, preliminary solution-phase studies (Scheme 4-5) were carried out to survey the 
required reaction conditions and establish the optimizations required for SPS.  
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4.2.1.1 Synthesis of benzyl 3-benzylidenecarbazate (4-9) 
In our initial synthetic strategy, we had intended to prepared benzyl carbazate from benzyl 
alcohol, the Wang resin mimic. Various existing routes to benzyl carbazate (4-8) (Scheme 4-6) 
were explored: Route A and route B could not be adapted for our solid-phase synthesis as they 
could result in a premature cleavage from the solid support. Synthesis of 4-8 via Route C 
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involved the preparation of an intermediate which was highly unstable and difficult to handle. 
Hence, we thought that Route D would probably be the best method to 4-8. Unfortunately 
self-condensation of methyl carbazate occurred readily and the desired 4-8 was not observed. 
Although this problem could have been circumvented by protecting the primary amine of 
methyl carbazate, we perceived that a protection de-protection strategy would add two more 
steps to the solid-phase synthesis, thus making it less elegant. Considering that the next step 
was to convert the primary amine to an imine, we decided to synthesize the imine before 
attaching it to the polymeric support. By doing so, 4-9 could be prepared in a single step, 
instead of three steps, on solid-phase. 
Methyl 3-benzylidenecarbazate (4-2a), which was prepared by reacting methyl carbazate (4-1) 
with benzyl aldehyde in MeOH, was treated with benzyl alcohol in the presence of DBU to 
give benzyl 3-benzylidenecarbazate (4-9) in 85% yield. The yield of this reaction was slightly 
lower than most typical ester exchange reactions because, in our reaction, benzyl alcohol had 










































4.2.1.2 Synthesis of benzyl 3-benzylidene-2-methylcarbazate (4-10) 
According to Lawton’s procedure,12 4-9 could be converted to benzyl 
3-benzylidene-2-methylcarbazate (4-10) by using K2CO3 as a base for the alkylation. 
However K2CO3 has poor solubility in the organic solvents, which provide good resin 
swelling. Hence we were required to search for an alternative base for our solid-phase 
reaction (Table 4-1). Despite using the strongest alkylating agent, CH3I, all reactions carried 
out using amine bases failed. This may be attributed to the amines, which were too weakly 
basic to remove the proton on the nitrogen of 4-9. Similar reactions carried out using 
inorganic salts such as KOtBu and NaH worked very well. It is interesting to note that 
alkylation with CH3I using KOtBu as base gave a better yield than NaH, but alkylation with 
other alkylating agents, such as BnBr, PrBr and allyl bromide, gave better yields with NaH 
rather than with KOtBu. These results could possibly be due to a combination of the 
alkylating ability of the reagents and the basicity of bases: CH3I is the strongest alkylating 
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agent, and NaH is a stronger base than KOtBu. Thus a reaction involving CH3I and NaH 
would be much harsher than if other combinations of alkylating agent and base were used and 
the reaction may give byproducts which results in a lower yield. By the same token, BnBr, 
PrBr and allyl bromide are weaker alkylating regents compared to CH3I, and thus would 
require a stronger base, such as NaH, to give a higher yield. Based on our experimental results, 
two alkylation conditions (entries 8 and 11 in Table 4-1) were select for application on SPS.  
Table 4-1 Synthesis of 4-10 
Entry Base Alkylating agent Solvent Conditions Result 
1 K2CO3 BnBr/BrCH2COOEt Acetone reflux, 24 h 90% yield 
2 TEA CH3I/BnBr/BrCH2COOEt CH2Cl2/THF rt/reflux No product 
3 DIEA CH3I/BnBr/BrCH2COOEt CH2Cl2/THF rt/reflux No product 
4 Urea BrCH2COOEt Acetone reflux No product 
5 TMG BrCH2COOEt Acetone reflux No product 
6 DBU BnBr/BrCH2COOEt Acetone reflux Trace product
7 KOtBu CH3I tBuOH/THF rt, 2 h 58% yield 
8 KOtBu CH3I THF/DMF
 
rt, 2 h 92% yield 
9 KOtBu BnBr/BrCH2COOEt THF/DMF rt, 12 h 22-47% yield
10 NaH CH3I THF/DMF rt, 2 h 60% yield 
11 NaH BnBr/BrCH2COOEt DMF rt, 12 h 86-76% yield
 
4.2.1.3 Synthesis of benzyl 3-benzyl-2-methylcarbazate (4-11) 
We had earlier reported a modified methodology for imine reduction (using NaBH(OAc)3 and 
HOAc in DMF (1%)).13 However attempts to reduce 4-10 using this methodology failed to 
provide the desired 4-11. Replacing NaBH(OAc)3 with a stronger reducing agent such as 
NaBH4 in MeOH, THF or DMF and in the presence or absence of an acid catalyst also failed 
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to provide the desired compound. Using H2 with palladium-charcoal was not considered 
because of the insolubility of the catalyst, which can not be used in solid-phase reactions. 
Finally we tried NaBH3CN with dilute HCl,12 which gave 4-11 in 95% yield. 
4.2.1.4 Synthesis of benzyl 3-benzyl-3-ethoxycarbonylacetyl-2-methylcarbazate (4-12) 
It was reported earlier12 that acylation of 4-11 with ethoxycarbonylacetyl chloride and TEA in 
benzene gave 3-benzyl-3-ethoxycarbonylacetyl-2-methylcarbazate (4-12) in 84% yield. 
Unfortunately, in our hands, we were unable to reproduce this result. Attempts to vary the 
reaction conditions (Table 4-2) failed to improve the reaction. An alternative was to conduct a 
coupling reaction using ethyl hydrogen malonate and different coupling reagents in DMF. 
DCC and a catalytic amount DMAP gave the product 4-12 in 66% yield, but there was always 
some starting material 4-11 leftover, even after increasing the quantities of ethyl hydrogen 
malonate and DCC, prolonging the reaction or heating. Using stronger coupling reagents such 
as BOP, HATU also proved to be ineffective in improving the yield. Eventually, we sought to 
carry out the reaction under microwave conditions. To our delight, the reaction worked 
remarkably well under microwave irradiation and 4-12 was obtained in 93% yield. 
Optimization of the microwave reaction indicated that the best reaction condition was at 90 
°C for 1 h. 
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Table 4-2 Synthesis of 4-12 
Entry Base Reagent Solvent Conditions Result 





0 °C, rt, reflux No product
2 DIEA EtO2CCH2COCl CH2Cl2/THF rt/reflux No product
3 DBU EtO2CCH2COCl CH2Cl2/THF rt/reflux No product
4 KOtBu EtO2CCH2COCl tBuOH, THF rt 46% yield 
5 KOtBu EtO2CCH2COCl THF rt 43% yield 
6 KOtBu EtO2CCH2COCl DMSO rt No product
7 NaH EtO2CCH2COCl DMF rt No product



















































4.2.1.5 Synthesis of 1-benzyl-4-ethoxycarbonyl-2-methylpyrazolidine-3,5-dione (4-7-2a) 
Subsequently, 4-12 was cyclized with NaOEt in MeOH and THF to give 4-7-2a in 
quantitative yield. Under microwave irradiation, the reaction was completed within 5 min 
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whilst conventional heating required 0.5 h. 
4.2.1.6 Synthesis of 1-benzyl-2-methylpyrazolidine-3,5-dione (4-7-1a) 
Compound 4-7-2a was decarboxylated using H2O and MeCN in the presence of catalytic 
amounts of dilute HCl to afford 4-7-1a. Under conventional heating, the decarboxylation 
reaction was complete in 3 h, whereas for microwave-assisted reactions needed only 5 min to 
complete. It is worth noting that 4-7-1a could also be obtained directly from 4-12 by 
treatment with TFA in CH2Cl2. Although the yields are generally good, but compared to the 
two-step cyclization-decarboxylation reaction, the overall yield for the two step reaction is 
higher than the one-pot transformation. 
4.2.1.7 Synthesis of 1-benzyl-2,4-dimethyl-4-ethoxycarbonylpyrazolidine-3,5-dione 
(4-7-3a) 
To obtain 4-substituted-4-ethoxycarbonyl pyrazolidine-3,5-dione, 4-7-2a was alkylated with 
CH3I in the presence of a base. Various bases were tested and DIEA proved to be better than 
TEA, DBU, Li2CO3, and NaOEt. In addition, the reaction time could be significantly reduced 
from 16 h to 20 min by microwave irradiation. 
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4.2.2 Solid-phase synthesis of pyrazolidine-3,5-diones 
With the solution-phase pathway established, we proceeded to prove the versatility of this 
methodology for SPS (Scheme 4-7). 
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(1) NaOEt, THF, MeOH
     mw, 110 oC, 5 min
(2) R4X, DIEA, DMF
     mw, 140 oC, 5 min
 
Methyl carbazate (4-1) was reacted with an equal molar of the respective aldehyde in MeOH 
to give 4-2. The crude 4-2 obtained was subsequently treated with Wang resin by an ester 
exchange reaction to give 4-3 (Scheme 4-7). This reaction was amenable to KBr FTIR 
monitoring (disappearance of the OH stretch at 3566.0 cm-1 and appearance of a strong ester 
peak at 1739.6 cm-1). Using the reaction conditions established in our solution-phase study 
(Table 4-1), resin 4-3 was alkylated with different alkylating agents to afford 4-4. To ensure 
that the reaction proceeded to completion, resin 4-3 was stirred with KOtBu or NaH in DMF 
for 1 h before the alkylating agent was added. Resin 4-4 was subsequently reduced with 
 93
NaBH3CN to afford resin 4-5. Formation of resin 4-5 could be monitored using KBr FTIR by 
the appearance of an NH stretch at 3299.1 cm-1. Using the acylation conditions established in 
our solution-phase study, we proceeded to acylate 4-5 by microwave irridiation. Ethyl 
hydrogen malonate, cynoacetic acid, 4-nitrophenyl acetic acid and diphenyl acetic acid were 
selected as examples for the acylation reaction. However only the first 3 acids were applicable 
because the product from diphenyl acetic acid could not be cyclized. With resin 4-6 in hand, 
we proceeded to synthesize various 1,2,4-trisubstituted pyrazolidine-3,5-diones (4-7-2) by 
treating the resin with NaOEt in EtOH and THF under microwave irradiation. A one-pot 
cyclization-alkylation could also be carried out by further treating the crude reaction mixture 
with various alkyl halides under microwave irradiation to afford compound 4-7-3. 
Alternatively, the crude mixture could also be reacted with HCl in CH3CN under microwave 
conditions to facilitate a one-pot decarboxylation to give 1,2-substituted 
pyrazolidine-3,5-diones (4-7-1). To illustrate the versatility of this chemistry, a representative 
set of 27 compounds, including 9 disubstituted, 11 trisubstituted and 7 tetrasubstituted 
pyrazolidine-3,5-diones was prepared (Figure 4-2). Only product 4-7-1d could not be formed 
under base cleavage method and was prepared via an acid cleavage method. The overall 
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4.3 Conclusion 
This project investigated a solid-phase methodology for the preparation of 
pyrazolidine-3,5-diones. A preliminary solution-phase study was successfully carried out to 
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obtain the required reaction conditions, which were eventually adapted onto the solid-phase 
format. In this study, microwave irradiation was used in several steps of both the solid-phase 
and solution-phase syntheses to accelerate the reactions. These microwave-assisted reactions 
provided better yields than the traditional oil bath heating method. To the best of my 
knowledge, this is the first reported solid-phase synthesis of pyrazolidine-3,5-diones. 
4.4 Experimental 
Wang resin was purchased from Tianjin Nankai Hecheng Science and Technology Co 
(100-200 mesh, 1.4 mmol/g, 1% divinylbenzene cross-linking). All other chemical reagents 
were obtained from Aldrich, Merck, Lancaster or Fluka and used without further purification. 
The solid-phase rt reactions were agitated on a SF1 flask shaker (Stuart Scientific). Analytical 
TLC was carried out on pre-coated plates (Merck silica gel 60, F254) and visualized with UV 
light or stained with ninhydrin. CC was performed with silica (Merck, 70-230 mesh). 1H 
NMR and 13CNMR spectra were measured at 298 K on a Bruker DPX 300 or DPX 500 
Fourier Transform spectrometer. Chemical shifts are reported in δ (ppm), relative to the 
internal standard of TMS. The signals observed are described as: s, d, t, q, m. The number of 
protons (n) for a given resonance is indicated as nH. All Infra-red spectra were recorded on a 
Bio-Rad FTS 165 spectrometer. Mass spectra were performed on VG Micromass 7035 
spectrometer under EI, Finnigan/MAT LCQ under ESI (Normal), and Finnigan/MAT 95XL-T 
under ESI (Accurate). 
4.4.1 Synthesis of benzyl 3-benzylidenecarbazate (4-9) 
Benzyl alcohol (1.0000 g, 9.25 mmol), toluene (15 mL), methyl 3-benzylidenecarbazate (4-2a) 
(2.4720 g, 13.87 mmol) and DBU (0.4 mL, 2.775 mmol) were placed in a round bottom flask. 
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The mixture was refluxed for 3 h, then it was concentrated and purified by CC 
(EtOAc:hexane = 1:3) to give 4-9 as a white solid (2.000 g, 85% yield). 1H NMR (CDCl3): δ 
8.67 (s, NH, 1H), 7.84 (s, CH, 1H), 7.67-7.33 (m, ArH, 10H), 5.25 (s, CH2, 2H); 13C NMR 
(CDCl3): δ 153.7, 145.0, 135.8, 133.7, 129.9, 128.5, 128.3, 128.2, 127.5, 127.2, 126.9, 67.4; 
Mass spectrum (EI) m/z 254.0 (M+) Exact mass calcd for C15H14N2O2: m/z 254.1055; found 
254.1048. 
4.4.2 Synthesis of benzyl 3-benzylidene-2-methylcarbazate (4-10) 
Compound 4-9 (0.5000 g, 1.966 mmol) was dissolved in DMF (10 mL). KOtBu (0.4500 g, 
3.933 mmol) was then added and the mixture was stirred at rt for 10 min. Subsequently it was 
cooled in an ice-water bath and CH3I (0.4 mL, 5.9 mmol) was added dropwise. After that the 
mixture was stirred at rt for another 2 h, quenched with saturated NH4Cl solution and 
extracted with ether (20 mL x 3). The combined organic layer was dried with MgSO4, filtered, 
concentrated and purified by CC (EtOAc:hexane = 1:5). A colorless oil 4-10 was obtained 
(0.4858 g, 92% yield). 1H NMR (CDCl3): δ 7.76-7.34 (m, ArH and CH, 11H), 5.36 (s, CH2, 
2H), 3.38 (s, CH3, 3H); 13C NMR (CDCl3): δ 154.3, 139.7, 136.1, 134.6, 129.3, 128.4, 128.2, 
127.8, 127.7, 126.9, 67.8, 30.7; Mass spectrum (EI) m/z 267.9 (M+) Exact mass calcd for 
C16H16N2O2: m/z 268.1212; found 268.1212. 
4.4.3 Synthesis of benzyl 3-benzyl-2-methylcarbazate (4-11) 
To compound 4-10 (0.2560 g, 0.954 mmol) in MeOH (5 mL) and THF (5 mL) was added 
NaBH3CN (0.1800 g, 2.86 mmol) and trace amounts of bromocresol green indicator. The 
resulting dark blue mixture was stirred at rt while 1.5 M HCl was added dropwise to just 
maintain the yellow color of the reaction mixture. When the yellow color persisted for 0.5 h 
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without further addition of acid, the mixture was concentrated and purified by CC 
(EtOAc:hexane = 1:5) to give 4-11 as a colorless oil (0.2448 g, 95% yield). 1H NMR (CDCl3): 
δ 7.47-7.30 (m, ArH, 10H), 5.22 (s, ArCH2OOC, 2H), 4.02 (s, ArCH2NH, 2H), 3.04 (s, CH3, 
3H); 13C NMR (CDCl3): δ 156.5, 137.1, 136.2, 128.9, 128.2, 128.1, 127.8, 127.7, 127.2, 67.2, 
53.8, 36.9; Mass spectrum (EI) m/z 270.1 (M+) Exact mass calcd for C16H18N2O2: m/z 
270.1368; found 270.1366. 
4.4.4 Synthesis of benzyl 3-benzyl-3-ethoxycarbonylacetyl-2-methylcarbazate (4-12) 
To compound 4-11 (0.230 g, 0.85 mmol) in DMF (5 mL) was added ethyl hydrogen malonate 
(0.30 mL, 2.55 mmol), DCC (0.530 g, 2,55 mmol) and DMAP (catalytic amount) in the stated 
order. The mixture was heated by microwave irradiation at 90 °C for 1 h, quenched with H2O 
and extracted with ether (10 mL x 3). The combined organic layer was dried with MgSO4, 
filtered, concentrated and purified by CC (EtOAc:hexane = 1:5, then 1:2) to provide 4-12 
(0.305 g, 93% yield) as a colorless oil. 1H NMR (CDCl3): δ 7.29-7.19 (m, ArH, 10H), 
5.11-4.27 (m, ArCH2, 4H), 4.14-4.06 (q, J = 7.20 Hz, CH3CH2, 2H), 3.36-3.21 (m, CH2, 2H), 
2.80 (s, CH3, 3H), 1.22-1.68 (t, J = 7.14 Hz, CH3CH2, 3H); 13C NMR (CDCl3): δ 168.4, 167.0, 
155.2, 139.7, 135.3, 129.3, 128.7, 128.6, 128.5, 128.1, 128.0, 68.4, 61.4, 50.1, 40.2, 14.0; 
Mass spectrum (EI) m/z 383.9 (M+) Exact mass calcd for C21H24N2O5: m/z 384.1685; found 
384.1677. 
4.4.5 Synthesis of 1-benzyl-4-ethoxycarbonyl-2-methylpyrazolidine-3,5-dione (4-7-2a) 
To a solution of 4-12 (0.223 g, 0.58 mmol) in EtOH (5 mL) and THF (5 mL) was added 
NaOEt (21% (w/w) in denatured EtOH, 0.65 mL, 1.74 mmol). The mixture was heated by 
microwave irradiation at 110 °C for 5 min, then concentrated and purified by CC 
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(MeOH:CH2Cl2 = 1:5) to give 4-7-2a (0.118 g, 99% yield) as a white solid. 1H NMR 
(CD3OD): δ 7.22 (s, ArH, 5H), 4.80 (s, ArCH2, 2H), 4.27-4.20 (q, J = 6.96 Hz, CH3CH2, 2H), 
3.02 (s, CH3, 3H), 1.29-1.25 (t, J = 6.98 Hz, CH3CH2, 3H); 13C NMR (CD3OD): δ 172.1, 
170.7, 169.8, 137.9, 129.5, 129.0, 128.6, 82.5, 61.3, 47.8, 31.3, 14.9; Mass spectrum (EI) m/z 
276.0 (M+) Exact mass calcd for C14H16N2O4: m/z 276.1110; found 276.1112. 
4.4.6 Synthesis of 1-benzyl-2-methylpyrazolidine-3,5-dione (4-7-1a) 
Method A: To a solution of 4-12 (0.223 g, 0.58 mmol) in EtOH (5 mL) and THF (5 mL) was 
added NaOEt (21% (w/w) in denatured EtOH, 0.65 mL, 1.74 mmol). The mixture was heated 
by microwave irradiation at 110 °C for 5 min, then acidified, concentrated and dried in 
vacuum. To the resulting residue was added. 1.5 M HCl in MeCN (AR grade, 5 mL) and H2O 
(5 mL). Then the mixture was heated under microwave irradiation at 140 °C for 5 min, 
concentrated and purified by CC (EtOAc:hexane = 1:1) to give product 4-7-1a (0.1100 g, 
93% yield) as a white solid. 
Method B: To the stirring mixture of 4-12 (0.0228 g, 0.0593 mmol) in CH2Cl2 (5 mL) was 
added TFA (1 mL) dropwise. The reaction mixture was stirred at rt for 3 h then concentrated 
and purified by CC (EtOAc:hexane = 1:1) to give 4-7-1a (0.087 g, 73% yield). 1H NMR 
(CDCl3): δ 7.30-7.19 (m, ArH, 5H), 4.78 (s, ArCH2, 2H), 3.17 (s, CH2, 2H), 3.02 (s, CH3, 3H); 
13C NMR (CDCl3): δ 167.0, 166.8, 134.8, 129.0, 128.4, 127.5, 46.9, 36.3, 30.5; Mass 





4.4.7 Synthesis of 1-benzyl-2,4-dimethyl-4-ethoxycarbonylpyrazolidine-3,5-dione 
(4-7-3a) 
To a solution of 4-12 (0.223 g, 0.58 mmol) in EtOH (5 mL) and THF (5 mL) was added 
NaOEt (21% (w/w) in denatured EtOH, 0.65 mL, 1.74 mmol). The mixture was heated under 
microwave irradiation at 110 °C for 5 min, concentrated and dried in vacuum. The resulting 
residue was diluted with DMF (5 mL), and DIEA (0.60 mL, 3.48 mmol) and CH3I (0.11 mL, 
1.74 mmol) were added. The reaction mixture was heated under microwave irradiation at 140 
°C for 20 min, concentrated and purified by CC (EtOAc:hexane = 1:3) to afford 4-7-3a (0.076 
g, 45% yield) as a colorless oil. 1H NMR (CDCl3): δ 7.37-7.29 (m, ArH, 5H), 5.01-4.78 (m, 
ArCH2, 2H), 4.25-4.18 (q, J = 7.08 Hz, CH3CH2, 2H), 3.14 (s, N2CH3, 3H), 1.60 (s, CH3, 3H), 
1.28-1.23 (t, J = 7.14 Hz, CH3CH2, 3H); 13C NMR (CDCl3): δ 168.1, 167.8, 164.9, 134.4, 
129.0, 128.5, 127.6, 77.2, 62.8, 46.6, 30.7, 16.5, 13.9; Mass spectrum (EI) m/z 290.1 (M+) 
Exact mass calcd for C15H18N2O4: m/z 290.1267; found 290.1267. 
4.4.8 Preparation of methyl 3-alkylidenecarbazate (4-2) 
To a solution of methyl carbazate (2.7 g, 30 mmol) in MeOH (AR grade, 30 mL) was added 
the respective aldehyde (30 mmol) and HOAc (glacial, 0.3 mL) (for benzaldehyde HOAc was 
unnecessary). The mixture was stirred at rt for 30 min and concentrated. The resulting white 
solid obtained was dried in a vacuum oven and used without further purification. 
Methyl 3-benzylidenecarbazate (4-2a): 1H NMR (CDCl3): δ 8.54 (s, NH, 1H), 7.89 (s, CH, 
1H), 7.67-7.35 (m, ArH, 5H), 3.80-3.76 (s, CH3, 3H); 13C NMR (CDCl3): δ 154.6, 144.9, 
133.7, 129.9, 128.5, 127.2, 52.8; Mass spectrum (EI) m/z 177.9 (M+) Exact mass calcd for 
C9H10N2O2: m/z 178.0742; found 178.0746. 
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Methyl 3-(2,4-dimethoxybenzylidene)carbazate (4-2b): 1H NMR (CDCl3): δ 8.55 (s, NH, 
1H), 8.16 (s, CH, 1H), 7.87-6.36 (m, ArH, 3H), 3.80-3.76 (m, CH3 and OCH3, 9H); 13C NMR 
(CDCl3): δ 162.5, 159.0, 140.9, 127.8, 115.0, 105.4, 97.9, 55.4, 55.3, 52.7; Mass spectrum (EI) 
m/z 238.2 (M+) Exact mass calcd for C11H14N2O4: m/z 238.0954; found 238.0952. 
Methyl 3-propylidenecarbazate (4-2c): 1H NMR (CDCl3): δ 7.85 (s, NH, 1H), 7.16 (s, CH, 
1H), 3.81 (s, CH3, 3H), 2.37-2.28 (m, CH2, 2H), 1.12-1.07 (t, J = 7.50 Hz, CH3CH2, 3H); 13C 
NMR (CDCl3): δ 154.6, 149.5, 52.8, 25.5, 10.9; Mass spectrum (EI) m/z 129.8 (M+) Exact 
mass calcd for C5H10N2O2: m/z 130.0742; found 130.0741. 
4.4.9 Preparation of benzyl 3-alkylidenecarbazate resin (4-3) 
A mixture of Wang resin (5 g, 7 mmol), 4-2 (14 mmol), DBU (0.32 mL, 2.1 mmol) and 
toluene (40 mL) was refluxed for 24 h. The resin was then filtered, washed with DMF (20 mL 
x 3), H2O (20 mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 mL x 3), Et2O (20 mL x 3) and dried 
overnight at 50 °C in a vacuum oven. 
4.4.10 Preparation of benzyl 3-alkylidene-2-substitutedcarbazate resin (4-4) 
A mixture of 4-3 (2 g, 2.213 mmol), KOtBu (0.4970 g, 4.426 mmol) [or NaH (60% dispersion 
in mineral oil, 0.177 g, 4.426 mmol)] and DMF (15 mL) was stirred at rt for 1 h. 
Subsequently the mixture was cooled in an ice-water bath and CH3I (0.4 mL, 6.639 mmol) [or 
RX (other alkylating agents, 6.639 mmol)] was added dropwise. The mixture was then stirred 
at rt for another 12 h. The resin was then filtered, washed with DMF (20 mL x 3), H2O (20 
mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 mL x 3), Et2O (20 mL x 3) and dried overnight at 50 
°C in a vacuum oven. 
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4.4.11 Preparation of benzyl 2,3-substitutedcarbazate resin (4-5) 
To a suspension of 4-4 (2.0520 g, 2.213 mmol) in MeOH (8 mL) and THF (13 mL) was added 
NaBH3CN (0.4170 g, 6.639 mmol) and bromocresol green indicator (half spatula). 1.5 M HCl 
was then added dropwise to just maintain the yellow color of the solution. When the yellow 
color persisted for 1 h without further addition of acid, the resin was filtered, washed with 
DMF (20 mL x 3), H2O (20 mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 mL x 3), Et2O (20 mL x 
3) and dried overnight at 50 °C in a vacuum oven.  
4.4.12 Preparation of benzyl 3-substitutedacetyl-2,3-substitutedcarbazate resin (4-6) 
To 4-5 (1 g, 1.1 mmol) in DMF (10 mL) was added the respective substituted acetic acids (2.2 
mmol), DCC (0.4540 g, 2.2 mmol) and DMAP (0.0400 g, 0.33 mol) in the stated order. The 
mixture was heated under microwave irradiation at 90 °C for 1 h then the resin was filtered, 
washed with DMF (20 mL x 3), H2O (20 mL x 3), EtOH (20 mL x 3), CH2Cl2 (20 mL x 3), 
Et2O (20 mL x 3) and dried overnight at 50 °C in a vacuum oven. 
4.4.13 Preparation of 4-ethoxycarbonyl-1,2-substitutedpyrazolidine-3,5-dione (4-7-2) 
A mixture of resin 4-6 (1.100 g, 1.1 mmol), NaOEt (21% (w/w) in denatured EtOH, 1.2 mL, 
3.3 mmol), THF (6 mL) and EtOH (6 mL) was heated under microwave irradiation at 110 °C 
for 5 min. The resin was then filtered and washed with MeOH (10 mL x 3). The combined 
filtrate was concentrated and purified by CC (EtOAc:hexane = 1:1, MeOH:CH2Cl2 =1:5) to 
give product 4-7-2. 
4.4.14 Preparation of 4-cyano/(4-nitro)phenyl-1,2-substitutedpyrazolidine-3,5-dione 
(4-7-2) 
A mixture of resin 4-6 (1.100 g, 1.1 mmol), NaOEt (21% (w/w) in denatured EtOH, 1.2 mL, 
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3.3 mmol), THF (6 mL) and EtOH (6 mL) was heated under microwave irradiation at 110 °C 
for 5 min. The resin was then filtered and washed with MeOH (10 mL x 3). The combined 
filtrate was concentrated, diluted with H2O and, extracted with ether. The aqueous layer was 
acidified with 1.5 M HCl and the solid which precipitated was collected and washed with H2O 
to give 7-2. If no ppt formed, the acidified aqueous layer was extracted with CH2Cl2 and the 
CH2Cl2 extract obtained was dried with MgSO4, filtered, concentrated to dryness to give 
product 4-7-2. 
4.4.15 Preparation of 1,2-substitutedpyrazolidine-3,5-dione (4-7-1) A mixture of resin 4-6 
(1.100 g, 1.1 mmol), NaOEt (21% (w/w) in denatured EtOH, 1.2 mL, 3.3 mmol), THF (6 mL) 
and EtOH (6 mL) was heated under microwave irradiation at 110 °C for 5 min. After the 
mixture has cooled, it was acidified with 1.5 M HCl and concentrated. To the resulting solid 
was added MeCN (10 mL), H2O (10 mL) and a few drops 1.5 M HCl. The mixture was 
heated under microwave irradiation at 140 °C for 5 min, filtered and washed with MeOH (10 
mL x 3). The combined filtrate was concentrated and purified by CC (EtOAc:hexane = 1:1) to 
give product 4-7-1. For compound 4-7-1d, an acid cleavage method was used. 
4.4.16 Preparation of 1,2,4,4-substitutedpyrazolidine-3,5-dione (4-7-3) 
A mixture of resin 4-6 (1.100 g, 1.1 mmol), NaOEt (21% (w/w) in denatured EtOH, 1.2 mL, 
3.3 mmol), THF (6 mL) and EtOH (6 mL) was heated under microwave irradiation at 110 °C 
for 5 min. After which, it was concentrated and dried. The resulting residue was diluted with 
DMF (10 mL), and DIEA (1.14 mL, 6.6 mmol) and CH3I (0.21 mL, 3.3 mmol) were added. 
The reaction mixture was heated under microwave irradiation at 140 °C for 20 min, filtered 
and the resin was washed with MeOH (10 mL x 3). The combined filtrate was concentrated 
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and purified by CC (EtOAc:hexane = 1:3) to give product 4-7-3. 
4-7-1b: 2-Allyl-1-benzylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 7.37-7.21 (m, ArH, 
5H), 5.76-5.63 (m, CH2CHCH2N, 1H), 5.25-5.18 (m, CH2CHCH2N, 2H), 4.80 (s, ArCH2, 2H), 
4.11-4.09 (d, J = 5.55 Hz, CH2CHCH2N, 2H), 3.25 (s, CH2, 2H); 13C NMR (CDCl3): δ 167.0, 
166.9, 134.6, 130.9, 128.9, 128.3, 127.5, 119.4, 46.7, 45.6, 36.3; Mass spectrum (EI) m/z 
229.8 (M+) Exact mass calcd for C13H14N2O2: m/z 230.1055; found 230.1055. 
4-7-1c: 1-Benzyl-2-propylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 7.31-7.17 (m, ArH, 
5H), 4.74 (s, ArCH2, 2H), 3.44-3.39 (t, J = 7.32 Hz, CH3CH2CH2, 2H), 3.17 (s, CH2, 2H), 
1.50-1.37 (m, CH3CH2CH2, 2H), 0.78-0.73 (t, J = 7.32 Hz, CH3CH2CH2, 3H); 13C NMR 
(CDCl3): δ 167.9, 167.0, 134.7, 129.0, 128.4, 127.6, 47.1, 44.8, 36.5, 20.4, 11.0; Mass 
spectrum (EI) m/z 232.0 (M+) Exact mass calcd for C13H16N2O2: m/z 232.1212; found 
232.1211. 
4-7-1d: 1-Benzyl-2-ethoxycarbonylmethylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 
7.30-7.16 (m, ArH, 5H), 4.71 (s, ArCH2, 2H), 4.10 (s, CH2N, 2H), 4.00-3.93 (q, J = 7.08 Hz, 
CH3CH2, 2H), 3.26 (s, CH2, 2H), 1.11-1.06 (t, J = 7.14 Hz, CH3CH2, 3H); 13C NMR (CDCl3): 
δ 170.3, 167.0, 166.4, 134.7, 128.8, 128.2, 127.5, 61.9, 47.5, 46.2, 36.1, 13.8; Mass spectrum 
(EI) m/z 276.1 (M+) Exact mass calcd for C14H16N2O4: m/z 276.1110; found 276.1114. 
4-7-1e: 1,2-Dibenzylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 7.32-7.13 (m, ArH, 10H), 
4.68 (s, ArCH2, 4H), 3.31 (s, CH2, 2H); 13C NMR (CDCl3): δ 166.9, 134.6, 128.9, 128.2, 
127.3, 46.7, 36.4; Mass spectrum (EI) m/z 280.1 (M+) Exact mass calcd for C17H16N2O2: m/z 
280.1212; found 280.1219. 
4-7-1f: 1-(2,4-Dimethoxybenzyl)-2-methylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 
 104
7.16-6.40 (m, ArH, 3H), 4.79 (s, ArCH2, 2H), 3.80-3.79 (d, OCH3, 6H), 3.17 (s, CH2, 2H), 
3.06 (s, CH3, 3H); 13C NMR (CDCl3): δ 167.6, 167.3, 161.1, 158.3, 130.6, 114.9, 104.6, 98.5, 
55.4, 55.3, 42.2, 36.4, 30.5; Mass spectrum (ESI) m/z 263.3 (M-H+) Exact mass calcd for 
C13H15N2O4: m/z 263.1032; found 263.1033. 
4-7-1g: 2-Benzyl-1-(2,4-dimethoxybenzyl)pyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 
7.35-6.44 (m, ArH, 8H), 4.69 (s, ArCH2, 4H), 3.80-3.80 (d, OCH3, 6H), 3.23 (s, CH2, 2H); 13C 
NMR (CDCl3): δ 167.6, 167.3, 161.0, 158.2, 134.8, 130.4, 128.7, 128.1, 127.5, 114.7, 104.6, 
98.5, 55.3, 55.2, 46.5, 42.2, 36.5; Mass spectrum (ESI) m/z 363.2 (M+Na+) Exact mass calcd 
for C19H20NaN2O4: m/z 363.1321; found 363.1310. 
4-7-1h: 2-Allyl-1-propylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 5.82-5.69 (m, 
CH2CHCH2N, 1H), 5.30-5.24 (m, CH2CHCH2N, 2H), 4.21-4.19 (d, J = 5.91 Hz, 
CH2CHCH2N, 2H), 3.56-3.51 (t, J = 7.31 Hz, CH3CH2CH2N, 2H), 3.17 (s, CH2, 2H), 
1.65-1.52 (m, CH3CH2CH2N, 2H), 0.91-0.86 (t, J = 7.31 Hz, CH3CH2CH2N, 3H); 13C NMR 
(CDCl3): δ 167.8, 167.0, 130.9, 119.5, 45.7, 44.4, 36.3, 20.4, 11.0; Mass spectrum (EI) m/z 
182.0 (M+) Exact mass calcd for C9H14N2O2: m/z 182.1055; found 182.1055. 
4-7-1i: 2-Benzyl-1-propylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 7.38-7.24 (m, ArH, 
5H), 4.81 (s, ArCH2, 2H), 3.50-3.46 (t, J = 7.32 Hz, CH3CH2CH2N, 2H), 3.24 (s, CH2, 2H), 
1.57-1.44 (m, CH3CH2CH2N, 2H), 0.85-0.80 (t, J = 7.49 Hz, CH3CH2CH2N, 3H); 13C NMR 
(CDCl3): δ 167.8, 167.0, 134.7, 128.9, 128.3, 127.6, 47.1, 44.7, 36.5, 20.4, 10.9; Mass 
spectrum (EI) m/z 232.0 (M+) Exact mass calcd for C13H16N2O2: m/z 232.1212; found 
232.1207. 
4-7-2b: 2-Allyl-1-benzyl-4-ethoxycarbonylpyrazolidine-3,5-dione. 1H NMR (CD3OD, 500 
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MHz): δ 7.21-7.18 (m, ArH, 5H), 5.68-5.60 (m, CH2CHCH2N, 1H), 5.12-5.04 (m, 
CH2CHCH2N, 2H), 4.74 (s, ArCH2, 2H), 4.25-4.20 (q, J = 7.14 Hz, CH3CH2, 2H), 4.08-4.07 
(d, J = 5.70 Hz, CH2CHCH2N, 2H), 1.28-1.25 (t, J = 7.25 Hz, CH3CH2, 3H); 13C NMR 
(CD3OD, 126 MHz): δ 171.7, 171.6, 169.3, 138.2, 133.9, 129.4, 128.9, 128.4, 118.3, 83.2, 
60.6, 47.9, 47.2, 15.0; Mass spectrum (ESI) m/z 325.2 (M+Na+) Exact mass calcd for 
C16H18NaN2O4: m/z 325.1164; found 325.1172. 
4-7-2c: 1-Benzyl-4-ethoxycarbonyl-2-propylpyrazolidine-3,5-dione. 1H NMR (CD3OD): δ 
7.22 (s, ArH, 5H), 4.77 (s, ArCH2, 2H), 4.27-4.20 (q, J = 7.08 Hz, CH3CH2, 2H), 3.47 (s, 
CH3CH2CH2N, 2H), 1.47-1.40 (m, CH3CH2CH2N, 2H), 1.30-1.25 (t, J = 6.98 Hz, CH3CH2, 
3H), 0.77-0.72 (t, J = 7.32 Hz, CH3CH2CH2N, 3H); 13C NMR (CD3OD): δ 171.8, 171.3, 
169.4, 138.3, 129.4, 128.9, 128.5, 83.0, 60.5, 47.9, 45.8, 21.5, 15.0, 11.5; Mass spectrum (ESI) 
m/z 327.1 (M+Na+) Exact mass calcd for C16H20NaN2O4: m/z 327.1321; found 327.1334. 
4-7-2d: 1-(2,4-Dimethoxybenzyl)-4-ethoxycarbonyl-2-methylpyrazolidine-3,5-dione. 1H 
NMR (CD3OD): δ 7.05-6.31 (m, ArH, 3H), 4.76 (s, ArCH2, 2H), 4.27-4.20 (q, J = 6.97 Hz, 
CH3CH2, 2H), 3.80 (s, OCH3, 3H), 3.71 (s, OCH3, 3H), 3.01 (s, CH3, 3H), 1.29-1.25 (t, J = 
6.78 Hz, CH3CH2, 3H); 13C NMR (CD3OD): δ 171.8, 170.6, 169.8, 162.0, 159.6, 131.2, 118.2, 
105.7, 99.0, 82.6, 61.2, 55.9, 55.7, 41.7, 31.4, 14.9; Mass spectrum (ESI) m/z 335.4 (M-H+) 
Exact mass calcd for C16H19N2O6: m/z 335.1243; found 335.1246. 
4-7-2e: 2-Benzyl-1-(2,4-dimethoxybenzyl)-4-ethoxycarbonylpyrazolidine-3,5-dione. 1H 
NMR (CD3OD): δ 7.16-6.23 (m, ArH, 8H), 4.68-4.65 (d, ArCH2, 4H), 4.24-4.17 (q, J = 6.96 
Hz, CH3CH2, 2H), 3.77 (s, OCH3, 3H), 3.70 (s, OCH3, 3H), 1.26-1.22 (t, J = 7.14 Hz, 
CH3CH2, 3H); 13C NMR (CD3OD): δ 171.4, 171.0, 169.3, 161.8, 159.4, 138.2, 131.2, 129.3, 
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128.8, 128.3, 118.2, 105.7, 99.0, 83.4, 60.6, 55.8, 55.7, 47.6, 41.3, 15.0; Mass spectrum (ESI) 
m/z 411.2 (M-H+) Exact mass calcd for C22H23N2O6: m/z 411.1556; found 411.1552. 
4-7-2f: 2-Benzyl-4-ethoxycarbonyl-1-propylpyrazolidine-3,5-dione. 1H NMR (CD3OD): δ 
7.22 (s, ArH, 5H), 4.78 (s, ArCH2, 2H), 4.26-4.19 (q, J = 6.96 Hz, CH3CH2, 2H), 3.51-3.46 (t, 
J = 6.74 Hz, CH3CH2CH2N, 2H), 1.48-1.41 (m, CH3CH2CH2N, 2H), 1.29-1.24 (t, J = 7.07 
Hz, CH3CH2, 3H), 0.77-0.73 (t, J = 6.83 Hz, CH3CH2CH2N, 3H); 13C NMR (CD3OD): δ 
172.5, 170.6, 169.6, 138.0, 129.4, 128.9, 128.6, 82.7, 61.2, 47.8, 45.7, 21.5, 14.9, 11.5; Mass 
spectrum (ESI) m/z 327.1 (M+Na+) Exact mass calcd for C16H20NaN2O4: m/z 327.1321; 
found 327.1334. 
4-7-2g: 1-Benzyl-4-cyano-2-methylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 7.32-7.19 
(m, ArH, 5H), 4.99 (s, ArCH2, 2H), 3.21 (s, CH3, 3H); 13C NMR (CDCl3): δ 164.2, 164.1, 
134.6, 129.0, 128.3, 127.2, 112.6, 64.4, 47.1, 30.7; Mass spectrum (EI) m/z 229.0 (M+) Exact 
mass calcd for C11H11N3O2: m/z 229.0851; found 229.0818. 
4-7-2h: 1-Benzyl-4-cyano-2-propylpyrazolidine-3,5-dione. 1H NMR (CDCl3): δ 7.24-7.11 
(m, ArH, 5H), 4.88 (s, ArCH2, 2H), 3.53-3.48 (t, J = 7.31 Hz, CH3CH2CH2, 2H), 1.38-1.29 (m, 
CH3CH2CH2, 2H), 0.67-0.62 (t, J = 7.32 Hz, CH3CH2CH2, 3H); 13C NMR (CDCl3): δ 164.9, 
164.0, 134.6, 128.8, 128.1, 127.1, 112.3, 64.8, 47.4, 45.7, 21.1, 10.7; Mass spectrum (EI) m/z 
257.0 (M+) Exact mass calcd for C14H15N3O2: m/z 257.1164; found 257.1162. 
4-7-2i: 1,2-Dibenzyl-4-cyanopyrazolidine-3,5-dione. 1H NMR (DMSO-d6): δ 7.28-7.13 (m, 
ArH, 10H), 4.45 (s, ArCH2, 4H); 13C NMR (DMSO-d6): δ 164.6, 134.4, 128.8, 128.0, 127.0, 
112.6, 65.1, 47.6; Mass spectrum (EI) m/z 305.0 (M+) Exact mass calcd for C18H15N3O2: m/z 
305.1164; found 305.1165. 
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4-7-2j: 1-Benzyl-2-methyl-4-(4-nitrophenyl)pyrazolidine-3,5-dione. 1H NMR (DMSO-d6): 
δ 8.35-8.32 (d, J = 9.06 Hz, ArH, 2H), 8.10-8.07 (d, J = 9.06 Hz, ArH, 2H), 7.33-7.21 (m, 
ArH, 5H), 4.80 (s, ArCH2, 2H), 3.04 (s, CH3, 3H); 13C NMR (DMSO-d6): δ 166.0, 165.6, 
142.1, 141.9, 136.5, 128.4, 127.8, 127.5, 123.6, 123.5, 46.9, 40.9, 32.3; Mass spectrum (EI) 
m/z 325.1 (M+) Exact mass calcd for C17H15N3O4: m/z 325.1063; found 325.1061. 
4-7-2k: 1,2-Dibenzyl-4-(4-nitrophenyl)pyrazolidine-3,5-dione. 1H NMR (DMSO-d6): δ 
8.42-8.39 (d, J = 9.06 Hz, ArH, 2H), 8.05-8.02 (d, J = 9.06 Hz, ArH, 2H), 7.33-7.18 (m, ArH, 
10H), 4.67 (s, ArCH2, 4H); 13C NMR (DMSO-d6): δ 168.0, 144.2, 140.5, 137.0, 128.2, 128.1, 
127.2, 123.5, 122.1, 47.0, 41.0; Mass spectrum (EI) m/z 401.1 (M+) Exact mass calcd for 
C23H19N3O4: m/z 401.1376; found 401.1379. 
4-7-3b: 4-Allyl-1-benzyl-4-ethoxycarbonyl-2-methylpyrazolidine-3,5-dione. 1H NMR 
(CDCl3): δ 7.38-7.29 (m, ArH, 5H), 5.63-5.49 (m, CH2CHCH2C, 1H), 5.26-4.66 (m, ArCH2, 
and CH2CHCH2C, 4H), 4.25-4.18 (q, J = 7.20 Hz, CH3CH2, 2H), 3.10 (s, N2CH3, 3H), 
2.99-2.86 (m, CH2CHCH2C, 2H), 1.27-1.23 (t, J = 7.14 Hz, CH3CH2, 3H); 13C NMR (CDCl3): 
δ 167.1, 166.1, 164.3, 134.4, 130.0, 128.9, 128.4, 127.8, 121.2, 77.21, 62.8, 46.6, 35.4, 30.7, 
13.9; Mass spectrum (EI) m/z 316.1 (M+) Exact mass calcd for C17H20N2O4: m/z 316.1423; 
found 316.1421. 
4-7-3c: 1,4-Dibenzyl-4-ethoxycarbonyl-2-methylpyrazolidine-3,5-dione. 1H NMR (CDCl3): 
δ 7.29-6.90 (m, ArH, 10H), 4.85-4.45 (m, N1CH2, 2H), 4.30-4.23 (q, J = 7.19 Hz, CH3CH2, 
2H), 3.52-3.51 (d, J = 2.43 Hz, ArCH2, 2H), 2.69 (s, N2CH3, 3H), 1.31-1.26 (t, J = 7.14 Hz, 
CH3CH2, 3H); 13C NMR (CDCl3): δ 167.1, 165.6, 164.5, 134.2, 133.8, 130.3, 128.7, 128.5, 
128.1, 127.5, 127.1, 77.2, 62.9, 46.1, 37.0, 30.6, 13.9; Mass spectrum (EI) m/z 366.2 (M+) 
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Exact mass calcd for C21H22N2O4: m/z 366.1580; found 366.1580. 
4-7-3d: 4-Cyano-1,2-di(4-methoxybenzyl)-4-methylpyrazolidine-3,5-dione. 1H NMR 
(CDCl3): δ 7.15-6.88 (m, ArH, 8H), 4.69 (s, ArCH2, 4H), 3.82 (s, OCH3, 6H), 1.72 (s, CH3, 
3H); 13C NMR (CDCl3): δ 164.3, 160.0, 129.0, 128.2, 125.5, 114.7, 77.2, 55.3, 47.0, 19.8; 
Mass spectrum (EI) m/z 380.4 (M+) Exact mass calcd for C21H21N3O4: m/z 379.1532; found 
379.1534. 
4-7-3e: 4-Benzyl-4-cyano-1,2-di(4-methoxybenzyl)pyrazolidine-3,5-dione. 1H NMR 
(CDCl3): δ 7.43-6.63 (m, ArH, 13H), 4.55-4.29 (m, NCH2, 4H), 3.79 (s, OCH3, 6H), 3.62 (s, 
ArCH2, 2H); 13C NMR (CDCl3): δ 161.8, 159.6, 131.7, 130.7, 129.0, 128.5, 128.1, 125.4, 
114.4, 113.2, 77.2, 55.3, 46.6, 38.8; Mass spectrum (EI) m/z 455.3 (M+) Exact mass calcd for 
C27H25N3O4: m/z 455.1845; found 455.1850. 
4-7-3f: 1-Benzyl-2,4-dimethyl-4-(4-nitrophenyl)pyrazolidine-3,5-dione. 1H NMR (CDCl3): 
δ 8.20-8.17 (d, J = 9.06 Hz, CArH, 2H), 7.71-7.68 (d, J = 8.70 Hz, CArH, 2H), 7.34-7.21 (m, 
ArH, 5H), 4.91 (s, ArCH2, 2H), 3.21 (s, N2CH3, 3H), 1.73 (s, CCH3, 3H); 13C NMR (CDCl3): 
δ 171.2, 170.9, 147.5, 143.2, 134.4, 129.1, 128.7, 127.8, 127.7, 123.8, 51.2, 46.9, 30.6, 22.5; 
Mass spectrum (EI) m/z 339.1 (M+) Exact mass calcd for C18H17N3O4: m/z 339.1219; found 
339.1213. 
4-7-3g: 4-Benzyl-1,2-di(4-methoxybenzyl)-4-(4-nitrophenyl)pyrazolidine-3,5-dione. 1H 
NMR (CDCl3): δ 8.25-8.23 (d, J = 8.73 Hz, CArH, 2H), 7.99-7.96 (d, J = 9.06 Hz, CArH, 
2H), 7.40-7.35 (m, CCH2ArH, 5H), 6.65-6.51 (NCH2ArH, 8H), 4.55-4.32 (m, NCH2, 4H), 
3.76 (s, OCH3, 6H), 3.51 (s, CCH2, 2H); 13C NMR (CDCl3): δ 168.8, 159.3, 147.5, 142.8, 
134.6, 130.7, 128.8, 128.7, 128.2, 127.7, 126.1, 123.8, 114.1, 58.4, 55.2, 46.2, 43.1; Mass 
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Chapter 5 Development of a Polymer-Supported Hantzsch Ester 
5.1 Introduction 
The synthesis of organic compounds using polymer-supported reagents and catalysts,1 has 
been of great interest in recent years, especially in pharmaceutical research community.2 
Organic synthesis using polymer-supported reagents and catalysts offers a number of 
advantages over traditional solution-phase synthesis. The first and most important advantage 
is the easy separation of the supported and non-supported species by filtration at the end of 
the reaction. This greatly simplifies purification processes, such as column chromatography, 
distillation or recrystallization. In addition, high concentrations of reagents can be used to 
drive the reaction to completion as byproducts or excess reagents can be easily removed. The 
reagents and catalysts recovered could, at times, be recycled, thus reducing the cost of the 
synthesis.3 The second advantage involves safety consideration. Chemicals are always 
thought to be toxic, odorous and harmful. If they were immobilized to a polymer, they would 
be much easier and safer to handle. Since they are less toxic and non-odorous, the synthesis 
involving them will be more environmentally benign.4 The third advantage concerns the 
unique microenvironment created within the polymer, which could improve the performance 
of reagents or catalysts in reactions. It has been reported that polymer-supported catalysts 
have improved stability,5 increased selectivity,6 enhanced regioselectivity due to steric 
hindrance,7 and could possess superior activity due to site cooperation.8 
5.1.1 Soluble polymer-supported reagents and catalysts 
There are two kinds of polymer-supported reagents and catalysts, those that are immobilized 
to insoluble polymers and those that are immobilized to soluble polymers. Initially, soluble 
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polymer supports did not receive as much attention as their cross-linked insoluble 
counterparts.9 However, the heterogeneous reaction condition associated with using insoluble 
polymers presents several limitations, for example nonlinear kinetic behavior, unequal 
distribution or access to chemical reactions, solvation problems, and synthetic difficulties in 
transferring standard organic reactions to the solid-phase. Thus soluble polymers as supports 
have received significant attention in recent years.9 As soluble polymers dissolve in specific 
solvents and precipitate out when other solvents are added, reactions with them combine the 
advantages of insoluble polymer-supported synthesis with traditional solution-phase synthesis. 
To date, various soluble polymer-supported reagents and catalysts have been developed. 
These include phosphines,10 Swern oxidant,11 borane complex,12 alkali metal,13 amorphous 
selenium,14 hydrogenation catalysts,15 chinchona alkaloid ligands for the Sharpless 
asymmetric dihydroxylation,16 epoxidation catalysts,17 and so on. These polymer-supported 
reagents and catalysts have been immobilized on different kinds of polymer supports so that 
they can be applied under different reaction conditions. 
5.1.1.1 Soluble polymer supports 
Many types of polymers have been used as supports for immobilizing reagents and catalysts. 
These include polystyrene, polyvinyl alcohol, polyethylene imine, polyacrylic acid, 
polyacrylamide, polymethylene oxide, PEG, polypropylene oxide, cellulose, and so on.18 
Amongst them, non-cross-linked polystyrene and PEG are the most commonly used 
polymeric supports. 
Non-cross-linked polystyrene is readily prepared from styrene and AIBN. Its remarkable 
solubility properties make it extremely useful to organic synthesis. It is soluble in THF, 
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CH2Cl2, CHCl3, benzene, toluene, DMF, acetone and EtOAc and is insoluble in H2O and 
MeOH. 
PEG is a linear polymer formed from the polymerization of ethylene oxide. It exhibits 
solubility in a wide range of solvents including DMF, CH2Cl2, toluene, MeCN, and H2O, but 
is insoluble in hexane, Et2O, tert-butyl methyl ether and isopropyl alcohol.19 
5.1.1.2 Characterizations of soluble polymer-supported reagents and catalysts 
Although the characterization of insoluble polymer-supported intermediates can be done by 
gel-phase MAS NMR and single bead IR, the inherent heterogeneity of solid-phase systems 
precludes the use of many traditional characterization methods. Soluble polymers do not 
suffer from this drawback and they can be characterized by many routine techniques such as 
NMR, UV-visible, IR, and high resolution mass spectroscopies. Circular dichroism 
measurements have also been used for analyzing PEG bound peptides.20 
5.1.2 Hantzsch ester 
Dihydropyridine chemistry began in 1882 when Hantzsch published the synthesis which now 
bears his name.21 After the discovery in 1930s that a dihydropyridine (NADH, a 
dihydronicotinamide derivative) was a “hydrogen-transferring coenzyme” for oxidation and 
reduction in biological systems,22 it has been a stimulus for using Hantzsch ester (Figure 5-1) 
and other 1,4-dihydropyridines as biomimic reducing agents in synthetic organic chemistry.23 
Evidence shows that they may reduce substrates by a one-step hydride transfer or by a 
multip-step electron-transfer-initiated hydride transfer.23d,23e 
To date, dihydropyridines have been successfully applied for the reduction of ketones,24 
aldehydes25 and α,β-unsaturated compounds.26 They have also found applications in 
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asymmetric reductions27 and reductive aminations.28 


























In addition to their reducing function, Hantzsch ester and 1,4-dihydropyridines are an 
important class of calcium channel blockers and one of the most important class of drugs for 
the treatment of cardiovascular diseases.29 Many compounds carrying a dihydropyridine 
heterocyclic ring are used as vasodilator, bronchodilator, antiatherosclerotic, antitumor, 
geroprotective, heptaprotective, and antidiabetic agents.30 
In the original synthesis of Hantzsch ester,21 an aldehyde, acetoacetic ester, and ammonium 
hydroxide were mixed together to give the product (Route A, Scheme 5-1). This classical 
method usually gave the products in low yields, especially when sterically hindered aldehydes 
were used. Several improved procedures have been reported31a-31h and these include a high 
yielding microwave-assisted synthesis of substituted 1,4-dihydropyridines (Route B, Scheme 
5-1);31e condensation of an aldehyde, acetoacetic ester and ethyl 3-aminocrotonate in the 
absence of an ammonia source,31f reaction of 1,5-diketones with ammonia to yield Hantzsch 
















































5.1.3 Objectives and scope of this study 
Although the Hantzsch ester has been widely used as a reductant in synthetic organic 
chemistry, the study of soluble polymer-supported Hantzsch ester has not been explored. Thus 
this project aims to develop a soluble polymer-supported Hantzsch ester and investigate its 
reductive properties. 
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5.2 Results and Discussion 
5.2.1 Design and synthesis of monomers 
To begin our investigation, we had to design and prepare a monomer which contains a 
Hantzsch ester. Our first monomer design was 5-1, a ROMP monomer (Figure 5-2), and two 
synthetic methods were designed for synthesizing it (Route A and B, Scheme 5-2). In the first 
method, although 5-6 could be easily prepared from 5-5, attempts to synthesize 5-1 from 5-6 
failed to give the desired product. The specific rigidity of the bridged structure of norbornene 
5-6 and the short distance between the norbornene ring and keto ester were thought to be the 
reasons for the failed synthesis. To verify this hypothesis, we proceeded to synthesize 
analogues 5-11 and 5-14. Although the precursors 5-10 and 5-13 could be prepared 
successfully, we were unable to effect the condensations to give 5-11 and 5-14. We next 
explored the possibility of coupling a diacid 5-8 with a diol 5-5 (Route B, Scheme 5-2). 
However attempts to hydrolyze 5-8 to 5-7 were met with great difficulties. Since monomer 
5-1 could not be synthesized satisfactorily, we decided to explore the possibility of using 
compound 5-2 in reductions. Compound 5-2 was synthesized in good yield by using Guo’s 
method.31e However when it was applied to a reduction reaction, it did not show any reducing 
ability. This implied that for dihydropyridines to behave as a reductant in reduction, the C4 
position could not be substituted. Substitution on N1, as shown in monomer 5-3, was not 
advisable as a substituent at this position could affect the reactivity. Hence we eventually 
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5.2.2 Synthesis of a polymer-supported Hantzsch ester 
5.2.2.1 Synthesis of 4-vinylbenzyl alcohol (5-16) 
In the initial synthesis of a polymer-supported Hantzsch ester, monomer 5-4 was prepared and 
copolymerized with styrene to give polymer 5-18 (Scheme 5-3). 














Cl NaOH, TBAB, H2O























Compound 5-16 was prepared by first hydrolyzing 4-vinylbenzyl chloride (5-15) to 
4-vinylbenzyl alcohol (5-16). Unlike the hydrolysis of benzyl chloride which proceeded very 
efficiently, the hydrolysis of 4-vinylbenzyl chloride was complicated and gave byproduct 
(di-(4-vinylbenzyl) ether) easily. Different hydrolysis conditions were attempted to decrease 
the formation of the byproduct (Table 5-1) and the best result was obtained using NaOH (0.1 
equiv) in H2O and TBAB as phase-transfer catalyst (Entry 8, Table 5-1). 
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Table 5-1 Synthesis of 5-16 
Entry Reagent and Solvent Conditions Result 
1 NaOH (1 equiv),TBAB, H2O rt, 3 h Reaction very slow 
2 NaOH (1 equiv), TBAB, H2O 
95 °C, 110 °C, 130 
°C, 10 min to 1 h 
p: 24%-40%, 
byp: major 
3 NaOH (2 equiv), TBAI, KI, H2O rt, 2 h Reaction very slow 
4 NaOH (2 equiv), TBAI, KI, H2O 65 °C, 5 h p: traces, byp: major
5 NaOH (2 equiv), H2O, EtOH rt, 24 h p: 19%, byp: 81% 
6 H2O 
reflux under N2 
3 h 
p: 70% 
7 NaOH (0.1 equiv), TBAB, H2O 125 °C, 10 min 
p: 58%, byp: traces, 
5-15: 37% 
8 NaOH (0.1 equiv), TBAB, H2O 125 °C, 20 min p: 98%, byp: traces 
 
5.2.2.2 Synthesis of 4-vinylbenzyl acetoacetate (5-17) 
Compound 5-16 was then reacted with methyl acetoacetate in the presence of DBU to afford 
5-17. This reaction gave 5-17 in 52% yield when the mixture was refluxed for 2 h. Prolong 
heating time resulted in a lower yield due to the formation of byproducts. 
5.2.2.3 Synthesis of 3-(4-vinylbenzyl)-5-methyl-2,6-dimethyl-1,4-dihydropyridine-3,5- 
dicarboxylate (5-4) 
Using a modified version of the method described in Scheme 5-1, monomer 5-4 was prepared 
directly from 5-17 in 63% yield. 
5.2.2.4 Synthesis of polymer 5-18 
With monomer 5-4 in hand, we proceeded to copolymerize it with styrene by standard radical 
polymerization method. Analysis of this polymer-supported Hantzsch ester 5-18 by 1H NMR 
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showed that 40% of the 5-18 had decomposed during the polymerization to its pyridine 
cousin, which does not have reducing ability (Scheme 5-3). This was not ideal because the 
active part of 5-18 was dramatically reduced. Since long heating time is often required in 
radical polymerization, we thought that it could be difficult to prevent Hantzsch ester 
decomposition during the polymerization of 5-4. To circumvent this problem, we decided to 
polymerize 5-17 (Scheme 5-4). 
Scheme 5-4 Synthesis of a Polymer-Supported Hantzsch Ester 5-20 
AIBN (1%)



























5.2.2.5 Synthesis of polymer 5-19 
Monomer 5-17 was copolymerized with styrene by standard radical polymerization method to 
give polymer-supported ketoester 5-19. This product formation was amenable to KBr FTIR 
monitoring (i.e. the appearance of C=O stretch at 1744.2 cm-1 and 1719.7 cm-1, indicating the 
presence of this product) and 1H NMR. Through 1H NMR analysis, the loading of ketoester in 
5-19 could also be determined, and was found to be 1.562 mmol/g. 
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5.2.2.6 Synthesis of polymer 5-20 
Efforts to synthesize polymer 5-20 by heating 5-19 with methyl 3-aminocrotonate and HCHO 
resulted in the decomposition of Hantzsch ester. Attempts to reduce the heating time gave an 
incomplete reaction. Inspired by Guo’s synthesis,31e we thought that microwave irradiation 
could be a solution for this problem as it may shorten heating time thus could prevent the 
decomposition. Hence we carried out the reaction in THF and microwave irradiation. 1H 
NMR monitoring showed that 20 min irradiation was required for 5-19 to be totally consumed 
and the resultant polymer was no better than the one obtained by normal heating (38% 
decomposition) (Entry 1, Table 5-2). After giving the reaction much thought, we realized that 
the presence of H2O could possibly prevent the decomposition and speed up the reaction. 
Therefore different percentages of H2O in THF were added to the reaction system and tested 
under microwave irradiation. We observed that small percentages such as one drop, 5%, 10% 
did not improve the results significantly (Entries 2, 3 and 4, Table 5-2). However, to our 
delight, 20% H2O in THF gave a significantly better result and the decomposition product 
was dramatically reduced to a very low level (Entry 5, Table 5-2). Further experimentation, 
such as using shorter reaction time and higher reaction temperature did not provide better 
results (Entries 6 and 7, Table 5-2). Since polystyrene does not dissolve in H2O, 20% was the 
maximum percentage of H2O used in our reaction. Further addition of H2O resulted in the 





Table 5-2 Synthesis of Polymer 5-20 
Entry Solvent Conditions Result 
1 THF mw, 100 °C, 20 min n1/(n1+n2) = 62% 
2 THF/H2O (1 drop) mw, 100 °C, 20 min n1/(n1+n2) = 63% 
3 THF:H2O = 1:0.05 mw, 100 °C, 20 min n1/(n1+n2) = 62% 
4 THF:H2O = 1:0.1 mw, 100 °C, 20 min n1/(n1+n2) = 67% 
5 THF:H2O = 1:0.2 mw, 100 °C, 20 min n1/(n1+n2) = 89% 
6 THF:H2O = 1:0.2 mw, 100 °C, 10 min n1/(n1+n2) = 85%, traces of 5-19
7 THF:H2O = 1:0.2 mw, 120 °C, 5 min n1/(n1+n2) = 82%, traces of 5-19
 
5.2.3 Reduction of α,β-unsaturated aldehydes by polymer-supported Hantzsch ester 
Recently List26d reported an organic ammonium salt catalyzed reduction of α,β-unsaturated 
aldehydes by using the Hantzsch ester (Scheme 5-5). To validate our polymer-supported 
Hantzsch ester, the reduction of α,β-unsaturated aldehydes was carried out. 














As shown in Scheme 5-6, trans-4-nitrocinnamaldehyde was reduced to its saturated 
counterpart 5-21a using 5-20 as a reductant under a similar condition as that reported by List 
and the yield obtained was also comparable to the solution-phase reduction.26d However with 
5-20, the reaction needed 24 h to complete. Thus a screening was carried out to search for a 
better catalyst (Table 5-3). Four ammonium salt catalysts (Figure 5-3) were synthesized, and 
tested for this reduction. Reactions with catalysts 5A and 5C required a longer reaction time 
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than with 5B and 5D. Since catalyst 5D was easier to prepare than 5B, catalyst 5D was chosen 
for the reduction of α,β-unsaturated aldehydes with 5-20. 
Scheme 5-6 Reduction of α,β-Unsaturated Aldehydes by Polymer 5-20 
CHO CHO























Table 5-3 Catalysts Screening for Reduction of α,β-Unsaturated Aldehydes 
Entry Catalyst Concentration of polymer 5-20 Time Result (By TLC)
1 5A 0.05 M 48 h 100% conversion
2 5B 0.05 M 24 h 100% conversion
3 5C 0.05 M 48 h 100% conversion
4 5D 0.05 M 24 h 100% conversion
 
A solvent screening with 5D as catalyst was conducted to find the optimal solvent for this 
reaction (Table 5-4). CH2Cl2 was found to be the best solvent as the reaction was completed 
within 12 h. When the concentration of 5-20 was increased to 0.2 M (Entries 6 and 7, Table 
5-4), the reaction was completed within 4 h. These conditions were more efficient than the 
ones used in the reported reduction26d where the concentration of the Hantzsch ester was 
0.275 M and the reaction time was 5-6 h. Thus Entry 6 (Table 5-4) was selected as the 
standard conditions for further investigation of this reduction. 
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Table 5-4 Solvents Screening for Reduction of α,β-Unsaturated Aldehydes 
Entry Solvent Concentration of polymer 5-20 Time Result (By GC) 
1 THF 0.05 M 12 h 52% conversion
2 CH2Cl2 0.05 M 12 h 100% conversion
3 CHCl3 0.05 M 12 h 81% conversion
4 DMF 0.05 M 12 h 14% conversion
5 Toluene 0.05 M 12 h 82% conversion
6 CH2Cl2 0.1 M 7 h 100% conversion
7 CH2Cl2 0.2 M 4 h 100% conversion
 
Table 5-5 Reduction of α,β-Unsaturated Aldehydes 





















4 CHO  
CHO
5-21d  
65% (5 h)b 
94% (18 h)b 
99% (23 h)b 
5 CHO  
CHO
5-21e
99% (4 h)c 
a Yield of isolated product. b Yield determined by GC. c Yield determined by GC-MS. 
To prove the versatility of 5-20 in the reduction of α,β-unsaturated aldehydes, 5 different 
substrates were tested (Table 5-5). The results obtained showed that, in general, both aromatic 
and aliphatic substrates could be reduced to the corresponding saturated products in good 
yields within 4 h. These results imply that 5-20 was applicable for the reduction of 
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α,β-unsaturated aldehydes, and the ease of workup made it more practical than a 
non-supported Hantzsch ester. 
5.2.4 Reductive amination by polymer-supported Hantzsch ester 
Reductive amination with the Hantzsch ester has been studied by many research 
groups.27e,27g,28 Various catalyst, such as Bronsted acids,27e,27g Lewis acids [Mg2+,28a SiO2,28b 
Al2O3,28b Sc(OTf)328c,28d], and thiourea,28e have been used for this reaction. Generally, these 
reactions required a few hours to a few days to complete. To widen the application of 5-20, 
we decide to conduct reductive amination with it. Prior to the reductive amination reaction, 
we carried out a search for a new catalyst which would improve the reaction condition. 
Reaction with catalyst 5D gave the product in 27% yield after 3 h at rt (Scheme 5-7), which 
was not as good as the results obtained using reported catalysts.30 Incidentally, we discovered 
that this reaction occurred rapidly in the presence of 1.5 M HCl to give the product in 
excellent yield (Scheme 5-8). Hence 1.5 M HCl was used to examine the reductive amination 
of various aldehydes and amines in the presence of 5-20 (Table 5-6). 
Scheme 5-7 Reductive Amination by Polymer 5-20 with 5D 








Scheme 5-8 Reductive Amination by Polymer 5-20 with HCl 










Table 5-6 Reductive Amination of Aldehydes and Amines 
























































































5.2.5 Aromatization of benzoquinone by polymer-supported Hantzsch ester 
To further prove the application of 5-20, aromatization of an activated-benzoquinone was 
conducted and was found to be completed within 5 min at rt. The reaction did not require the 
use of a catalyst and the product was obtained in quantitative yield (Scheme 5-9). 















rt, 5 min, THF
5-23  
5.3 Conclusion 
This project investigated the design, development and applications of a soluble 
polymer-supported Hantzsch ester as a reducing agent. An efficient synthetic method was 
discovered for the synthesis of this polymer-supported Hantzsch ester. The polymer-supported 
Hantzsch ester was successfully applied for the reduction of α,β-unsaturated aldehydes, 
reductive amination between aldehydes and aniline and reduction of benzoquinones. 
 
5.4 Experimental 
All chemical reagents were obtained from Aldrich, Merck, Lancaster or Fluka and used 
without further purification. Analytical TLC was carried out on pre-coated plates (Merck 
silica gel 60, F254) and visualized with UV light or stained with ninhydrin. CC was 
performed with silica (Merck, 70-230 mesh). 1H NMR and 13C NMR spectra were measured 
at 298 K on a Bruker DPX 300 or DPX 500 Fourier Transform spectrometer. Chemical shifts 
are reported in δ (ppm), relative to the internal standard of TMS. The signals observed are 
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described as: s, d, t, q, m. The number of protons (n) for a given resonance is indicated as nH. 
All Infra-red spectra were recorded on a Bio-Rad FTS 165 spectrometer. Mass spectra were 
performed on VG Micromass 7035 spectrometer under EI, Finnigan/MAT LCQ under ESI 
(Normal), and Finnigan/MAT 95XL-T under ESI (Accurate). GC analysis were performed on 
Agilent 6890 series GC system using column DB-1 (30 m x 250 µm x 0.25 µm) (Oven: 50 °C, 
Injector: 230 °C, Detector: 250 °C). GC-MS analysis were performed on Hewlett Packard 
6890 series GC system integrated with HP 5973 mass selective detector using column ZB-1 
(30 m x 250 µm x 0.25 µm) (Oven: 50 °C, Injector: 230 °C, Detector: 250 °C). 
5.4.1 Synthesis of 4-vinylbenzyl alcohol (5-16) 
To NaOH (0.04 g, 1 mmol) and TBAB (3.224 g, 10 mmol) in H2O (50 mL) was added 
4-vinylbenzyl chloride (1.409 mL, 10 mmol). The mixture was heated at 125 °C for 20 min 
and subsequently cooled in an ice-water bath. Upon cooling, the mixture was extracted with 
EtOAc (50 mL x 3) and the combined organic layer was dried with MgSO4, filtered, 
concentrated and purified by CC (EtOAc:hexane = 1:5) to give 5-16 as a colorless oil (1.310 g, 
98% yield). 1H NMR (CDCl3): δ 7.28-7.15 (m, ArH, 4H), 6.65-6.56 (m, CHCH2, 1H), 
5.67-5.61 (d, J = 17.4 Hz, CHCH2, 1H), 5.16-5.12 (d, J = 10.8 Hz, CHCH2, 1H), 4.48 (s, CH2, 
2H), 2.47 (s, OH, 1H); 13C NMR (CDCl3): δ 140.4, 136.8, 136.4, 127.1, 126.2, 113.7, 64.7; 
Mass spectrum (EI) m/z 133.9 (M+) Exact mass calcd for C9H10O: m/z 134.0732; found 
134.0732. 
5.4.2 Synthesis of 4-vinylbenzyl acetoacetate (5-17) 
To methyl acetoacetate (1.1 mL, 10.188 mmol), DBU (0.385 mL, 2.547 mmol) and toluene 
(30 mL) was added 5-16 (1.1393 g, 8.49 mmol) and the mixture was refluxed at 125 °C for 1 
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h. After which, another 1.1 mL methyl acetoacetate was added, and the mixture was further 
refluxed for 1 h and then concentrated and purified by CC (EtOAc:hexane = 1:5) to give 5-17 
as a colorless oil (0.963 g, 52% yield). 1H NMR (CDCl3): δ 7.42-7.30 (m, ArH, 4H), 
6.75-6.66 (m, CHCH2, 1H), 5.79-5.73 (d, J = 17.4 Hz, CHCH2, 1H), 5.28-5.25 (d, J = 10.8 
Hz, CHCH2, 1H), 5.16 (s, ArCH2, 2H), 3.49 (s, COCH2CO, 2H), 2.24 (s, CH3, 3H); 13C NMR 
(CDCl3): δ 200.2, 166.8, 137.8, 136.2, 134.7, 128.6, 126.4, 114.4, 66.8, 50.0, 30.0; Mass 
spectrum (EI) m/z 218.0 (M+) Exact mass calcd for C13H14O3: m/z 218.0943; found 218.0946. 
5.4.3 Synthesis of monomer 5-4 
To compound 5-17 (0.8548 g, 3.917 mmol) in THF (20 mL) was added methyl 
3-aminocrotonate (0.4548 g, 3.917 mmol) and HCHO (37% solution, 0.108 mL, 3.917 mmol). 
The mixture was refluxed for 3 h then concentrated and purified by CC (EtOAc:hexane = 1:3) 
to give 5-4 as a yellow solid (0.807 g, 63% yield). 1H NMR (CDCl3): δ 7.32-7.22 (m, ArH, 
4H), 6.67-6.57 (m, CHCH2, 1H), 5.69-5.63 (d, J = 17.8 Hz, CHCH2, 1H), 5.18-5.14 (d, J = 
10.8 Hz, CHCH2, 1H), 5.07 (s, ArCH2, 2H), 3.60 (s, CO2CH3, 2H), 3.23 (s, CH2, 2H), 2.09 (s, 
CH3, 6H); 13C NMR (CDCl3): δ 168.4, 167.6, 145.7, 145.2, 141.0, 137.1, 136.4, 128.0, 126.2, 
113.9, 99.2, 98.9, 65.1, 50.9, 24.8, 19.1, 18.9; Mass spectrum (EI) m/z 327.3 (M+) Exact mass 
calcd for C19H21NO4: m/z 327.1471; found 327.1470. 
5.4.4 Synthesis of polymer 5-18 
To monomer 5-4 (0.5 g, 1.53 mmol) and styrene (1.05 mL, 9.13 mmol) in toluene (8.7 mL) 
was added AIBN (0.0175 g, 0.1066 mmol). The mixture was purged with N2 at rt for 0.5 h 
and then heated at 85 °C for 24 h under N2. After which, the solution was concentrated and 
the resulting residue was dissolved in THF (5 mL) and added slowly into vigorously stirred 
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cold MeOH (0 °C, 50 mL). The resulting suspension was filtered by suction filtration to 
afford polymer 5-18 (0.80 g, 55% yield). Loading calcd by 1H NMR: 0.780 mmol/g. 1H NMR 
(CDCl3): δ 8.75 (s, CH (byp), 1H), 7.11-6.61 (m, ArH, 98H), 5.31 (s, ArCH2 (byp), 4H), 5.14 
(s, ArCH2 (p), 4H), 3.87 (s, CO2CH3 (byp), 4H), 3.67 (s, CO2CH3 (p), 6H), 3.38 (s, CH2 (p), 
3H), 2.88 (s, CH3 (byp), 8H), 2.20 (s, CH3 (p), 16H), 1.87-0.97 (m, 66H). IR (KBr, cm-1): 
3422.7, 3058.8, 3025.0, 2921.9, 2852.5, 1944.9, 1880.1, 1701.7, 1611.9, 1510.9, 1451.8, 
1380.9, 1008.4, 820.1, 758.2, 698.3, 540.0. 
5.4.5 Synthesis of polymer 5-19 
Polymer 5-19 was prepared using the same procedure as described for the synthesis of 5-18 
(62% yield). Loading calcd by 1H NMR: 1.562 mmol/g. 1H NMR (CDCl3): δ 7.05-6.48 (m, 
ArH, 26H), 5.09 (s, ArCH2, 2H), 3.47 (s, COCH2CO, 2H), 2.21 (s, CH3, 3H), 1.96-0.89 (m, 
18H). IR (KBr, cm-1): 3448.8, 3059.7, 3026.0, 2923.5, 2849.8, 1744.2, 1719.7, 1601.4, 1493.2, 
1452.7, 1150.1, 1028.8, 759.2, 699.6, 540.5. 
5.4.6 Synthesis of polymer 5-20 
To polymer 5-19 (1.042 g, 1.6272 mmol) in THF (20 mL) and H2O (4 mL) was added methyl 
3-aminocrotonate (0.1873 g, 1.6272 mmol) and HCHO (37% solution, 0.122 mL, 1.6272 
mmol). The mixture was heated under microwave irradiation at 100 °C for 20 min and then 
added slowly into vigorously stirred cold MeOH (0 °C, 200 mL). The resulting suspension 
was filtered by suction filtration to afford polymer 5-20 (1.17 g, 96% yield). Loading calcd by 
1H NMR: 0.925 mmol/g, loading calcd by elemental analysis: 0.908 mmol/g. 1H NMR 
(CDCl3): δ 8.80 (s, CH (byp), 1H), 7.07-6.49 (m, ArH, 420H), 5.27 (s, ArCH2 (byp), 9H), 
5.10 (s, ArCH2 (p), 25H), 3.87 (s, CO2CH3 (byp), 4H), 3.65 (s, CO2CH3 (p), 29H), 3.35 (s, 
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CH2 (p), 15H), 2.94 (s, CH3 (byp), 7H), 2.19 (s, CH3 (p), 69H), 1.82-0.94 (m, 318H). IR (KBr, 
cm-1): 3468.9, 3409.6, 3082.3, 3059.2, 3025.5, 2922.8, 2849.6, 1736.02, 1716.55, 1601.8, 
1493.2, 1452.4, 1271.2, 1184.2, 1114.0, 759.9, 699.3, 540.4. 
5.4.7 General procedure for reduction of α,β-unsaturated aldehydes 
To trans-4-nitrocinnamaldehyde (0.0354 g, 0.2 mmol) in CH2Cl2 (1.5 mL) was added 
polymer 5-20 (0.324 g, 0.3 mmol) and catalyst 5D. This mixture was allowed to stir at rt for 4 
h. After which, the mixture was filtered and washed with a mixture of EtOAc:hexane = 1:3  
and filtered through silica gel. The filtrate was concentrated to afford 5-21a as a pale yellow 
solid (0.032 g, 90% yield). 1H NMR (CDCl3): δ 9.77 (s, CHO, 1H), 8.04-8.02 (d, J = 8.7 Hz, 
ArH, 2H), 7.34-7.31 (d, J = 8.7 Hz, ArH, 2H), 3.03-2.98 (t, J = 7.2 Hz, CH2CH2CHO, 2H), 
2.85-2.81 (m, CH2CH2CHO, 2H); 13C NMR (CDCl3): δ 200.2, 148.3, 146.1, 129.0, 123.3, 
44.0, 27.4; Mass spectrum (EI) m/z 179.0 (M+) Exact mass calcd for C9H9NO3: m/z 179.0582; 
found 179.0581. 
5.4.8 General procedure for reductive amination 
To benzyl aldehyde (0.0203 mL, 0.2 mmol), aniline (0.0182 mL, 0.2 mmol) and polymer 5-20 
(0.324 g, 0.3 mmol) in THF (3 mL) was added one drop of 1.5 M HCl. The mixture was 
allowed to stir at rt for 5 min. After which, the mixture was filtered and washed with a 
mixture of EtOAc:hexane = 1:5 and filtered through silica gel. The filtrate was then 
concentrated to afford 5-22a (0.033 g, 90% yield). 1H NMR (CDCl3): δ 7.27-6.51 (m, ArH, 
10H), 4.21 (s, CH2, 2H), 3.66 (s, NH, 1H); 13C NMR (CDCl3): δ 148.0, 139.4, 129.2, 128.6, 
127.5, 127.2, 117.6, 112.9, 48.2; Mass spectrum (EI) m/z 183.0 (M+) Exact mass calcd for 
C13H13N: m/z 183.1048; found 183.1047. 
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5.4.9 General procedure for aromatization of benzoquinone 
To 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.0454 g, 0.2 mmol) in THF (2 mL) was 
added polymer 5-20 (0.324 g, 0.3 mmol). The mixture was allowed to stir at rt for 5 min. 
After which, it was added into cold MeOH (20 mL), filtered and concentrated to afford 5-23 
as a yellow solid (0.0455 g, 99% yield). 13C NMR (CDCl3): δ 150.8, 129.2, 113.7, 101.7; 
Mass spectrum (EI) m/z 227.8 (M+) Exact mass calcd for C8H2Cl2N2O2: m/z 227.9493; found 
227.9491. 
5-21b: 3-Phenylpropanal. 1H NMR (CDCl3): δ 9.74 (s, CHO, 1H), 7.24-7.10 (m, ArH, 5H), 
2.91-2.86 (t, J = 7.5 Hz, CH2CH2CHO, 2H), 2.72-2.67 (m, CH2CH2CHO, 2H); 13C NMR 
(CDCl3): δ 201.5, 140.3, 128.6, 128.2, 126.3, 45.2, 28.1; Mass spectrum (EI) m/z 133.9 (M+) 
Exact mass calcd for C9H10O: m/z 134.0732; found 134.0728. 
5-21c: 3-(4-Methoxyphenyl)propanal. 1H NMR (CDCl3): δ 9.80 (s, CHO, 1H), 7.12-7.10 (d, 
J = 8.7 Hz, ArH, 2H), 6.85-6.82 (d, J = 8.7 Hz, ArH, 2H), 3.78 (s, OCH3, 3H), 2.93-2.88 (t, J 
= 7.5 Hz, CH2CH2CHO, 2H), 2.76-2.71 (m, CH2CH2CHO, 2H); 13C NMR (CDCl3): δ 201.7, 
158.1, 132.3 129.2, 114.0, 55.2, 45.5, 27.2; Mass spectrum (EI) m/z 163.9 (M+) Exact mass 
calcd for C10H12O2: m/z 164.0837; found 164.0832. 
5-22b: N-(4-Methoxybenzyl)benzenamine. 1H NMR (CDCl3): δ 7.32-6.66 (m, ArH, 9H), 
4.27 (s, CH2, 2H), 3.82 (s, OCH3, 3H); 13C NMR (CDCl3): δ 158.9, 147.9, 131.2, 129.2, 128.8, 
117.7, 114.0, 113.0, 55.3, 47.9; Mass spectrum (EI) m/z 213.0 (M+) Exact mass calcd for 
C14H15NO: m/z 213.1154; found 213.1156. 
5-22c: N-(4-Nitrobenzyl)benzenamine. 1H NMR (CDCl3): δ 8.20-6.59 (m, ArH, 9H), 4.48 (s, 
CH2, 2H); 13C NMR (CDCl3): δ 147.3, 147.2, 147.1, 129.4, 127.7, 123.8, 118.4, 113.1, 47.7; 
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Mass spectrum (EI) m/z 228.0 (M+) Exact mass calcd for C13H12N2O2: m/z 228.0899; found 
228.0900. 
5-22d: N-(2-Pyridinylmethyl)benzenamine. 1H NMR (CDCl3): δ 8.60-6.66 (m, ArH, 9H), 
4.48 (s, CH2, 2H), 3.82 (s, NH, 1H); 13C NMR (CDCl3): δ 158.4, 148.8, 147.8, 136.9, 129.2, 
122.2, 121.7, 117.6, 113.0, 49.1; Mass spectrum (EI) m/z 183.9 (M+) Exact mass calcd for 
C12H12N2: m/z 184.1000; found 184.0994. 
5-22e: N-(2-Furanylmethyl)benzenamine. 1H NMR (CDCl3): δ 7.39 (s, ArH, 1H), 7.39-6.26 
(m, ArH, 7H), 4.34 (s, CH2, 2H), 3.73 (s, NH, 1H); 13C NMR (CDCl3): δ 152.6, 147.5, 141.9, 
129.2, 118.1, 113.2, 110.3, 107.0, 41.5; Mass spectrum (EI) m/z 173.0 (M+) Exact mass calcd 
for C11H11NO: m/z 173.0841; found 173.0835. 
5-22f: N-(2-Thiophenylmethyl)benzenamine. 1H NMR (CDCl3): δ 7.26-6.70 (m, ArH, 8H), 
4.54 (s, CH2, 2H), 3.76 (s, NH, 1H); 13C NMR (CDCl3): δ 147.4, 142.8, 129.2, 126.8, 125.1, 
124.6, 118.2, 113.3, 43.5; Mass spectrum (EI) m/z 189.0 (M+) Exact mass calcd for C11H11NS: 
m/z 189.0612; found 189.0614. 
5-22g: N-Benzyl-4-chlorobenzenamine. 1H NMR (CDCl3): δ 7.36-6.56 (m, ArH, 9H), 4.31 
(s, CH2, 2H); 13C NMR (CDCl3): δ 146.4, 138.7, 129.1, 128.7, 127.5, 127.4, 122.4, 114.1, 
48.5; Mass spectrum (EI) m/z 217.0 (M+) Exact mass calcd for C13H12ClN: m/z 217.0658; 
found 217.0655. 
5-22h: N-Benzyl-4-nitrobenzenamine. 1H NMR (CDCl3): δ 8.09-8.06 (d, J = 9.1 Hz, ArH, 
2H), 7.40-6.31 (m, ArH, 5H), 6.59-6.56 (d, J = 9.1 Hz, ArH, 2H), 4.43 (s, CH2, 2H); 13C 
NMR (CDCl3): δ 153.0, 138.4, 137.3, 128.9, 127.8, 127.3, 126.4, 111.4, 47.7; Mass spectrum 
(EI) m/z 228.0 (M+) Exact mass calcd for C13H12N2O2: m/z 228.0899; found 228.0898. 
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5-22i: N-Benzyl-4-tert-butylbenzenamine. 1H NMR (CDCl3): δ 7.34-6.51 (m, ArH, 9H), 
4.22 (s, CH2, 2H), 1.19 (s, CH3, 9H); 13C NMR (CDCl3): δ 145.6, 140.5, 139.5, 128.6, 127.6, 
127.2, 126.0, 112.7, 48.8, 43.5, 31.5; Mass spectrum (EI) m/z 239.1 (M+) Exact mass calcd 
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Table 1. Crystal data and structure refinement for 2-1-10. 
Identification code  2-1-10 
Empirical formula  C15 H19 N3 O4 
Formula weight  305.33 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.4643(6) Å α = 87.911(2)°. 
 b = 9.8277(9) Å β = 85.389(2)°. 
 c = 11.9782(11) Å γ = 81.272(2)°. 
Volume 749.49(12) Å3 
Z 2 
Density (calculated) 1.353 Mg/m3 
Absorption coefficient 0.100 mm-1 
F(000) 324 
Crystal size 0.68 x 0.57 x 0.24 mm3 
Theta range for data collection 1.71 to 30.03°. 
Index ranges -9<=h<=9, -13<=k<=13, -16<=l<=16 
Reflections collected 11734 
Independent reflections 4347 [R(int) = 0.0249] 
Completeness to theta = 30.03° 99.2 %  
Absorption correction None 
Max. and min. transmission 0.9763 and 0.9357 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4347 / 0 / 203 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0521, wR2 = 0.1375 
R indices (all data) R1 = 0.0619, wR2 = 0.1452 
Largest diff. peak and hole 0.429 and -0.234 e.Å-3 
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for 2-1-10. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________  
 x y z U(eq) 
___________________________________________________________________________ 
O(1) 3579(1) 9556(1) 1391(1) 31(1) 
O(4) 8174(2) 6244(1) 7125(1) 33(1) 
N(1) 8288(2) 7098(1) 1761(1) 26(1) 
O(2) 6196(2) 9831(1) 2463(1) 42(1) 
C(8) 9191(2) 7173(1) 3729(1) 25(1) 
N(2) 7038(2) 5694(1) 657(1) 28(1) 
O(3) 11850(2) 8400(1) 4114(1) 37(1) 
C(4) 5428(2) 9131(1) 1841(1) 28(1) 
C(9) 10369(2) 7630(1) 4536(1) 25(1) 
C(10) 10000(2) 7307(1) 5663(1) 28(1) 
C(3) 5606(2) 6869(1) 783(1) 24(1) 
N(3) 3802(2) 7024(1) 253(1) 34(1) 
C(2) 6324(2) 7770(1) 1481(1) 24(1) 
C(13) 7652(2) 6398(1) 4088(1) 32(1) 
C(7) 9710(2) 7545(1) 2516(1) 28(1) 
C(12) 7240(2) 6068(1) 5218(1) 33(1) 
C(11) 8422(2) 6523(1) 5996(1) 26(1) 
C(1) 8604(2) 5888(1) 1258(1) 29(1) 
C(5) 2593(2) 10936(1) 1697(1) 39(1) 
C(15) 6309(2) 5727(2) 7531(1) 40(1) 
C(6) 639(2) 11288(2) 1097(1) 40(1) 
C(14) 12977(2) 9011(2) 4887(1) 40(1) 
___________________________________________________________________________
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 Table 3. Bond lengths [Å] and angles [°] for 2-1-10. 
_____________________________________________________  
O(1)-C(4)  1.3525(15) 
O(1)-C(5)  1.4552(15) 
O(4)-C(11)  1.3720(14) 
O(4)-C(15)  1.4218(16) 
N(1)-C(1)  1.3340(16) 
N(1)-C(2)  1.3993(15) 
N(1)-C(7)  1.4629(14) 
O(2)-C(4)  1.2139(15) 
C(8)-C(13)  1.3757(16) 
C(8)-C(9)  1.4044(15) 
C(8)-C(7)  1.5092(16) 
N(2)-C(1)  1.3280(15) 
N(2)-C(3)  1.3704(15) 
O(3)-C(9)  1.3633(14) 
O(3)-C(14)  1.4256(15) 
C(4)-C(2)  1.4412(17) 
C(9)-C(10)  1.3851(16) 
C(10)-C(11)  1.3944(17) 
C(3)-N(3)  1.3572(15) 
C(3)-C(2)  1.3937(15) 
C(13)-C(12)  1.3939(18) 
C(12)-C(11)  1.3784(16) 



































Symmetry transformations used to generate equivalent atoms:  
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Table 4. Anisotropic displacement parameters (Å2x 103) for 2-1-10. The anisotropic 
displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
___________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________ 
O(1) 31(1)  27(1) 36(1)  -8(1) -6(1)  -3(1) 
O(4) 39(1)  39(1) 23(1)  0(1) -4(1)  -10(1) 
N(1) 26(1)  30(1) 22(1)  -3(1) -5(1)  -6(1) 
O(2) 43(1)  38(1) 47(1)  -17(1) -12(1)  -7(1) 
C(8) 26(1)  26(1) 23(1)  -3(1) -5(1)  -6(1) 
N(2) 28(1)  30(1) 28(1)  -7(1) -6(1)  -2(1) 
O(3) 38(1)  51(1) 30(1)  -3(1) -6(1)  -26(1) 
C(4) 30(1)  29(1) 27(1)  -4(1) 0(1)  -8(1) 
C(9) 24(1)  26(1) 27(1)  -4(1) -5(1)  -6(1) 
C(10) 29(1)  30(1) 25(1)  -6(1) -7(1)  -6(1) 
C(3) 25(1)  27(1) 21(1)  -2(1) -2(1)  -5(1) 
N(3) 30(1)  32(1) 41(1)  -12(1) -13(1)  -1(1) 
C(2) 25(1)  28(1) 21(1)  -2(1) -2(1)  -6(1) 
C(13) 36(1)  38(1) 26(1)  -3(1) -8(1)  -17(1) 
C(7) 27(1)  37(1) 24(1)  -1(1) -6(1)  -12(1) 
C(12) 37(1)  37(1) 29(1)  0(1) -5(1)  -18(1) 
C(11) 31(1)  25(1) 23(1)  -2(1) -3(1)  -4(1) 
C(1) 28(1)  32(1) 27(1)  -4(1) -5(1)  -2(1) 
C(5) 41(1)  29(1) 45(1)  -10(1) -6(1)  1(1) 
C(15) 42(1)  48(1) 31(1)  4(1) 0(1)  -12(1) 
C(6) 40(1)  32(1) 46(1)  1(1) -4(1)  -1(1) 
C(14) 40(1)  49(1) 39(1)  -4(1) -13(1)  -22(1) 
___________________________________________________________________________
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 Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) 
for 2-1-10. 
___________________________________________________________________________  
 x  y  z  U(eq) 
___________________________________________________________________________  
H(10) 10804 7612 6196 33 
H(3A) 3549 6376 -169 41 
H(3B) 2899 7772 337 41 
H(13) 6854 6082 3557 39 
H(7A) 9649 8546 2437 34 
H(7B) 11150 7122 2293 34 
H(12) 6173 5543 5446 39 
H(1) 9815 5236 1322 35 
H(5A) 3554 11600 1486 47 
H(5B) 2251 10972 2509 47 
H(15A) 5097 6367 7323 60 
H(15B) 6269 5622 8340 60 
H(15C) 6287 4841 7205 60 
H(6A) 982 11207 297 60 
H(6B) 2 12226 1260 60 
H(6C) -339 10662 1345 60 
H(14A) 11994 9566 5404 60 
H(14B) 13888 9590 4482 60 




 Table 1. Crystal data and structure refinement for 2-1-7h. 
Identification code  2-1-7h 
Empirical formula  C11 H10 N4 O2 
Formula weight  230.23 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 17.503(3) Å α = 90°. 
 b = 8.0041(12) Å β = 95.742(4)°. 
 c = 7.6603(12) Å γ = 90°. 
Volume 1067.8(3) Å3 
Z 4 
Density (calculated) 1.432 Mg/m3 
Absorption coefficient 0.103 mm-1 
F(000) 480 
Crystal size 0.468 x 0.312 x 0.26 mm3 
Theta range for data collection 2.34 to 27.49°. 
Index ranges -22<=h<=21, -10<=k<=10, -6<=l<=9 
Reflections collected 3696 
Independent reflections 1232 [R(int) = 0.0211] 
Completeness to theta = 27.49° 100.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1232 / 29 / 105 
Goodness-of-fit on F2 1.167 
Final R indices [I>2sigma(I)] R1 = 0.1732, wR2 = 0.3154 
R indices (all data) R1 = 0.1777, wR2 = 0.3167 
Extinction coefficient 0.0060(13) 
Largest diff. peak and hole 0.701 and -0.660 e.Å-3 
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 Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for 2-1-7h. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________  
 x y z U(eq) 
___________________________________________________________________________  
C(1) 5000 3012(15) 2500 42(2) 
C(2) 4393(4) 378(9) 1581(9) 35(2) 
C(3) 5000 -466(12) 2500 36(2) 
C(4) 4059(9) -2058(19) 961(19) 41(4) 
C(5) 3807(4) 3020(10) 536(9) 40(2) 
C(6) 3250(20) 3480(50) 1750(50) 78(16) 
C(7) 3195(11) 3650(30) 1600(30) 30(5) 
C(8) 2806(12) 4320(30) 2380(30) 59(6) 
C(9) 2854(19) 3690(50) 3090(30) 126(13) 
N(1) 4729(8) -2096(14) 2010(18) 43(3) 
N(2) 3908(10) -721(19) 810(20) 36(2) 
N(3) 4426(3) 2110(7) 1570(8) 32(1) 
O(1) 5000 4517(8) 2500 42(2) 
O(2) 3816(8) -329(15) 693(19) 36(2) 
___________________________________________________________________________
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 Table 3. Bond lengths [Å] and angles [°] for 2-1-7h. 
_____________________________________________________  
C(1)-O(1)  1.205(13) 
C(1)-N(3)#1  1.376(8) 
C(1)-N(3)  1.376(8) 
C(2)-O(2)  1.290(17) 
C(2)-N(2)  1.32(2) 
C(2)-N(3)  1.387(9) 
C(2)-C(3)  1.389(9) 
C(3)-C(2)#1  1.389(9) 
C(3)-N(1)#1  1.426(13) 
C(3)-N(1)  1.426(13) 
C(4)-N(2)  1.11(2) 
C(4)-N(1)  1.35(2) 
C(4)-O(2)  1.456(19) 
C(5)-C(6)  1.466(10) 
C(5)-N(3)  1.469(9) 
C(5)-C(7)  1.500(9) 
C(6)-C(8)  1.162(10) 
C(7)-C(9)  1.338(10) 



































Symmetry transformations used to generate equivalent atoms:  
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 Table 4. Anisotropic displacement parameters (Å2x 103) for 2-1-7h. The anisotropic 
displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
___________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________  
C(1) 30(5)  49(6) 47(6)  0 6(4)  0 
C(2) 31(3)  40(4) 36(4)  -17(3) 10(3)  -10(3) 
C(3) 40(3)  17(4) 51(3)  0 11(2)  0 
C(4) 58(9)  35(7) 34(7)  -17(6) 21(6)  -27(7) 
C(5) 38(4)  42(4) 40(4)  0(3) 2(3)  1(3) 
C(6) 72(18)  77(18) 83(18)  1(9) 1(9)  7(9) 
C(7) 6(6)  26(8) 56(11)  0(7) 0(6)  8(5) 
C(8) 64(11)  62(11) 48(10)  -25(9) -10(8)  26(9) 
C(9) 130(20)  160(20) 100(20)  15(18) 17(16)  -95(19) 
N(1) 56(8)  19(5) 55(8)  -3(5) 11(6)  -5(5) 
N(2) 40(3)  17(4) 51(3)  0 11(2)  0 
N(3) 30(3)  30(3) 38(3)  -11(2) 6(2)  -5(2) 
O(1) 45(4)  16(3) 64(5)  0 -4(3)  0 
O(2) 40(3)  17(4) 51(3)  0 11(2)  0 
___________________________________________________________________________
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 Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) 
for 2-1-7h. 
___________________________________________________________________________  
 x  y  z  U(eq) 
___________________________________________________________________________  
  
H(7) 3781 -2975 465 50 
H(5A) 4011 4021 10 48 
H(5B) 3567 2309 -407 48 
H(6A) 2908 4404 852 36 
H(8) 2451 4997 2892 71 
H(9A) 3045 3023 4047 152 
H(9B) 2423 4373 3175 152 
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24. 1H NMR and 13C NMR of 3-5b 179
25. 1H NMR and 13C NMR of 3-6b 180
26. 1H NMR and 13C NMR of 3-7b 181
27. 1H NMR and 13C NMR of 3-8a 182
28. 1H NMR and 13C NMR of 3-9a 183
29. 1H NMR and 13C NMR of 3-9b 184
30. 1H NMR and 13C NMR of 3-9c 185
31. 1H NMR and 13C NMR of 3-9d 186
32. 1H NMR and 13C NMR of 3-9e 187
33. 1H NMR and 13C NMR of 3-9f 188
34. 1H NMR and 13C NMR of 4-9 189
35. 1H NMR and 13C NMR of 4-11 190
36. 1H NMR and 13C NMR of 4-7-1c 191
37. 1H NMR and 13C NMR of 4-7-2b 192
38. 1H NMR and 13C NMR of 4-7-3e 193
39. 1H NMR and 13C NMR of 5-16 194
40. 1H NMR and 13C NMR of 5-17 195
41. 1H NMR and 13C NMR of 5-4 196
42. 1H NMR and 5-18 and 5-19 197
43. 1H NMR and 5-20 198
 155
44. 1H NMR and 13C NMR of 5-21a 199
45. 1H NMR and 13C NMR of 5-22a 200
46. 1H NMR and 13C NMR of 5-22e 201
47. 13C NMR of 5-23 202
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